

BMJ Open

Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England and Wales

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005685
Article Type:	Research
Date Submitted by the Author:	12-May-2014
Complete List of Authors:	Scholes, Shaun; University College London, Health and Social Surveys Research Group, Dept of Epidemiology and Public Health London Moody, Alison; University College London, Health and Social Surveys Research Group, Dept of Epidemiology and Public Health London Mindell, Jenny; University College London,
Primary Subject Heading:	Public health
Secondary Subject Heading:	Respiratory medicine, Epidemiology, Research methods, Health informatics
Keywords:	EPIDEMIOLOGY, PUBLIC HEALTH, PRIMARY CARE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts

1
2
3 **Title:** Estimating population prevalence of potential airflow obstruction using different
4
5 spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England
6
7 and Wales
8

9
10 **Running head:** Comparison of different spirometric cut-offs
11

12 **Authors:** Shaun Scholes *research associate*,^{1*} Alison Moody *research associate*,¹ Jennifer S
13
14 Mindell *clinical senior lecturer*¹
15

16
17
18 ¹ Health and Social Surveys Research Group, Research Department of Epidemiology and
19
20 Public Health, University College London, 1-19 Torrington Place, London WC1E 6BT,
21
22 United Kingdom
23

24
25 * Corresponding author. (e-mail: s.scholes@ucl.ac.uk)
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Consistent estimation of the burden of chronic obstructive pulmonary disease (COPD) has been hindered by differences in methods, including different spirometric cut-offs for impaired lung function. The impact of different definitions on the prevalence of potential airflow obstruction, and its associations with key risk factors, is evaluated using cross-sectional data from two general population surveys.

Design: Pooled cross-sectional analysis of Wave 2 of the UK Household Longitudinal Survey and the Health Survey for England 2010, including 7879 participants, aged 40-95 years, who lived in England and Wales, without diagnosed asthma, and with good-quality spirometry data. Potential airflow obstruction was defined using self-reported physician-diagnosed COPD; a fixed threshold (FT) forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio <0.70; and an age-, sex-, height- and ethnic-specific lower limit of normal (LLN). Standardised questions elicited self-reported information on demography, smoking history, ethnicity, occupation, respiratory symptoms, and cardiovascular disease.

Results: Consistent across definitions, participants classed with obstructed airflow were more likely to be older, currently smoke, have higher pack-years of smoking, and be engaged in routine occupations. The prevalence of airflow obstruction was 2.8% (95% CI 2.3-3.2), 22.2% (21.2-23.2), and 13.1% (12.2-13.9) according to diagnosed COPD, FT and LLN, respectively. The gap in prevalence between FT and LLN increased in older age-groups. Sex differences in the risk of obstruction, after adjustment for key risk factors, was sensitive to the choice of spirometric cut-off, being significantly higher in men when using FT, compared with no significant difference using LLN.

Conclusions: Applying FT or LLN spirometric cut-offs gives a different picture of the size and distribution of the disease burden. Longitudinal studies examining differences in

1
2
3 unscheduled hospital admissions and risk of death between FT and LLN may inform the
4
5 choice as to the best way to include spirometry in assessments of airflow obstruction.
6
7

8 **Word count:** 3985
9

10 **Non-text material:** 4 Tables
11

12
13 **Keywords:** airflow obstruction; chronic obstructive pulmonary disease; fixed thresholds;
14
15 Health Survey for England; lower limit of normal; respiratory; sensitivity; specificity;
16
17 spirometry; United Kingdom Household Longitudinal Survey
18
19

20 **Strengths and limitations of this study** 21

- 22
23 • Estimates of the burden of chronic obstructive pulmonary disease (COPD) using
24
25 spirometry data collected in epidemiological studies are inconsistent through
26
27 differences in methods, including different spirometric cut-offs.
28
29
- 30 • Our study combined two nationally representative samples of adults living in England
31
32 and Wales, with standardised protocols and objective measurements of lung function,
33
34 and a wide-range of clinically-relevant conditions including self-reported respiratory
35
36 symptoms and breathlessness.
37
38
- 39 • Consistent definitions and up-to-date reference equations were used, providing
40
41 baseline data for monitoring purposes in the UK, and facilitating comparison with
42
43 international studies.
44
45
- 46 • Prevalence estimates were based on pre-bronchodilator lung function measurements,
47
48 and so are likely to overestimate true prevalence.
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterised by a progressive decline in lung function.^{1,2} 2.9 million deaths were attributed to COPD in 2010, making it the third leading global cause of death.³ The National Outcomes Strategy for COPD estimated that 835,000 people living in the UK are currently diagnosed with COPD, with a further 2.2 million being undiagnosed.⁴ COPD is the second most common cause of emergency hospital admission and is one of the most costly diseases in terms of acute hospital care in England.⁴ Budgeting of healthcare is often contingent upon the estimated burden of disease. Spirometry, the mainstay of lung function assessment, has been used in nationally-representative surveys to estimate the COPD burden in terms of prevalence, associated comorbidities, and mortality. Estimation of the disease burden has been hindered, however, by differences in methods, including different spirometric cut-offs.⁵⁻⁸ Fixed thresholds (FTs) use cut-offs for lung function measurements (e.g., forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio <0.70) regardless of age, sex, height, and ethnicity.⁹ An additional threshold for percent-of-predicted FEV₁ (expected for persons of a given age, sex, height and ethnicity) is also commonly used for severity classification. In contrast, a lower limit of normal (LLN) cut-off uses a statistical definition of abnormal/normal (e.g., below/above the lower 5th percentile of the distribution of age-, sex-, height-, and ethnic-specific FEV₁/FVC values from a healthy, lifelong non-smoking population).¹⁰

At present, applying FTs such as FEV₁/FVC <0.70 is the standard approach. However, the European Respiratory Society Task Force on epidemiology recently advocated using the LLN in epidemiological studies as FTs both overestimate airflow obstruction in older populations, due to the physiological reduction of FEV₁/FVC with age, and underestimate in young adults, compared with LLN.¹¹⁻¹⁶ The controversy over FT-versus-LLN thresholds is well-known and

1
2
3 has been fiercely debated with no signs of a consensus among expert groups being agreed.¹⁷⁻

4
5 21

6
7
8 Partly as a result of this controversy, the COPD epidemiological database, within and across
9
10 countries, shows heterogeneity in both definitions and consequential estimates of the disease
11
12 burden.^{5;22} Therefore, the primary objective of the present study was to compare the
13
14 prevalence of 'potential' airflow obstruction according to FT- and LLN-thresholds in a
15
16 representative sample of persons aged 40-95 years living in England and Wales: potential in
17
18 the sense that the administration of bronchodilators to measure the extent of reversibility in
19
20 airflow obstruction was not used. As a secondary aim, we compared the sensitivity of
21
22 associations with risk factors including age, sex, smoking history, and socioeconomic
23
24 position. Using the same variables, we also examined the characteristics associated with
25
26 spirometry in connection with self-reported physician-diagnosed COPD.
27
28

29 30 31 **METHODOLOGY**

32 33 **Study design and setting**

34
35
36 Two nationally-representative samples, Wave 2 (2010-2012) of the UK Household
37
38 Longitudinal Survey (UKHLS, 'Understanding Society') and the Health Survey for England
39
40 (HSE) 2010, were pooled to increase sample size. Both surveys selected participants using
41
42 stratified multi-stage probability sampling designs²³, with similar measurement protocols and
43
44 specialist equipment for collecting spirometry.
45

46
47 Self-reported health information, risk factors and demographics was collected through face-
48
49 to-face interviews, followed by a visit from a trained nurse during which lung function was
50
51 measured. Response rates for the Wave 2 interview (among individuals issued) and nurse-
52
53 visit (among eligible participants in the Wave 2 interview) were 61% and 59% respectively in
54
55 UKHLS. In HSE 2010, interview (among the estimated total number of adults in sampled
56
57

1
2
3 households) and nurse-visit (adults in co-operating households) response rates were 59% and
4
5 57%. Sampling methods are described in detail elsewhere.²⁴⁻²⁶ Ethical approval for the
6
7 UKHLS was obtained from the Oxfordshire A Research Ethics Committee (10/H0604/2);
8
9 approval for HSE 2010 was obtained from the Oxfordshire B Research Ethics Committee
10
11 (09/H0605/73). Eligible participants gave written consent to participate in spirometry.
12
13

14 **Questionnaire and procedures**

15
16
17 Participants were excluded from spirometry for the following safety reasons: pregnancy; had
18
19 in the last 3 months abdominal or chest surgery, a heart attack, detached retina or eye or ear
20
21 surgery; admitted to hospital with a heart complaint in the preceding month; a resting pulse
22
23 rate >120 beats/minute; or currently taking medications for the treatment of tuberculosis.
24
25 Spirometry, without bronchodilator use, was conducted using NDD EasyOne PCC
26
27 spirometers (NDD Medical Technologies, Zurich, Switzerland), a hand-held, battery-operated
28
29 device that uses an ultrasonic sensor to measure airflow. Calibration of spirometers was
30
31 checked with a 3l syringe prior to use the following day. Participants performed the
32
33 manoeuvre in a sitting position wearing a nose-clip to prevent air leaks during testing.
34
35 Systematic quality control procedures were used, summarised in a session grade based on the
36
37 number of technically acceptable blows and their reproducibility. Sessions graded A (3
38
39 acceptable manoeuvres, 2 highest FVC and FEV₁ within 100 ml), B (3 acceptable
40
41 acceptable manoeuvres, 2 highest FVC and FEV₁ within 150 ml), and C (2 or 3 acceptable manoeuvres
42
43 within 200 ml) were considered good-quality. In HSE, 1-in-4 spirometry sessions were over-
44
45 read by an experienced respiratory physiology consultant. Full details on measurement
46
47 procedures are available elsewhere.^{25,27}
48
49
50
51
52

53 The highest values for FEV₁ and for FVC, from at least 3 and up to 8 blows, were used. Age-,
54
55 sex-, height-, and ethnic-specific predicted values and Z-scores (FEV₁, FVC and FEV₁/FVC)
56
57
58
59
60

1
2
3 were computed using the European Respiratory Society Global Lungs Initiative (GLI 2012,
4 www.lungfunction.org) reference equations. These have been prepared by an international
5 collaboration based on data spanning 26 countries from over 70,000 healthy individuals
6 across four ethnic groups (Caucasian, African-American, and North- and South-East Asian),
7 valid for persons aged 3-95 years^{28;29} and have been shown to fit contemporary Australasian
8 spirometric data.³⁰

16 ***FT and LLN spirometric cut-offs***

19 Using FTs, we applied the 2007 Global Initiative for Chronic Obstructive Lung Disease
20 (GOLD) classification³¹, which was designed for use with post-bronchodilator spirometry:
21 potential airflow obstruction was defined as $FEV_1/FVC < 0.70$ (FT). Disease stage was
22 defined by the reduction in FEV_1 relative to percent-of-predicted values as follows: stage I
23 ($FEV_1/FVC < 0.70$ and $FEV_1 \geq 80\%$ predicted); stage II ($FEV_1/FVC < 0.70$ and FEV_1 50-79%
24 predicted); and stage III+ ($FEV_1/FVC < 0.70$ and $FEV_1 < 50\%$ predicted).³² Participants with
25 $FEV_1/FVC \geq 0.70$ were defined as non-obstructed.

26 Using the lambda-mu-sigma method³³, participants with $FEV_1/FVC < LLN$ (below the lower
27 5th percentile of the distribution of Z-scores) were defined as obstructed (LLN). Disease stage
28 was defined by FEV_1 relative to LLN as follows: stage I ($FEV_1/FVC < LLN$ and FEV_1
29 $\geq LLN$), and stage II ($FEV_1/FVC < LLN$ and $FEV_1 < LLN$). Participants with FEV_1/FVC
30 $\geq LLN$ were defined as non-obstructed. The 5th percentile was chosen due to its established
31 associations with respiratory symptoms and all-cause mortality.³⁴

34 ***Physician-diagnosed COPD***

35 In UKHLS, disease status was ascertained through questions asking “*has a doctor or other*
36 *health professional ever told you that you have [disease]?*” Diagnosed COPD was defined as
37 a positive response to either chronic bronchitis or emphysema. In HSE, diagnosed COPD was
38

1
2
3 defined as a positive response to the question “*did a doctor ever tell you that you had chronic*
4
5 *bronchitis, emphysema or COPD?*”
6
7

8 ***Risk factors, measurements of lung function, and comorbidities***

9
10 Key subgroups were defined by age (40-54, 55-64, 65-74, 75-95); sex; smoking status
11
12 (current, former, never); pack-years of cigarette smoking (a cumulative total reflecting the
13
14 amount and duration of consumption, with 1 pack-year equating to an average of 20
15
16 cigarettes smoked/day for 1 year); and socioeconomic position, defined by the National
17
18 Statistics Socio-Economic Classification (NS-SEC), grouped into professional, intermediate,
19
20 and routine occupations.
21
22

23
24 Three lung function measurements (FEV₁, FVC, and FEV₁/FVC) on a continuous scale were
25
26 expressed as percent-of-predicted values. Additional variables included current use of
27
28 respiratory medicine; area of residence, defined as urban or rural, used as a possible proxy for
29
30 traffic-related air pollution; body mass index (BMI: weight in kilograms divided by the
31
32 square of height in metres), grouped into normal weight (18.5-24.9 kg/m²), overweight (25.0-
33
34 29.9 kg/m²), and obese (≥ 30 kg/m²); diagnosed diabetes; poor self-rated health; and reported
35
36 cardiovascular disease (stroke, angina, myocardial infarction). In HSE, participants were
37
38 asked to name any long-standing illnesses: respiratory diseases were identified using
39
40 *International Classification of Diseases, Tenth Revision* codes J00 to J99. Standard questions
41
42 in the HSE covered a range of respiratory symptoms including wheeze, dyspnoea, chronic
43
44 cough, and phlegm. Presence of respiratory symptoms was defined as usually coughing first
45
46 thing in the morning, for at least 3 months a year, and bringing up phlegm from the chest
47
48 most days for 3 consecutive months in a year. In the HSE, participants with some limitation
49
50 of activity due to breathlessness during daily life were identified by a score of 3+ on the
51
52 Medical Research Council (MRC) dyspnoea scale, a validated method of categorising
53
54
55
56
57
58
59
60

1
2
3 patients with COPD in terms of their disability.³⁵ Exposure to passive smoking in the HSE
4
5 was measured by reported number of weekly hours currently exposed to cigarette smoke (0,
6
7 1-9, and ≥ 10 hours).
8
9

10 **Statistical analyses**

11
12 A lower age limit of 40 years was used due to the low prevalence of non-asthma airflow
13
14 obstruction in the youngest age-groups.³⁶ As bronchodilators were not used, we excluded
15
16 participants who reported diagnosed asthma.^{34;37-39} Five sets of analyses were conducted
17
18 across the categories of diagnosed COPD, FT, and LLN. First, participants' characteristics
19
20 (demographics, health information, risk factors, comorbidities and percent-of-predicted
21
22 FEV₁, FVC, and FEV₁/FVC) were summarised as means, accompanied by standard
23
24 deviations, or as counts accompanied by percentages. Participants were counted under each
25
26 relevant definition. Participants with/without obstruction were compared using the χ^2 test and
27
28 analysis of variance for categorical and continuous variables respectively.
29
30
31

32
33 Secondly, prevalence estimates were computed for a subset of socio-demographic variables
34
35 defined by age, sex, smoking status, pack-years of cigarette smoking, and NS-SEC. Thirdly,
36
37 in the absence of a gold standard, we calculated the sensitivity and specificity of each
38
39 spirometric criterion, using the alternative cut-off as the reference standard.⁴⁰
40
41

42
43 Fourth, regression analyses were performed using age, sex, pack-years of smoking, and NS-
44
45 SEC as independent variables with airflow obstruction as outcome. Current smoking status
46
47 could not be entered in the same model as pack-years due to significant collinearity. The
48
49 dependent variable based on FTs had 4 categories: non-obstructed, stage I, stage II, and stage
50
51 III+. The LLN-derived outcome had 3 categories: non-obstructed, stage I, and stage II. In
52
53 each case, multinomial logistic regressions were used to estimate relative risk ratios (RRRs),
54
55 with non-obstructed as the reference category. Diagnosed COPD was analysed as a binary
56
57
58
59
60

1
2
3 dependent variable (not reported/reported): logistic regression was therefore used to estimate
4
5 odds ratios (ORs). The overall association with categorical independent variables was
6
7 computed using the adjusted Wald test. The likelihood-ratio test was used to estimate the
8
9 statistical significance of interaction terms: non-significant terms were excluded, and models
10
11 refitted with only the main effects.
12

13
14 Fifth, to examine risk factors associated with possible under-diagnosis, a four-category
15
16 outcome variable was created combining diagnosed COPD and spirometric criteria as
17
18 follows: (1) neither diagnosed nor spirometrically-defined obstruction; (2) physician-
19
20 diagnosed COPD but no obstructive spirometry; (3) spirometrically-defined but no diagnosed
21
22 COPD; and (4) both diagnosed and obstructive spirometry.⁴¹ FT and LLN cut-offs were
23
24 analysed separately. RRRs generated from multinomial logistic regressions were used to
25
26 examine associations between the same set of risk factors listed above and the composite
27
28 dependent variable.
29
30

31
32 Participants with missing values on covariates were excluded from relevant analyses. Tests of
33
34 statistical significance were based on two-sided probability ($P<0.05$). Dataset preparation was
35
36 performed in SPSS 20.0 (SPSS IBM Inc., Chicago, Illinois, USA), Stata 13.1 (StataCorp,
37
38 College Station, Texas, USA) and R (version 3.0.3; R Foundation, www.r-project.org).
39

40
41 Analysis was conducted in Stata accounting for the complex design of both surveys, using the
42
43 appropriate weighting variables and Primary Sampling Units. Both datasets are available via
44
45 the UK Data Service (www.ukdataservice.ac.uk).
46
47

48 49 **Sensitivity analyses**

50
51 Analyses were initially undertaken excluding participants with reported diagnosed asthma
52
53 and then repeated including those with asthma. In accordance with the UK National Institute
54
55 for Health and Care Excellence (NICE) criteria⁴², comparisons between FT and LLN were
56
57

1
2
3 rerun defining only the subset of FT participants with $FEV_1 < 80\%$ predicted (i.e., stage II+)
4
5 as having obstructed airflow.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

RESULTS

The analytical sample comprised 7879 participants (5936 and 1943 from UKHLS and HSE respectively) aged 40-95 years, who resided in England and Wales, did not report diagnosed asthma, had valid values of height and ethnicity, and provided good-quality spirometry.

Response flowcharts for the UKHLS and HSE are provided in Figures **S1** and **S2** (online supplementary appendix) respectively. Excluded participants were more likely to be older, engaged in routine occupations, and self-report respiratory symptoms (data not shown).

Descriptive characteristics of the analytical sample according to physician-diagnosed COPD, FT, and LLN are shown as supplementary data (Tables **S1-S2**). Overall, 46.8% of participants were male, with mean age 57.6 years (SD 12.3), 16.6% were current smokers, 4.6% had >50 pack-years of cigarette smoking, and 36.5% were engaged in professional occupations. 12 (0.1%) and 265 (3.2%) participants had missing values for pack-years and NS-SEC respectively. The prevalence of reported diagnosed COPD was similar between the sexes ($P=0.349$), but was higher for men using FT and LLN (both $P<0.001$). Participants with diagnosed COPD/obstructive spirometry were more likely to be older, currently smoke, have higher pack-years of smoking, and be engaged in routine occupations (all $P<0.001$). Prevalence of diagnosed COPD was higher in HSE vs. UKHLS ($P<0.001$), but survey-specific prevalence was similar for FT and for LLN. Participants with diagnosed COPD/obstructive spirometry were more likely to report respiratory symptoms and disease, current use of respiratory medications, cardiovascular disease, breathlessness, poor self-rated health and have, on average, lower (percent-of-predicted) values of FEV₁, FVC and FEV₁/FVC. The prevalence of respiratory symptoms was 13.7%, 10.2%, and 11.3% among participants classed as having airflow obstruction according to diagnosed COPD, FT, and LLN respectively; prevalence of having a score of 3+ on the MRC dyspnoea scale was 34.8%, 12.3% and 15.9%.

Prevalence of airflow obstruction

The prevalence of airflow obstruction was 2.8%, 22.2%, and 13.1% using diagnosed COPD, FT, and LLN respectively (**Table 1**). Using FTs, 11.6%, 8.9%, and 1.7% of participants were classed as stage I, stage II, and stage III+ respectively. LLN-derived obstruction was 6.6% (stage I) and 6.4% (stage II). For most subgroups, prevalence was highest for FT and lowest for diagnosed COPD, with LLN falling in-between. The gap in prevalence between FT and LLN increased in older age-groups. Prevalence among participants aged 40-54 years was 11.9% and 10.7% using FT and LLN respectively. Prevalence among participants aged 75-95 years was 45.0% and 17.2%.

Table 2 shows estimates of sensitivity and specificity for FT and LLN, using the alternative spirometric cut-off as the reference standard. When using LLN as reference, specificity - the percentage of participants classed as non-obstructed using LLN identified as non-obstructed using FT - decreased from 94.9% amongst participants aged 40-64 years to 74.4% amongst those aged 65-95 years.

Multivariate analyses of airflow obstruction

Table 3 shows the significant risk factors for diagnosed COPD, and the FT- and LLN-disease stage classifications (non-obstructed as reference category). For diagnosed COPD, the significant interaction between sex and age-group ($P=0.022$) suggested no difference in odds between the sexes among participants aged 40-64 years, but higher odds among men aged 65-95 years. Using FTs, being male was associated with a significantly increased risk of airflow obstruction: RRR 1.35 (95% CI: 1.16-1.58), RRR 1.35 (1.12-1.63), and RRR 1.72 (1.08-2.76) for stages I, II, and III+ respectively. In contrast, sex differences were not significant using LLN: RRR 1.07 (0.88-1.31) for stage I, and RRR 1.20 (0.96-1.50) for stage II.

1
2
3 Odds of diagnosed COPD increased significantly with age only in men ($P=0.022$ for the
4 interaction term). Using non-obstruction as reference, RRRs increased significantly with age
5 when using FTs ($P<0.001$ for each stage). The age-related difference using LLN was more
6 marked for stage II ($P=0.492$ and $P<0.001$ for stages I and II, respectively). A dose-related
7 increased risk with pack-years of cigarette smoking was observed across each definition
8 ($P<0.001$). The difference between NS-SEC levels was more marked with diagnosed COPD
9 ($P=0.012$) and the most restrictive FT- and LLN-categories (FT: $P=0.002$ stage III+; LLN:
10 $P<0.001$ stage II).

21 **Combination of diagnosed COPD and spirometric cut-offs**

22
23
24 The significant risk factors for the two four-category outcome variables created as a
25 composite of diagnosed COPD and obstructive spirometry are shown in **Table 4**. Relative to
26 the reference category (neither diagnosed nor spirometrically-defined obstruction), the risk of
27 having obstructed airflow using diagnosed COPD but no obstructive spirometry was
28 significantly lower in men using either spirometric criterion (FT: RRR 0.53 (95% CI: 0.32-
29 0.87); LLN: RRR 0.56 (0.35-0.89)). The risk of having obstructed airflow using spirometry
30 but with no diagnosed COPD – thereby indicating possible under-diagnosis - was
31 significantly higher in men, and in older age-groups, when using FT but not LLN. For both
32 spirometric criterion, increases in risk with increasing pack-years of cigarette smoking,
33 relative to the reference, was consistent across combinations of COPD/obstructive
34 spirometry; the difference between NS-SEC levels was more marked for obstructive
35 spirometry.

51 **Sensitivity analyses**

52
53 Repeating analyses by including 1183 participants with reported diagnosed asthma increased
54 prevalence of diagnosed COPD, FT and LLN by 2-3 percentage points (Figure S3, online
55
56
57

1
2
3 supplementary appendix), but led to similar patterns of association with risk factors.

4
5 Diagnosed asthma was a strong predictor of diagnosed COPD and obstructive spirometry
6
7 (P<0.001, data not shown).
8
9

10 Restricting FT-defined obstruction to the subset of FT participants with FEV₁ <80%
11
12 predicted (i.e., stage II+) more than halved the FT-derived prevalence (22.2% vs. 10.6%).
13

14 Amongst participants aged 65-95 years, specificity using LLN as the reference standard was
15
16 74.4% and 91.1% for FT and FT stage II+ respectively (**Table 2**). Patterns of association with
17
18 risk factors using FT stage II+ was similar to those shown for FT.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Consistent estimation of the COPD burden has been hindered by differences in methods, including disagreement among expert groups over the choice of FT-versus-LLN spirometric cut-offs.⁵⁻⁸ In this study, we combined two nationally-representative general population surveys, with standardised protocols and objective lung function measurements, to evaluate the impact of different definitions on the prevalence of potential airflow obstruction, and its associations with key risk factors. Participants with diagnosed COPD/obstructive spirometry were more likely to be older, currently smoke, have higher pack-years of cigarette smoking, be in lower socioeconomic groups, and report the presence of respiratory symptoms, cardiovascular disease, breathlessness, and poor self-rated health. Among persons aged 40-95 years without physician-diagnosed asthma, prevalence was 2.8%, 22.2%, and 13.1%, according to diagnosed COPD, FT, and LLN respectively. The gap in prevalence between FT and LLN increased in older age-groups. When using LLN as the reference standard, specificity for FT decreased from 94.9% amongst participants aged 40-64 years to 74.4% amongst participants aged 65-95 years, corresponding to false-positive rates of 5.1% and 25.6% respectively. Sex differences in the risk of obstructed airflow, after adjustment for potential confounders, was sensitive to spirometric criteria, being higher in men for FT, compared with no difference using LLN.

Strengths and limitations

Analyses were based on nationally-representative, random samples of the general population, with spirometry conducted by well-trained and supervised nurses using standardised protocols and modern, validated equipment. Combining two datasets ensured a sufficient sample size to estimate prevalence, and infer valid statistical associations. Predicted values and Z-scores were defined using the recently developed European Respiratory Society GLI 2012 reference equations²⁸, facilitating inclusion of older participants, non-white populations

1
2
3 and comparability with international studies. Our study has a number of limitations.
4
5 Reversibility in airflow obstruction could not be assessed due to bronchodilators not being
6
7 used. Spirometry-based prevalence, therefore, may be overestimated. Analysis of the
8
9 National Health and Nutrition Examination Survey (NHANES) 2007-2010 showed that FT-
10
11 and LLN-prevalence estimates among US adults aged 40-79 years decreased, in relative
12
13 terms, by approximately one-third after administration of bronchodilators.⁴³ Although recent
14
15 guidelines from the National Institute for Health and Care Excellence⁴⁴ and European
16
17 Respiratory Society¹³ recommend use of post-bronchodilator spirometry to confirm the
18
19 presence of airflow obstruction, debate continues over its use in epidemiological settings,
20
21 with the arguments against including ethical issues such as possible side-effects and
22
23 contraindications.⁴⁵ Potential misclassification of disease status through bronchodilators not
24
25 being used was reduced by excluding participants with physician-diagnosed asthma. Some
26
27 participants in the analytical sample, however, may be undiagnosed asthmatics. On the other
28
29 hand, the disease burden may be underestimated through excluding participants with poor-
30
31 quality spirometry. Participation in spirometry, and achievement of good-quality standards
32
33 among participants with any spirometry data, was higher among participants of younger age,
34
35 engaged in professional/managerial occupations, non-smokers, and with no self-reported
36
37 physician-diagnosed chronic bronchitis, emphysema or COPD. Lower survey participation
38
39 rates amongst socio-demographic groups at higher risk of airflow obstruction (e.g., older
40
41 persons, lower socioeconomic groups) would also have led to an underestimation of true
42
43 prevalence. These limitations, however, are unlikely to affect comparisons across definitions,
44
45 but may have led to an underestimate of risk associations.
46
47
48
49
50

51 52 **Comparisons with previous studies**

53
54 Earlier analyses of Health Survey for England data^{37;39;46} used older sets of reference
55
56 equations^{47;48} applicable only to white and younger populations. Nevertheless, estimates of
57
58
59
60

1
2
3 prevalence and their substantive conclusions of higher prevalence using FT-versus-LLN, with
4
5 a widening gap in prevalence in older age-groups, and sex differences when using FT but not
6
7 LLN were similar to ours: confirming findings reported in the US⁴³, Europe⁴⁹, Korea¹⁶,
8
9 internationally¹², and in recent literature reviews^{6;50}. A further strength of our study was the
10
11 wide range of clinically-relevant conditions examined in the context of disease staging, with
12
13 higher prevalence of self-reported respiratory symptoms, respiratory- and cardiovascular-
14
15 disease, breathlessness, and poor self-rated health among participants in the most restrictive
16
17 FT- and LLN-categories, confirming similar findings in the US.^{51;52} Whilst recent guidelines
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

13;44;53 recommend adopting multidimensional definitions of respiratory disease, our study outcomes were defined only using spirometry. While we acknowledge the merits of a multidimensional approach, and agree that neither spirometric cut-off is able to fully characterise the complex diagnostic features of COPD⁵⁴, our primary aim was to use up-to-date survey data to evaluate differences in prevalence according to FT- and LLN-thresholds, to provide baseline data for monitoring purposes in the UK, and promote comparability with international studies. Current recommendations regarding symptom criteria are less specific than those for spirometry. We chose, therefore, to examine the associations between disease staging assessed only using spirometry and presence of respiratory symptoms, rather than broaden the definition of disease.

Implications

Recent UK studies used administrative primary-care databases to report the number of diagnosed and treated patients, thereby missing undiagnosed cases. Such studies have reported prevalence below 2%.^{55;56} The disparity in prevalence from clinical-versus-epidemiological studies led to the development of the COPD prevalence model, with the HSE 2001 used as input data, to more accurately estimate prevalence.⁵⁷ In accordance with

1
2
3 National Institute for Health and Care Excellence criteria, COPD is currently defined in the
4
5 model as FT stage II+ ($FEV_1/FVC < 0.70$ and $FEV_1 < 80\%$ predicted), with the logistic
6
7 regression models showing sharp increases with age and a modifying effect of gender.^{58,59}
8
9 Similar to the findings reported by Jordan et al.³⁷, our study shows that the strength of
10
11 association between risk factors and airflow obstruction varies according to spirometric
12
13 criterion, with age- and sex-differences in risk being more marked for FT, and for FT stage
14
15 II+, than LLN. In the absence of agreement among expert groups, policy-makers, clinicians,
16
17 and researchers building the COPD epidemiological database, it is important to appreciate the
18
19 sensitivity of estimates of the disease burden, and its distribution across socio-demographic
20
21 groups, to differences in methods, including spirometric cut-offs.
22
23

24
25 The prevalence of reported physician-diagnosed COPD in our study was 2.8%, considerably
26
27 lower than spirometry-based estimates, possibly indicating considerable under-recognition by
28
29 both participants and physicians. Using the most restricted definitions, prevalence of reported
30
31 diagnosed COPD among participants with obstructive spirometry was 30.2% (FT stage III+)
32
33 and 14.7% (LLN stage II). Similar low rates of physician-diagnosis among participants
34
35 meeting spirometric criteria have been reported in New Zealand.⁶⁰
36
37

38 39 **Conclusion**

40
41 In summary, we have enhanced the COPD epidemiological database by evaluating the impact
42
43 of different definitions on the prevalence of potential airflow obstruction and its associations
44
45 with key risk factors and comorbidities. With no gold standard currently available,
46
47 longitudinal studies examining differences in unscheduled hospital admissions and risk of
48
49 death between FT and LLN may inform the choice as to the best way to include spirometry
50
51 data in multidimensional assessments of airflow obstruction in both clinical and
52
53 epidemiological settings.
54
55

1
2
3 **Abbreviations:** COPD, chronic obstructive pulmonary disease; ERS, European Respiratory
4 Society; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FT, fixed
5 thresholds; GLI, Global Lungs Initiative; GOLD, Global Initiative for Chronic Obstructive
6 Lung Disease; HSE, Health Survey for England; LLN, lower limit of normal; NICE, National
7 Institute for Health and Care Excellence; UKHLS, United Kingdom Household Longitudinal
8 Survey
9

10
11 **Acknowledgements:** The authors thank Deborah Jarvis, Janet Stocks and Jessica
12 Sheringham for helpful comments.
13

14 **Ethics approval:** Ethical approval for collecting biosocial data in UKHLS was obtained from
15 the Oxfordshire A Research Ethics Committee (10/H0604/2); approval for HSE 2010 was
16 obtained from the Oxfordshire B Research Ethics Committee (09/H0605/73). Eligible
17 participants gave written consent to participate in spirometry.
18
19

20 **Funding:** The study did not receive any specific funding. The Health Survey for England
21 2010 was funded by the Health and Social Care Information Centre (HSCIC). The views
22 expressed here are those of the authors and not of the HSCIC, Department of Health, or the
23 National Health Service.
24
25

26 **Competing interests:** All authors have completed the Unified Competing Interest form at
27 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
28 declare: no support from any organisation for the submitted work; no financial relationships
29 with any organisations that might have an interest in the submitted work in the previous 3
30 years; no other relationships or activities that could appear to have influenced the submitted
31 work.
32
33

34 "The Corresponding Author has the right to grant on behalf of all authors and does grant on
35 behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a
36 worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be
37 published in BMJ editions and any other BMJPGJL products and sublicences such use and
38 exploit all subsidiary rights, as set out in our licence."
39
40
41

42 **Data sharing:** Both datasets are available via the UK Data Service
43 (www.ukdataservice.ac.uk). Statistical code is available from the corresponding author at
44 s.scholes@ucl.ac.uk.
45

46 **Contributors:** All authors contributed to the design of the analysis. SS analysed the data and
47 wrote the first draft of the manuscript. All authors contributed to revising the final draft. SS is
48 the study guarantor. All authors had full access to all of the data in the study and can take
49 responsibility for the integrity of the data and the accuracy of the data analysis.
50
51
52
53
54
55
56
57
58
59
60

Reference List

- 1
2
3
4
5
6
7 (1) Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 2007; 370(9589):765-773.
- 8
9
10 (2) Raheerison C, Girodet PO. Epidemiology of COPD. *Eur Respir Rev* 2009; 18(114):213-221.
- 11
12 (3) Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional
13 mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis
14 for the Global Burden of Disease Study 2010. *Lancet* 2012; 380(9859):2095-2128.
- 15
16 (4) Department of Health. An Outcomes Strategy for COPD and asthma: NHS Companion
17 Document. 2012.
- 18
19 (5) Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease
20 key epidemiological data in Europe: systematic review. *BMC Med* 2011; 9:7.
- 21
22 (6) Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary
23 disease: a literature review. *Int J Chron Obstruct Pulmon Dis* 2012; 7:457-494.
- 24
25 (7) McLean S, Wild SH, Simpson CR, Sheikh A. Models for estimating projections for the
26 prevalence and disease burden of chronic obstructive pulmonary disease (COPD): systematic
27 review protocol. *Prim Care Respir J* 2013; 22(2):S8-21.
- 28
29 (8) Salvi SS, Manap R, Beasley R. Understanding the true burden of COPD: the epidemiological
30 challenges. *Prim Care Respir J* 2012; 21(3):249-251.
- 31
32 (9) Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the
33 diagnosis, management, and prevention of chronic obstructive pulmonary disease.
34 NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop
35 summary. *Am J Respir Crit Care Med* 2001; 163(5):1256-1276.
- 36
37 (10) Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Standardisation
38 of spirometry. *Eur Respir J* 2005; 26(2):319-338.
- 39
40 (11) Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data
41 using 80% predicted and fixed thresholds misclassifies more than 20% of patients. *Chest*
42 2011; 139(1):52-59.
- 43
44 (12) Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR et al. Using the
45 lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway
46 obstruction. *Thorax* 2008; 63(12):1046-1051.
- 47
48 (13) Bakke PS, Ronmark E, Eagan T, Pistelli F, Annesi-Maesano I, Maly M et al.
49 Recommendations for epidemiological studies on COPD. *Eur Respir J* 2011; 38(6):1261-
50 1277.
- 51
52 (14) Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use
53 percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. *Chest* 2007; 131(2):349-
54 355.
- 55
56
57
58
59
60

- 1
2
3 (15) Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG et al. FEV1/FVC
4 ratio of 70% misclassifies patients with obstruction at the extremes of age. *Chest* 2006;
5 130(1):200-206.
6
7 (16) Hwang YI, Kim CH, Kang HR, Shin T, Park SM, Jang SH et al. Comparison of the
8 prevalence of chronic obstructive pulmonary disease diagnosed by lower limit of normal and
9 fixed ratio criteria. *J Korean Med Sci* 2009; 24(4):621-626.
10
11 (17) Quanjer PH, Cole TJ. COPD and GOLD stage I. *Chest* 2012; 141(4):1122.
12
13 (18) Enright P, Brusasco V. Counterpoint: should we abandon FEV(1)/FVC < 0.70 to detect
14 airway obstruction? Yes. *Chest* 2010; 138(5):1040-1042.
15
16 (19) Quanjer PH, Enright PL, Miller MR, Stocks J, Ruppel G, Swanney MP et al. The need to
17 change the method for defining mild airway obstruction. *Eur Respir J* 2011; 37(3):720-722.
18
19 (20) Celli BR, Halbert RJ. Point: should we abandon FEV(1)/FVC < 0.70 to detect airway
20 obstruction? No. *Chest* 2010; 138(5):1037-1040.
21
22 (21) Falaschetti E, Swanney MP, Crapo RO, Hankinson JL, Jensen RL, Pedersen OF et al.
23 Diagnosis of COPD. *Thorax* 2007; 62(10):924-925.
24
25 (22) Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of
26 COPD: systematic review and meta-analysis. *Eur Respir J* 2006; 28(3):523-532.
27
28 (23) Mindell J, Biddulph JP, Hirani V, Stamatakis E, Craig R, Nunn S et al. Cohort profile: the
29 health survey for England. *Int J Epidemiol* 2012; 41(6):1585-1593.
30
31 (24) Joint Health Surveys Unit. The Health Survey for England 2010, Volume 1: Respiratory
32 Health. Craig R, Mindell J, editors. Respiratory health. 1. 2011. Leeds, NHS Information
33 Centre.
34
35 (25) Joint Health Surveys Unit. The Health Survey for England 2010, Volume 2: Methods and
36 Documentation. 2011. Leeds, The Information Centre for Health and Social Care.
37
38 (26) Lynn P. Sample design for Understanding Society. Understanding Society Working Paper
39 Series: 2009-01. 2009.
40
41 (27) McFall SL, Petersen J, Kaminska O, Lynn P. Understanding Society - The UK Household
42 Longitudinal Study: Wave 2 Nurse Health Assessment, 2010-2012 Guide to Nurse Health
43 Assessment. 2012. Colchester, University of Essex.
44
45 (28) Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al. Multi-ethnic reference
46 values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur*
47 *Respir J* 2012; 40(6):1324-1343.
48
49 (29) Quanjer PH, Brazzale DJ, Boros PW, Pretto JJ. Implications of adopting the Global Lungs
50 Initiative 2012 all-age reference equations for spirometry. *Eur Respir J* 2013; 42(4):1046-
51 1054.
52
53 (30) Hall GL, Thompson BR, Stanojevic S, Abramson MJ, Beasley R, Coates A et al. The Global
54 Lung Initiative 2012 reference values reflect contemporary Australasian spirometry.
55 *Respirology* 2012; 17(7):1150-1151.
56
57
58
59
60

- 1
2
3 (31) Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al. Global strategy for the
4 diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD
5 executive summary. *Am J Respir Crit Care Med* 2007; 176(6):532-555.
6
7 (32) COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for
8 the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of
9 the Standards of Care Committee of the BTS. *Thorax* 1997; 52 Suppl 5:S1-28.
10
11 (33) Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H et al. Reference ranges for
12 spirometry across all ages: a new approach. *Am J Respir Crit Care Med* 2008; 177(3):253-
13 260.
14
15 (34) Vaz Fragoso CA, Concato J, McAvay G, Van Ness PH, Rochester CL, Yaggi HK et al. The
16 ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary disease. *Am J*
17 *Respir Crit Care Med* 2010; 181(5):446-451.
18
19 (35) Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the
20 Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with
21 chronic obstructive pulmonary disease. *Thorax* 1999; 54(7):581-586.
22
23 (36) Deaths from chronic obstructive pulmonary disease--United States, 2000-2005. *MMWR Morb*
24 *Mortal Wkly Rep* 2008; 57(45):1229-1232.
25
26 (37) Jordan RE, Miller MR, Lam KB, Cheng KK, Marsh J, Adab P. Sex, susceptibility to smoking
27 and chronic obstructive pulmonary disease: the effect of different diagnostic criteria. Analysis
28 of the Health Survey for England. *Thorax* 2012; 67(7):600-605.
29
30 (38) Bhatt SP, Sieren JC, Dransfield MT, Washko GR, Newell JD, Jr., Stinson DS et al.
31 Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction.
32 *Thorax* 2013.
33
34 (39) Jordan RE, Cheng KK, Miller MR, Adab P. Passive smoking and chronic obstructive
35 pulmonary disease: cross-sectional analysis of data from the Health Survey for England. *BMJ*
36 *Open* 2011; 1(2):e000153.
37
38 (40) Loong TW. Understanding sensitivity and specificity with the right side of the brain. *BMJ*
39 2003; 327(7417):716-719.
40
41 (41) Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL et al. Prevalence and
42 underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary
43 care. *CMAJ* 2010; 182(7):673-678.
44
45 (42) Chronic obstructive pulmonary disease. National clinical guideline on management of chronic
46 obstructive pulmonary disease in adults in primary and secondary care. *Thorax* 2004; 59
47 Suppl 1:1-232.
48
49 (43) Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S. prevalence of
50 chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the
51 National Health and Nutrition Examination Survey (NHANES) 2007-2010. *Respir Res* 2013;
52 14:103.
53
54 (44) National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of
55 chronic obstructive pulmonary disease in adults in primary and secondary care. 2010.
56 London, National Clinical Guideline Centre.
57
58
59
60

- 1
2
3
4 (45) Quanjer PH, Stanojevic S, Swanney MP, Miller MR. Recommendations for epidemiological
5 studies on COPD. *Eur Respir J* 2012; 39(5):1277-1278.
6
7 (46) Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco
8 dependence of chronic obstructive pulmonary disease in a nationally representative
9 population sample. *Thorax* 2006; 61(12):1043-1047.
10
11 (47) Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes
12 and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests,
13 European Community for Steel and Coal. Official Statement of the European Respiratory
14 Society. *Eur Respir J Suppl* 1993; 16:5-40.
15
16 (48) Falaschetti E, Laiho J, Primatesta P, Purdon S. Prediction equations for normal and low lung
17 function from the Health Survey for England. *Eur Respir J* 2004; 23(3):456-463.
18
19 (49) Maio S, Sherrill DL, MacNee W, Lange P, Costabel U, Dahlen SE et al. The European
20 Respiratory Society spirometry tent: a unique form of screening for airway obstruction. *Eur*
21 *Respir J* 2012; 39(6):1458-1467.
22
23 (50) Mohamed Hoesein FA, Zanen P, Lammers JW. Lower limit of normal or FEV1/FVC < 0.70
24 in diagnosing COPD: an evidence-based review. *Respir Med* 2011; 105(6):907-915.
25
26 (51) Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes,
27 hypertension and cardiovascular disease in COPD. *Eur Respir J* 2008; 32(4):962-969.
28
29 (52) Ford ES, Wheaton AG, Mannino DM, Presley-Cantrell L, Li C, Croft JB. Elevated
30 cardiovascular risk among adults with obstructive and restrictive airway functioning in the
31 United States: a cross-sectional study of the National Health and Nutrition Examination
32 Survey from 2007-2010. *Respir Res* 2012; 13:115.
33
34 (53) Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A et al. Global strategy for
35 the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD
36 executive summary. *Am J Respir Crit Care Med* 2013; 187(4):347-365.
37
38 (54) Clini EM, Crisafulli E, Roca M, Malerba M. Diagnosis of chronic obstructive pulmonary
39 disease, simpler is better. Complexity and simplicity. *Eur J Intern Med* 2013; 24(3):195-198.
40
41 (55) Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L. The
42 distribution of COPD in UK general practice using the new GOLD classification. *Eur Respir*
43 *J* 2013.
44
45 (56) Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology of chronic obstructive
46 pulmonary disease in England: a national study of 51 804 patients. *Br J Gen Pract* 2010;
47 60(576):277-284.
48
49 (57) Walford H, Ramsey L. COPD Prevalence Modelling Briefing Document. 2011. ERPHO.
50
51 (58) Nacul LC, Soljak M, Meade T. Model for estimating the population prevalence of chronic
52 obstructive pulmonary disease: cross sectional data from the Health Survey for England.
53 *Popul Health Metr* 2007; 5:8.
54
55
56
57
58
59
60

- 1
2
3 (59) Nacul L, Soljak M, Samarasundera E, Hopkinson NS, Lacerda E, Indulkar T et al. COPD in
4 England: a comparison of expected, model-based prevalence and observed prevalence from
5 general practice data. *J Public Health (Oxf)* 2011; 33(1):108-116.
6
7 (60) Shirtcliffe P, Weatherall M, Marsh S, Travers J, Hansell A, McNaughton A et al. COPD
8 prevalence in a random population survey: a matter of definition. *Eur Respir J* 2007;
9 30(2):232-239.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Prevalence of Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria, Persons aged 40-95 years Without Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

	n	Diagnosed-COPD ^b	Fixed Thresholds ^c			Lower Limit of Normal ^d			
		% (95% CI)	Obstructed % (95% CI)	stage I % (95% CI)	stage II % (95% CI)	stage III+ % (95% CI)	Obstructed % (95% CI)	stage I % (95% CI)	stage II % (95% CI)
All	7879	2.8 (2.3-3.2)	22.2 (21.2-23.2)	11.6 (10.9-12.4)	8.9 (8.2-9.6)	1.7 (1.3-2.0)	13.1 (12.2-13.9)	6.6 (6.0-7.3)	6.4 (5.8-7.0)
Sex:									
Males	3335	3.0 (2.3-3.6)	26.3 (24.8-27.9)	13.2 (12.1-14.4)	10.7 (9.6-11.8)	2.4 (1.8-3.0)	15.0 (13.7-16.4)	7.2 (6.2-8.1)	7.9 (6.9-8.9)
Females	4544	2.6 (2.0-3.1)	18.6 (17.4-19.9)	10.2 (9.2-11.2)	7.4 (6.5-8.2)	1.0 (0.7-1.4)	11.3 (10.3-12.3)	6.2 (5.4-6.9)	5.1 (4.4-5.9)
Age-group:									
40-54	3472	1.7 (1.3-2.2)	11.9 (10.7-13.1)	7.0 (6.1-7.9)	4.6 (3.8-5.4)	0.3 (0.1-0.6)	10.7 (9.6-11.9)	6.7 (5.7-7.6)	4.1 (3.3-4.9)
55-64	2072	3.4 (2.5-4.2)	24.2 (22.2-26.1)	12.6 (11.1-14.1)	9.5 (8.1-10.9)	2.0 (1.4-2.7)	14.2 (12.6-15.8)	6.5 (5.4-7.7)	7.7 (6.4-8.9)
65-74	1557	3.9 (2.8-5.0)	32.6 (30.1-35.1)	16.5 (14.6-18.5)	12.9 (11.1-14.6)	3.2 (2.1-4.2)	15.0 (13.0-17.0)	6.4 (5.1-7.7)	8.6 (7.0-10.2)
75-95	778	3.9 (2.0-5.8)	45.0 (41.1-48.8)	21.1 (18.0-24.2)	19.6 (16.6-22.6)	4.3 (2.5-6.0)	17.2 (14.2-20.1)	7.2 (5.2-9.2)	9.9 (7.6-12.3)
Smoking status:									
Current	1198	4.7 (3.5-6.0)	37.0 (34.1-39.9)	14.5 (12.3-16.6)	18.2 (15.9-20.6)	4.2 (3.0-5.4)	29.8 (27.0-32.6)	13.5 (11.3-15.7)	16.2 (14.0-18.5)
Ex-regular	2547	3.6 (2.7-4.5)	26.8 (24.9-28.7)	14.1 (12.7-15.6)	10.5 (9.2-11.8)	2.2 (1.5-2.9)	14.5 (13.0-16.1)	7.2 (6.0-8.3)	7.4 (6.2-8.5)
Never	4134	1.6 (1.2-2.0)	14.7 (13.5-15.9)	9.2 (8.2-10.1)	5.0 (4.3-5.7)	0.5 (0.2-0.9)	6.8 (5.9-7.7)	4.1 (3.5-4.8)	2.7 (2.1-3.3)
Pack-years^e:									
0-0.9	4299	1.6 (1.2-2.0)	14.8 (13.6-16.0)	9.3 (8.4-10.3)	5.0 (4.3-5.7)	0.5 (0.2-0.8)	6.7 (5.9-7.6)	4.1 (3.5-4.7)	2.6 (2.0-3.2)
1-19.9	1905	2.3 (1.5-3.1)	22.3 (20.3-24.3)	12.9 (11.3-14.5)	7.5 (6.2-8.8)	1.9 (1.1-2.6)	13.4 (11.7-15.1)	7.6 (6.3-8.9)	5.8 (4.6-7.0)
20-49.9	1318	5.0 (3.6-6.5)	36.8 (34.0-39.6)	15.7 (13.5-17.9)	18.1 (15.9-20.4)	2.9 (2.0-3.9)	25.4 (22.8-27.9)	11.6 (9.5-13.6)	13.8 (11.8-15.8)
50+	345	10.5 (7.0-14.1)	53.7 (48.0-59.4)	16.0 (12.0-20.1)	28.0 (23.0-32.9)	9.7 (6.2-13.2)	39.3 (33.5-45.0)	12.4 (8.7-16.2)	26.9 (21.6-32.1)
NS-SEC^e:									
Professional	3050	1.9 (1.4-2.4)	17.1 (15.7-18.5)	10.4 (9.3-11.6)	5.7 (4.9-6.5)	1.0 (0.6-1.4)	9.1 (8.0-10.2)	5.6 (4.6-6.5)	3.6 (2.9-4.3)
Intermediate	1859	2.3 (1.6-3.0)	21.9 (19.9-23.9)	12.5 (10.9-14.1)	8.4 (7.0-9.7)	1.1 (0.5-1.7)	12.0 (10.5-13.5)	6.6 (5.4-7.8)	5.4 (4.3-6.5)
Routine	2705	4.0 (3.1-4.8)	26.6 (24.7-28.5)	11.6 (10.3-12.9)	12.3 (10.9-13.7)	2.7 (2.0-3.5)	17.4 (15.8-19.1)	7.7 (6.6-8.9)	9.7 (8.4-11.0)

Abbreviations used: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in 1 second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the lower 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; UKHLS, United Kingdom Household Longitudinal Survey.

1
2
3
4
5
6
7^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts are unweighted; prevalence estimates were weighted.

8^b HSE: reported diagnosed COPD, bronchitis or emphysema; UKHLS: diagnosed bronchitis or emphysema.

9^c FTs: Obstruction (FT): $FEV_1/FVC < 0.70$. Staging classification: stage I ($FEV_1/FVC < 0.70$ and $FEV_1 \geq 80\%$ of predicted); stage II ($FEV_1/FVC < 0.70$ and FEV_1 50-79% of predicted); stage III+ ($FEV_1/FVC < 0.70$ and $FEV_1 < 50\%$ of predicted).

10
11
12^d LLN: Obstruction (LLN): $FEV_1/FVC < LLN$. Staging classification: stage I ($FEV_1/FVC < LLN$ and $FEV_1 > LLN$); stage II ($FEV_1/FVC < LLN$ and $FEV_1 < LLN$).

13
14^e Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2 Sensitivity and Specificity of Fixed Thresholds and Lower Limit of Normal Spirometric Criteria by Age-group, Persons aged 40-95 years Without Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)

	40-64 (n=5544)	65-95 (n=2335)	40-64 (n=5544)	65-95 (n=2335)
	FT using LLN as reference standard		LLN using FT as reference standard	
False positives, (%)	5.1	25.6	0.4	0.0
False negatives, (%)	2.5	0.0	28.0	57.6
Sensitivity	0.975	1.000	0.720	0.424
Specificity	0.949	0.744	0.996	1.000
PPV	0.720	0.424	0.975	1.000
NPV	0.996	1.000	0.949	0.744
Kappa coefficient	0.801	0.479	0.801	0.479
Likelihood ratio positive	18.98	3.90	200.65	N/A
Likelihood ratio negative	0.027	0.000	0.281	0.576
	FT (stage II+) using LLN as reference standard		LLN using FT (stage II+) as reference standard	
False positives, (%)	1.3	8.9	6.3	5.2
False negatives, (%)	49.2	26.7	16.0	39.1
Sensitivity	0.508	0.733	0.840	0.609
Specificity	0.987	0.911	0.937	0.948
PPV	0.840	0.609	0.508	0.733
NPV	0.937	0.948	0.987	0.911
Kappa coefficient	0.597	0.596	0.597	0.596
Likelihood ratio positive	38.82	8.28	13.27	11.67
Likelihood ratio negative	0.499	0.292	0.170	0.412

Abbreviations used: FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); NPV, negative predictive value; PPV, positive predictive value; UKHLS, United Kingdom Household Longitudinal Survey.

Table 3 Results of Logistic and Multinomial Logistic Regressions for Reported Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria Among Persons Aged 40-95 years, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

Characteristics	Diagnosed-COPD ^b	Fixed Thresholds ^c			Lower Limit of Normal ^d		
		Non-obstructed as reference			Non-obstructed as reference		
		stage I	stage II	stage III+	stage I	stage II	
	N	OR (95% CI)	RRR (95% CI)	RRR (95% CI)	RRR (95% CI)	RRR (95% CI)	RRR (95% CI)
Sex:							
Females ^e	4372	1.00	1.00	1.00	1.00	1.00	1.00
Males	3231	0.60 (0.34-1.05)	1.35 (1.16-1.58)	1.35 (1.12-1.63)	1.72 (1.08-2.76)	1.07 (0.88-1.31)	1.20 (0.96-1.50)
<i>P-value</i>		0.075	<0.001	0.002	0.024	0.503	0.107
Age-group:							
40-54 ^e	3416	1.00	1.00	1.00	1.00	1.00	1.00
55-64	2022	1.66 (1.07-2.58)	2.00 (1.63-2.45)	2.13 (1.65-2.73)	6.05 (2.82-12.99)	0.92 (0.72-1.18)	1.57 (1.20-2.06)
65-74	1451	0.96 (0.54-1.70)	2.85 (2.30-3.53)	3.01 (2.32-3.89)	10.11 (4.55-22.49)	0.83 (0.63-1.09)	1.56 (1.16-2.12)
75+	714	1.20 (0.39-3.70)	4.72 (3.66-6.07)	6.67 (5.00-8.90)	22.26 (9.45-52.44)	1.06 (0.74-1.51)	2.20 (1.52-3.17)
<i>P-value</i>		0.104	<0.001	<0.001	<0.001	0.492	<0.001
Pack-years^f:							
0-0.9 ^e	4165	1.00	1.00	1.00	1.00	1.00	1.00
1-19.9	1835	1.38 (0.88-2.17)	1.61 (1.34-1.93)	1.66 (1.29-2.15)	3.82 (1.80-8.14)	1.94 (1.51-2.49)	2.22 (1.58-3.12)
20-49.9	1269	2.91 (1.91-4.45)	2.30 (1.86-2.85)	4.56 (3.64-5.72)	5.91 (2.81-12.45)	3.39 (2.61-4.41)	5.43 (3.98-7.41)
50+	334	5.64 (3.45-9.22)	2.34 (1.63-3.35)	6.83 (4.85-9.63)	17.27 (7.88-37.84)	4.50 (2.96-6.84)	11.20 (7.59-16.52)
<i>P-value</i>		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
NS-SEC^f:							
Professional ^e	3047	1.00	1.00	1.00	1.00	1.00	1.00
Intermediate	1855	1.03 (0.68-1.58)	1.18 (0.97-1.45)	1.34 (1.04-1.72)	1.01 (0.51-2.00)	1.14 (0.88-1.48)	1.35 (0.99-1.85)
Routine	2701	1.61 (1.13-2.31)	1.07 (0.89-1.29)	1.82 (1.47-2.26)	2.30 (1.36-3.88)	1.28 (1.01-1.63)	2.18 (1.67-2.85)
<i>P-value</i>		0.012	0.246	<0.001	0.002	0.123	<0.001
Sample:							
UKHLS ^e	5675	1.00	1.00	1.00	1.00	1.00	1.00
HSE	1928	2.22 (1.60-3.07)	0.95 (0.79-1.14)	0.97 (0.79-1.20)	0.99 (0.62-1.59)	1.05 (0.82-1.33)	0.99 (0.77-1.26)
<i>P-value</i>		<0.001	0.587	0.798	0.967	0.716	0.913
Males × age-group:							
40-54 ^e	1319	1.00	-	-	-	-	-

55-64	876	1.16 (0.54-2.45)	-	-	-	-	-
65-74	664	3.21 (1.40-7.39)	-	-	-	-	-
75+	372	2.61 (0.67-10.22)	-	-	-	-	-
<i>P-value</i>		<i>0.022</i>	-	-	-	-	-

Abbreviations used: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; OR, odds ratios; RRR; relative risk ratios; UKHLS, United Kingdom Household Longitudinal Survey.

^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts are unweighted; ORs and RRRs were weighted.

^b HSE: reported diagnosed COPD, bronchitis or emphysema; UKHLS: diagnosed bronchitis or emphysema.

^c FTs: stage I (FEV₁/FVC <0.70 and FEV₁ ≥80% of predicted); stage II (FEV₁/FVC <0.70 and FEV₁ 50-79% of predicted); stage III+ (FEV₁/FVC <0.70 and FEV₁ <50% of predicted). Reference category: FEV₁/FVC ≥0.70.

^d LLN: stage I (FEV₁/FVC <LLN and FEV₁ >LLN); stage II (FEV₁/FVC <LLN and FEV₁ <LLN). Reference category: FEV₁/FVC ≥LLN.

^e Reference category.

^f Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.

Table 4 Results of Multinomial Logistic Regressions for Combined Outcome Variable Based on Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria Among Persons aged 40-95 years, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-12)^a

Characteristics	Fixed Thresholds ^b			Lower Limit of Normal ^c			
	Neither diagnosed nor obstructive spirometry as reference			Neither diagnosed nor obstructive spirometry as reference			
	Diagnosed alone	Obstructive spirometry alone	Diagnosed and obstructive spirometry	Diagnosed alone	Obstructive spirometry alone	Diagnosed and obstructive spirometry	
	n	RRR (95% CI)	RRR (95% CI)	RRR (95% CI)	RRR (95% CI)	RRR (95% CI)	RRR (95% CI)
Sex:							
Females ^d	4372	1.00	1.00	1.00	1.00	1.00	1.00
Males	3231	0.49 (0.31-0.79)	1.31 (1.16-1.49)	2.23 (1.34-3.71)	0.52 (0.34-0.81)	1.05 (0.90-1.23)	2.15 (1.25-3.71)
<i>P-value</i>		0.003	<0.001	0.002	0.004	0.543	0.006
Age-group:							
40-54 ^d	3416	1.00	1.00	1.00	1.00	1.00	1.00
55-64	2022	1.26 (0.76-2.09)	2.08 (1.76-2.46)	4.06 (2.11-7.79)	1.34 (0.83-2.16)	1.09 (0.90-1.33)	2.91 (1.49-5.68)
65-74	1451	1.47 (0.84-2.55)	3.05 (2.56-3.63)	4.78 (2.38-9.57)	1.27 (0.74-2.15)	1.02 (0.82-1.27)	3.12 (1.53-6.36)
75+	714	1.95 (0.69-5.51)	5.89 (4.76-7.29)	7.55 (3.35-17.02)	1.60 (0.67-3.81)	1.42 (1.08-1.87)	3.47 (1.43-8.40)
<i>P-value</i>		0.388	<0.001	<0.001	0.535	0.085	<0.001
Pack-years^e:							
0-0.9 ^d	4165	1.00	1.00	1.00	1.00	1.00	1.00
1-19.9	1835	1.08 (0.61-1.92)	1.67 (1.42-1.96)	2.84 (1.30-6.23)	1.16 (0.68-2.00)	2.02 (1.63-2.50)	2.58 (1.10-6.01)
20-49.9	1269	3.05 (1.68-5.54)	3.18 (2.70-3.74)	6.70 (3.35-13.40)	2.98 (1.72-5.16)	4.23 (3.44-5.20)	5.74 (2.70-12.20)
50+	334	3.94 (1.70-9.13)	4.15 (3.13-5.49)	18.50 (8.41-40.70)	3.87 (1.81-8.29)	6.83 (4.98-9.37)	17.23 (7.37-40.28)
<i>P-value</i>		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
NS-SEC^e:							
Professional ^d	3047	1.00	1.00	1.00	1.00	1.00	1.00
Intermediate	1855	0.76 (0.45-1.30)	1.20 (1.02-1.41)	1.84 (0.87-3.87)	0.83 (0.50-1.40)	1.19 (0.97-1.47)	1.57 (0.72-3.44)
Routine	2701	0.93 (0.59-1.48)	1.31 (1.12-1.53)	3.65 (1.89-7.06)	1.08 (0.70-1.67)	1.54 (1.27-1.87)	3.37 (1.70-6.68)
<i>P-value</i>		0.612	0.002	<0.001	0.632	<0.001	<0.001
Sample:							
UKHLS ^d	5675	1.00	1.00	1.00	1.00	1.00	1.00
HSE	1928	2.38 (1.54-3.69)	0.94 (0.81-1.09)	1.92 (1.21-3.05)	2.21 (1.46-3.35)	0.96 (0.79-1.16)	2.13 (1.31-3.48)
<i>P-value</i>		<0.001	0.420	0.006	<0.001	0.664	0.002

1
2
3
4
5
6
7
8 **Abbreviations used:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second;
9 FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-
10 scores); NS-SEC, National Statistics Socio-Economic Classification; OR, odds ratios; RRR; relative risk ratios; UKHLS, United Kingdom
11 Household Longitudinal Survey.

12
13 ^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts unweighted; RRRs estimated using
14 survey weights.

15 ^b FTs: Obstruction (FT): FEV₁/FVC <0.70. Diagnosed COPD: HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS:
16 diagnosed bronchitis or emphysema.

17 ^c LLN: Obstruction (LLN): FEV₁/FVC <LLN. Diagnosed COPD: HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS:
18 diagnosed bronchitis or emphysema.

19 ^d Reference category.

20 ^e Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

SUPPLEMENTARY DATA


Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England and Wales

Authors: Shaun Scholes *research associate*,^{1*} Alison Moody *research associate*,¹ Jennifer S Mindell *clinical senior lecturer*¹

¹ Health and Social Surveys Research Group, Research Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London WC1E 6BT, United Kingdom

* Corresponding author. (e-mail: s.scholes@ucl.ac.uk)

Figure S1 Response Flowchart for Wave 2 of UK Household Longitudinal Survey 2010-2012^a




^a Detailed flow diagram of participation in the Wave 2 Nurse Health Assessment can be found in McFall *et al.*

^b Lung function measurements in UKHLS were conducted with two different devices: in England and Wales, the electronic NDD Easy on-PCC spirometer (NDD Medical Technologies, Zurich, Switzerland), and in Scotland the Vitalograph Escort (Vitalograph, Buckingham, UK). For this reason, UKHLS residents living in Scotland were excluded from the analytical sample.

^c Quality criteria for spirometry sessions were as follows (Grades A-C required for inclusion in analytical sample):


Grade	Number of acceptable forced expiratory manoeuvres	Additional criteria
A	At least three	Two highest FVC and FEV ₁ within 100 ml
B	At least three	Two highest FVC and FEV ₁ within 150 ml
C	At least two	Two highest FVC and FEV ₁ within 200 ml
D	Only one	Or best two FEV ₁ or FVC were not within 200 ml
F	None	N/A

Figure S2 Response Flowchart in Health Survey for England 2010

^a Quality criteria for spirometry sessions were as follows (Grades A-C required for inclusion in analytical sample):

Grade	Number of acceptable forced expiratory manoeuvres	Additional criteria
A	At least three	Two highest FVC and FEV ₁ within 100 ml
B	At least three	Two highest FVC and FEV ₁ within 150 ml
C	At least two	Two highest FVC and FEV ₁ within 200 ml
D	One	Or best two FEV ₁ or FVC were not within 200 ml
F	None	N/A

Figure S3 Prevalence of Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometry-Based Definitions, Persons aged 40-95 years, Including and Excluding Participants With Reported Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)



Abbreviations used: FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); UKHLS, United Kingdom Household Longitudinal Survey.

Table S1 Characteristics of Participants in the Analytical Sample, With Diagnosed COPD, and According to Fixed Thresholds and Lower Limit of Normal Spirometry-based Severity Classifications, Persons aged 40-95 years Without Reported Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

	All participants	Reported diagnosed COPD ^b	P value ^c	Fixed Thresholds ^d			P value ^c	Lower Limit of Normal ^e		P value ^c
				stage I	stage II	stage III+		stage I	stage II	
n	7879	207		926	681	116		503	468	
Diagnosed COPD, n (%)	207 (2.8)	207 (100.0)		17 (2.1)	48 (7.1)	33 (30.2)	<0.001	19 (3.9)	65 (14.7)	<0.001
Sex, n (%):										
Males	3335 (46.8)	94 (50.4)	0.349	461 (53.3)	375 (56.0)	75 (66.9)	<0.001	231 (50.5)	255 (57.3)	<0.001
Females	4544 (53.3)	113 (49.7)		465 (46.7)	306 (44.0)	41 (33.1)		272 (49.5)	213 (42.7)	
Age-group, n (%):										
40-54	3472 (46.6)	64 (29.3)	<0.001	235 (28.1)	144 (23.9)	9 (9.3)	<0.001	221 (46.7)	125 (29.8)	<0.001
55-64	2072 (24.8)	69 (30.3)		260 (26.9)	191 (26.5)	38 (29.8)		129 (24.4)	156 (29.6)	
65-74	1557 (17.4)	52 (24.7)		262 (24.8)	195 (25.2)	42 (32.7)		98 (16.8)	115 (23.4)	
75-95	778 (11.1)	22 (15.7)		169 (20.2)	151 (24.5)	27 (28.2)		55 (12.1)	72 (17.2)	
Mean age, years (SD)	57.6 (12.3)	61.8 (11.9)	0.011	62.9 (12.5)	64.4 (12.2)	67.8 (10.1)	<0.001	57.6 (12.1)	61.9 (11.6)	<0.001
Smoking status, n (%):										
Current	1198 (16.6)	61 (28.5)	<0.001	172 (20.7)	218 (33.9)	49 (41.5)	<0.001	156 (33.8)	191 (42.0)	<0.001
Ex-regular	2547 (31.7)	80 (41.6)		369 (38.6)	265 (37.2)	51 (41.8)		174 (34.2)	178 (36.5)	
Never	4134 (51.7)	66 (29.9)		385 (40.8)	198 (28.9)	16 (16.7)		173 (32.0)	99 (21.6)	
Pack-years^f, n (%):										
0-0.9	4299 (53.9)	69 (31.2)	<0.001	406 (43.2)	207 (30.1)	16 (16.7)	<0.001	180 (33.2)	101 (22.1)	<0.001
1-19.9	1905 (24.3)	41 (20.1)		252 (27.0)	137 (20.3)	30 (27.1)		138 (27.8)	101 (22.0)	
20-49.9	1318 (17.2)	63 (31.4)		209 (23.2)	241 (34.9)	38 (29.9)		144 (29.9)	180 (36.9)	
50+	345 (4.6)	33 (17.4)		56 (6.3)	94 (14.3)	32 (26.3)		39 (8.5)	86 (19.1)	
NS-SEC^f, n (%):										
Professional	3050 (36.5)	60 (25.4)	<0.001	312 (32.7)	180 (23.4)	27 (20.8)	<0.001	162 (30.5)	106 (20.3)	<0.001
Intermediate	1859 (23.4)	42 (19.4)		242 (25.2)	152 (21.9)	18 (15.1)		126 (23.3)	97 (19.6)	
Routine	2705 (36.9)	100 (53.2)		322 (36.9)	321 (50.9)	65 (59.6)		195 (43.0)	244 (55.9)	

Abbreviations used: COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the lower 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; SD, standard deviation; UKHLS, United Kingdom Household Longitudinal Survey.

^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts unweighted; means and percentages estimated using survey weights.

^b HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.

^c Within each definition of obstruction, Chi-squared test used to compare categorical variables; ANOVA used to compare mean values of continuous variables.

^d Staging classification for FTs: stage I (FEV₁/FVC <0.70 and FEV₁ ≥80% of predicted); stage II (FEV₁/FVC <0.70 and FEV₁ 50-79% of predicted); stage III+ (FEV₁/FVC <0.70 and FEV₁ <50% of predicted).

^e Staging classification for LLN: stage I (FEV₁/FVC <LLN and FEV₁ >LLN); stage II (FEV₁/FVC <LLN and FEV₁ <LLN).

^f Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.

Table S2 Characteristics of Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometry-based Definitions, Persons aged 40-95 years Without Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

	All participants	Reported diagnosed COPD ^b	P value ^c	Fixed Thresholds ^d			P value ^c	Lower Limit of Normal ^e		P value ^c
				stage I	stage II	stage III+		stage I	stage II	
n	7879	207		926	681	116		503	468	
UKHLS, n (%)	5936 (75.3)	121 (59.6)	<0.001	705 (76.2)	517 (75.6)	87 (74.9)	0.932	377 (75.0)	356 (76.1)	0.922
HSE, n (%)	1943 (24.7)	86 (40.4)		221 (23.8)	164 (24.4)	29 (25.1)		126 (25.0)	112 (23.9)	
Exposure to passive smoking, hours per week (p/w), n (%)^f:										
0	1599 (81.1)	64 (74.8)	0.407	184 (81.4)	130 (76.7)	20 (69.6)	0.233	93 (69.9)	86 (73.7)	0.007
1-9	256 (14.1)	16 (19.3)		32 (15.8)	22 (15.0)	6 (24.4)		25 (23.9)	17 (16.8)	
10+	82 (4.8)	4 (6.0)		5 (2.8)	11 (8.3)	2 (6.1)		7 (6.2)	8 (9.5)	
Mean exposure, hours p/w (SD)	1.8 (7.7)	2.4 (10.1)	0.966	1.5 (7.3)	3.5 (11.7)	3.3 (13.0)	0.068	2.5 (9.2)	3.8 (11.7)	0.091
Lung function measurements, percent-of-predicted, mean (SD)^g:										
FEV ₁	92.0 (16.5)	75.0 (23.4)	<0.001	92.7 (10.0)	69.0 (7.8)	40.2 (7.2)	<0.001	87.2 (8.2)	59.4 (12.9)	<0.001
FVC	97.1 (15.0)	88.6 (15.7)	<0.001	109.2 (11.5)	87.5 (10.9)	65.4 (12.9)	<0.001	108.1 (10.2)	82.5 (14.2)	<0.001
FEV ₁ /FVC	94.2 (9.7)	82.8 (18.2)	<0.001	84.6 (4.6)	78.9 (7.9)	62.9 (13.2)	<0.001	80.4 (4.5)	71.6 (10.6)	<0.001
Comorbidities, n (%)^h:										
Respiratory disease ^{f, h}	65 (3.8)	33 (42.1)	<0.001	6 (3.3)	15 (9.0)	15 (51.5)	<0.001	5 (4.2)	24 (21.7)	<0.001
Respiratory symptoms ^{f, i}	69 (4.0)	12 (13.7)	<0.001	14 (6.4)	16 (11.7)	8 (27.3)	<0.001	7 (5.7)	18 (17.4)	<0.001
Respiratory medicine	375 (4.8)	71 (36.1)	<0.001	41 (4.3)	70 (9.6)	49 (42.7)	<0.001	30 (5.8)	95 (20.2)	<0.001
Cardiovascular disease ^j	493 (6.5)	20 (11.5)	0.012	84 (9.9)	74 (11.1)	24 (24.1)	<0.001	32 (6.8)	49 (12.3)	<0.001
Diabetes	543 (7.1)	18 (10.9)	0.128	54 (6.3)	67 (9.6)	17 (13.1)	0.007	20 (4.4)	39 (7.8)	0.087
Poor self-rated health	398 (5.7)	40 (23.4)	<0.001	37 (4.9)	58 (9.1)	23 (22.8)	<0.001	30 (7.2)	55 (12.6)	<0.001
Breathlessness ^{f, k}	100 (6.7)	23 (34.8)	<0.001	10 (6.9)	18 (13.1)	11 (43.9)	<0.001	8 (10.5)	21 (21.6)	<0.001
Area of residence, n (%)^l:										
Urban	5791 (75.8)	154 (77.2)	0.654	656 (72.6)	515 (76.8)	89 (79.3)	0.125	372 (75.1)	358 (78.0)	0.528
Rural	2087 (24.2)	53 (22.8)		270 (27.4)	166 (23.2)	27 (20.7)		131 (25.0)	110 (22.0)	
BMI:										

Normal	2122 (27.0)	56 (25.7)	0.751	347 (38.0)	182 (27.6)	35 (34.7)	<0.001	202 (40.6)	147 (32.6)	<0.001
Overweight	3235 (41.9)	79 (40.4)		393 (43.4)	298 (44.6)	37 (34.3)		214 (42.8)	177 (38.4)	
Obese	2369 (31.1)	66 (33.8)		165 (18.7)	187 (27.8)	36 (31.0)		77 (16.6)	132 (29.0)	

Abbreviations used: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the lower 5th percentile of Z-scores); MRC, Medical Research Council; NS-SEC, National Statistics Socio-Economic Classification; SD, standard deviation; UKHLS, United Kingdom Household Longitudinal Survey.

^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts unweighted; means and percentages estimated using survey weights.

^b HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.

^c Within each definition of obstruction, Chi-squared test used to compare categorical variables; ANOVA used to compare mean values of continuous variables.

^d Staging classification for FTs: stage I (FEV₁/FVC <0.70 and FEV₁ ≥80% of predicted); stage II (FEV₁/FVC <0.70 and FEV₁ 50-79% of predicted); stage III+ (FEV₁/FVC <0.70 and FEV₁ <50% of predicted).

^e Staging classification for LLN: stage I (FEV₁/FVC <LLN and FEV₁ >LLN); stage II (FEV₁/FVC <LLN and FEV₁ <LLN).

^f Measured in HSE 2010 only.

^g Percent-of-predicted defined as the observed value divided by the predicted value estimated for a person of the same age, gender, ethnicity, and height using the European Respiratory Society Global Lungs Initiative 2012 reference equations¹.

^h Respiratory disease: ICD-10 codes J00-J99.

ⁱ Respiratory symptoms: defined as usually coughing first thing in the morning, for at least 3 months a year, and bringing up phlegm from the chest most days for 3 consecutive months in a year. Missing data: 1 case with missing value.

^j Cardiovascular disease: HSE (longstanding illness): stroke; heart attack/angina; UKHLS (health conditions): coronary heart disease; angina; heart attack/myocardial infarction; stroke.

^k MRC dyspnoea scale: 63 participants with unspecified shortness of breath excluded. MRC grades as follows: 0, only breathless with strenuous exercise; 1: breathless when hurrying on level or up a slight hill; 2: walk slower than people of same age on the level due to breathlessness or stop for breath when walking on level at own pace; 3: stop for breath after walking 100 yards or a few minutes on the level; 4: too breathless to leave house or breathless when dressing.

For peer review only

Reference List

- (1) Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; 40(6):1324-1343.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England and Wales

Shaun Scholes, Alison Moody, Jennifer S Mindell

	Item No	Recommendation	Action taken
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes, we have used pooled cross-sectional analysis in the title.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Structured abstract as in BMJ instructions for authors.
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Background and rationale reported.
Objectives	3	State specific objectives, including any prespecified hypotheses	Specific objectives of the study reported.
Methods			
Study design	4	Present key elements of study design early in the paper	Key elements presented. We have pooled 2 recent cross-sectional surveys containing lung function data.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Settings, locations, and dates specified.
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Eligibility criteria and methods of selection explained. Reason for excluding the Scottish component of UKHLS described in Supplementary data. Response flowcharts for HSE and UKHLS provided as supplementary data.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	All variables in the study clearly described, highlighting, where relevant, differences between the two surveys.
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Data sources, including choice of reference equations for predicted values and Z-scores clearly described.

Bias	9	Describe any efforts to address potential sources of bias	We undertook descriptive analysis of participants with and without good-quality spirometry data. Implications of bias are mentioned in the discussion.
Study size	10	Explain how the study size was arrived at	Response flowcharts for HSE and UKHLS provided as supplementary data.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Groupings of quantitative variables clearly set out in the method section.
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Statistical methods described in detail.
		(b) Describe any methods used to examine subgroups and interactions	Statistical methods described in detail.
		(c) Explain how missing data were addressed	Exclusion of participants with missing data for two variables clearly set out in the methods section.
		(d) If applicable, describe analytical methods taking account of sampling strategy	Described in the statistical analyses section. We accounted for the clustering of observations using the svy module in Stata.
		(e) Describe any sensitivity analyses	Sensitivity analyses described in detail.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Response flowcharts for HSE and UKHLS provided as supplementary data.
		(b) Give reasons for non-participation at each stage	Response flowcharts for HSE and UKHLS provided as supplementary data.
		(c) Consider use of a flow diagram	Response flowcharts for HSE and UKHLS provided as supplementary data.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Characteristics of study participants (across all variables) are provided as supplementary data.
		(b) Indicate number of participants with missing data for each variable of interest	Numbers with missing data presented as footnote in the tables.

Outcome data	15*	Report numbers of outcome events or summary measures	Outcome data is presented as prevalence.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Both sets of estimates (unadjusted and adjusted) presented.
		(b) Report category boundaries when continuous variables were categorized	Details provided.
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Results of sensitivity analyses provided.
Discussion			
Key results	18	Summarise key results with reference to study objectives	Details provided.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Limitations and potential biases discussed in detail.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Cautious throughout.
Generalisability	21	Discuss the generalisability (external validity) of the study results	Generalisability briefly discussed.
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Details provided.

BMJ Open

Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England and Wales

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005685.R1
Article Type:	Research
Date Submitted by the Author:	07-Jul-2014
Complete List of Authors:	Scholes, Shaun; University College London, Health and Social Surveys Research Group, Dept of Epidemiology and Public Health London Moody, Alison; University College London, Health and Social Surveys Research Group, Dept of Epidemiology and Public Health London Mindell, Jenny; University College London, Dept of Epidemiology and Public Health London
Primary Subject Heading:	Public health
Secondary Subject Heading:	Respiratory medicine, Epidemiology, Research methods, Health informatics
Keywords:	EPIDEMIOLGY, PUBLIC HEALTH, PRIMARY CARE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts

1
2
3 **Title:** Estimating population prevalence of potential airflow obstruction using different
4
5 spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England
6
7 and Wales
8
9

10 **Running head:** Comparison of different spirometric cut-offs
11

12 **Authors:** Shaun Scholes *research associate*,^{1*} Alison Moody *research associate*,¹ Jennifer S
13
14 Mindell *clinical senior lecturer*¹
15

16
17
18 ¹ Health and Social Surveys Research Group, Research Department of Epidemiology and
19
20 Public Health, University College London, 1-19 Torrington Place, London WC1E 6BT,
21
22 United Kingdom
23

24
25 * Corresponding author. (e-mail: s.scholes@ucl.ac.uk)
26
27

28
29
30 **Keywords:** airflow obstruction; chronic obstructive pulmonary disease; fixed thresholds;
31
32 Health Survey for England; lower limit of normal; respiratory; sensitivity; specificity;
33
34 spirometry; United Kingdom Household Longitudinal Survey
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Consistent estimation of the burden of chronic obstructive pulmonary disease (COPD) has been hindered by differences in methods, including different spirometric cut-offs for impaired lung function. The impact of different definitions on the prevalence of potential airflow obstruction, and its associations with key risk factors, is evaluated using cross-sectional data from two nationally-representative population surveys.

Design: Pooled cross-sectional analysis of Wave 2 of the UK Household Longitudinal Survey and the Health Survey for England 2010, including 7879 participants, aged 40-95 years, who lived in England and Wales, without diagnosed asthma, and with good-quality spirometry data. Potential airflow obstruction was defined using self-reported physician-diagnosed COPD; a fixed threshold (FT) forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio <0.70; and an age-, sex-, height- and ethnic-specific lower limit of normal (LLN). Standardised questions elicited self-reported information on demography, smoking history, ethnicity, occupation, respiratory symptoms, and cardiovascular disease.

Results: Consistent across definitions, participants classed with obstructed airflow were more likely to be older, currently smoke, have higher pack-years of smoking, and be engaged in routine occupations. The prevalence of airflow obstruction was 2.8% (95% CI 2.3-3.2), 22.2% (21.2-23.2), and 13.1% (12.2-13.9) according to diagnosed COPD, FT and LLN, respectively. The gap in prevalence between FT and LLN increased in older age-groups. Sex differences in the risk of obstruction, after adjustment for key risk factors, was sensitive to the choice of spirometric cut-off, being significantly higher in men when using FT, compared with no significant difference using LLN.

Conclusions: Applying FT or LLN spirometric cut-offs gives a different picture of the size and distribution of the disease burden. Longitudinal studies examining differences in

1
2
3 unscheduled hospital admissions and risk of death between FT and LLN may inform the
4
5 choice as to the best way to include spirometry in assessments of airflow obstruction.
6
7

8 **Word count:** 3940
9

10 **Non-text material:** 4 Tables
11

12 **Strengths and limitations of this study** 13

- 14
15
16 • Estimates of the burden of chronic obstructive pulmonary disease (COPD) using
17 spirometry data collected in epidemiological studies are inconsistent through
18 differences in methods, including different spirometric cut-offs.
19
20
21
22
- 23 • Our study combined two nationally representative samples of adults living in England
24 and Wales, with standardised protocols and objective measurements of lung function,
25 and a wide-range of clinically-relevant conditions including self-reported respiratory
26 symptoms (chronic cough and phlegm) and breathlessness.
27
28
29
- 30 • Consistent definitions and up-to-date reference equations were used, providing
31 baseline data for monitoring purposes in the UK, and for facilitating comparison with
32 international studies.
33
34
35
- 36 • Prevalence estimates were based on pre-bronchodilator lung function measurements,
37 and so are likely to overestimate true prevalence.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterised by a progressive decline in lung function.^{1,2} 2.9 million deaths were attributed to COPD in 2010, making it the third leading global cause of death.³ The National Outcomes Strategy for COPD estimated that 835,000 people living in the UK are currently diagnosed with COPD, with a further 2.2 million being undiagnosed.⁴ COPD is the second leading cause of emergency hospital admission and is one of the most costly diseases in terms of acute hospital care in England.⁴ Healthcare budgeting is often contingent upon the estimated burden of disease. Spirometry, the mainstay of lung function assessment, has been used in nationally-representative surveys to estimate the COPD burden in terms of prevalence, associated comorbidities, and mortality. Estimation of the disease burden has been hindered, however, by differences in methods, including spirometric cut-offs.⁵⁻⁸ Fixed thresholds (FTs) use cut-offs for lung function measurements (e.g., forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio <0.70) regardless of age, sex, height, and ethnicity.⁹ An additional threshold for percent-of-predicted FEV₁ (expected for persons of a given age, sex, height and ethnicity) is also commonly used for severity classification. In contrast, a lower limit of normal (LLN) cut-off uses a statistical definition of abnormal/normal (e.g., below/above the lower 5th percentile of the distribution of age-, sex-, height-, and ethnic-specific FEV₁/FVC values from a healthy, lifelong non-smoking population).¹⁰

At present, applying FTs such as FEV₁/FVC <0.70 is the standard approach. However, the European Respiratory Society (ERS) Task Force on epidemiology recently advocated using the LLN in epidemiological studies as FTs both overestimate airflow obstruction in older populations, due to the physiological reduction of FEV₁/FVC with age, and underestimate in

1
2
3 young adults, compared with LLN.¹¹⁻¹⁶ The controversy over FT-versus-LLN thresholds is
4
5 well-known with no signs of a consensus among expert groups being agreed.¹⁷⁻²¹
6
7

8 Partly as a result of this controversy, the COPD epidemiological database shows
9
10 heterogeneity in definitions and consequential estimates of the disease burden.^{5;22} Two
11
12 nationally-representative samples, Wave 2 (2010-2012) of the UK Household Longitudinal
13
14 Survey (UKHLS, 'Understanding Society') and the Health Survey for England (HSE) 2010,
15
16 collected lung function data using identical measurement protocols and specialist equipment,
17
18 providing an opportunity to increase statistical precision by combining both datasets.
19

20
21 Therefore, the primary objective of the present study was to compare the prevalence of
22
23 'potential' airflow obstruction according to FT- and LLN-thresholds among persons aged 40-
24
25 95 years living in England and Wales: potential in the sense that the administration of
26
27 bronchodilators to measure the extent of reversibility in airflow obstruction was not used. As
28
29 a secondary aim, we compared the sensitivity of associations with risk factors including age,
30
31 sex, smoking history, and socioeconomic position. Using the same variables, we also
32
33 examined the characteristics associated with spirometry in connection with self-reported
34
35 physician-diagnosed COPD.
36
37

38 39 **METHODOLOGY**

40 41 **Study design and setting**

42
43 Both the UKHLS and HSE selected participants using stratified multi-stage probability
44
45 sampling designs.²³ Self-reported health information, risk factors and demographics was
46
47 collected through face-to-face interviews, followed by a visit from a trained nurse during
48
49 which lung function was measured. Response rates for the Wave 2 interview (among
50
51 individuals issued) and nurse-visit (among eligible participants in the Wave 2 interview) were
52
53 61% and 59% respectively in UKHLS. In HSE 2010, interview (among the estimated total
54
55
56
57

1
2
3 number of adults in sampled households) and nurse-visit (adults in co-operating households)
4
5 response rates were 59% and 57%. Sampling methods are described elsewhere.²⁴⁻²⁶ Ethical
6
7 approval was obtained from the Oxfordshire A (UKHLS) and B (HSE 2010) Research Ethics
8
9 Committees.. Eligible participants gave written consent to participate in spirometry.
10

11 12 **Questionnaire and procedures**

13
14 Participants were excluded from spirometry for the following safety reasons: pregnancy; had
15
16 in the last 3 months abdominal/chest surgery, a heart attack, detached retina or eye or ear
17
18 surgery; admitted to hospital with a heart complaint in the preceding month; a resting pulse
19
20 rate >120 beats/minute; or currently taking medications for the treatment of tuberculosis.
21
22

23 Spirometry, without bronchodilator use, was conducted using NDD EasyOne PCC
24
25 spirometers (NDD Medical Technologies, Zurich, Switzerland). Quality control was
26
27 summarised in a session grade based on the number of technically acceptable blows and their
28
29 reproducibility. Grades A (3 acceptable manoeuvres, 2 highest FVC and FEV₁ within 100
30
31 ml), B (3 acceptable manoeuvres, 2 highest FVC and FEV₁ within 150 ml), and C (2 or 3
32
33 acceptable manoeuvres within 200 ml) were considered good-quality. Full details on
34
35 measurement procedures are available elsewhere.²⁵⁻²⁷
36
37

38
39 The highest values for FEV₁ and for FVC, from at least 3 and up to 8 blows, were used. Age-,
40
41 sex-, height-, and ethnic-specific predicted values and Z-scores (FEV₁, FVC and FEV₁/FVC)
42
43 were computed using the ERS Global Lungs Initiative (GLI 2012, www.lungfunction.org)
44
45 reference equations. These have been prepared by an international collaboration based on
46
47 data spanning 26 countries from >70,000 healthy individuals across four ethnic-groups
48
49 (Caucasian, African-American, and North- and South-East Asian), valid for persons aged 3-
50
51 95 years^{28,29} and have been shown to fit contemporary Australasian spirometric data.³⁰
52
53
54

55 56 ***FT and LLN spirometric cut-offs***

Using FTs, we applied the 2007 Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification³¹, which was designed for use with post-bronchodilator spirometry: potential airflow obstruction was defined as $FEV_1/FVC < 0.70$ (FT). Disease stage was defined by the reduction in FEV_1 relative to percent-of-predicted values as follows: stage I ($FEV_1/FVC < 0.70$ and $FEV_1 \geq 80\%$ predicted); stage II ($FEV_1/FVC < 0.70$ and FEV_1 50-79% predicted); and stage III+ ($FEV_1/FVC < 0.70$ and $FEV_1 < 50\%$ predicted).³² Participants with $FEV_1/FVC \geq 0.70$ were defined as non-obstructed.

Participants with $FEV_1/FVC < LLN$ (below the lower 5th percentile of the distribution of Z-scores) were defined as obstructed (LLN). To examine possible heterogeneity among participants with $FEV_1/FVC < LLN$, disease stage was defined by FEV_1 relative to LLN as follows: stage I ($FEV_1/FVC < LLN$ and $FEV_1 \geq LLN$), and stage II ($FEV_1/FVC < LLN$ and $FEV_1 < LLN$).³³ Participants with $FEV_1/FVC \geq LLN$ were defined as non-obstructed. The 5th percentile was chosen due to its established associations with respiratory symptoms and all-cause mortality.³⁴

Physician-diagnosed COPD

In UKHLS, disease status was ascertained through questions asking “*has a doctor or other health professional ever told you that you have [disease]?*” Diagnosed COPD was defined as a positive response to either chronic bronchitis or emphysema. In HSE, diagnosed COPD was defined as a positive response to the question “*did a doctor ever tell you that you had chronic bronchitis, emphysema or COPD?*”

Risk factors, measurements of lung function, and comorbidities

Key subgroups were defined by age (40-54, 55-64, 65-74, 75-95); sex; smoking status (current, former, never); pack-years of cigarette smoking (a cumulative total reflecting the amount and duration of consumption, with 1 pack-year equating to an average of 20

1
2
3 cigarettes smoked/day for 1 year); and socioeconomic position, defined by the National
4
5 Statistics Socio-Economic Classification (NS-SEC), grouped into professional, intermediate,
6
7 and routine occupations.
8

9
10 FEV₁, FVC, and FEV₁/FVC, on a continuous scale, were expressed as percent-of-predicted
11
12 values. Additional variables included current use of respiratory medicine; area of residence
13
14 (urban/rural); body mass index (BMI: weight in kilograms divided by the square of height in
15
16 metres), grouped into normal weight (18.5-24.9kg/m²), overweight (25.0-29.9kg/m²), and
17
18 obese (≥ 30 kg/m²); diagnosed diabetes; poor self-rated health; and reported cardiovascular
19
20 disease (stroke, angina, myocardial infarction). In HSE, participants were asked to name any
21
22 long-standing illnesses: respiratory diseases were identified using *International Classification*
23
24 *of Diseases, Tenth Revision* codes J00-J99. In the HSE, presence of respiratory symptoms
25
26 was defined as usually coughing first thing in the morning, for at least 3 months/year, and
27
28 bringing up phlegm from the chest most days for 3 consecutive months in a year. In the HSE,
29
30 participants with some limitation of activity due to breathlessness during daily living were
31
32 identified by a score of 3+ on the Medical Research Council (MRC) dyspnoea scale.
33
34 Exposure to passive smoking in the HSE was measured by reported number of hours/week
35
36 currently exposed to cigarette smoke (0, 1-9, and ≥ 10 hours).
37
38
39
40

41 **Statistical analyses**

42
43
44 A lower age limit was used of 40 years due to the low prevalence of non-asthma airflow
45
46 obstruction in the youngest age-groups.³⁵ As bronchodilators were not used, we excluded
47
48 participants who reported diagnosed asthma.^{34;36-38} Five sets of analyses were conducted
49
50 across the categories of diagnosed COPD, FT, and LLN. First, participants' characteristics
51
52 (demographics, risk factors, comorbidities and percent-of-predicted FEV₁, FVC, and
53
54 FEV₁/FVC) were summarised as means, accompanied by standard deviations, or as counts
55
56
57
58
59
60

1
2
3 accompanied by percentages. Participants were counted under each relevant definition.

4
5 Participants with/without obstruction were compared using the χ^2 test and analysis of
6
7 variance for categorical and continuous variables respectively.³⁹
8
9

10 Secondly, prevalence estimates were computed for a subset of socio-demographic variables
11
12 defined by age, sex, smoking status, pack-years of cigarette smoking, and NS-SEC. Thirdly,
13
14 in the absence of a gold standard, we calculated the sensitivity and specificity of each
15
16 spirometric criterion, using the alternative cut-off as the reference standard.⁴⁰
17
18

19 Fourth, regression analyses were performed using age, sex, pack-years of smoking, and NS-
20
21 SEC as independent variables with airflow obstruction as outcome. Current smoking status
22
23 could not be entered in the same model as pack-years due to significant collinearity. The
24
25 dependent variable based on FTs had 4 categories: non-obstructed, stage I, stage II, and stage
26
27 III+. The LLN-derived outcome had 3 categories: non-obstructed, stage I, and stage II. In
28
29 each case, multinomial logistic regression was used to estimate relative risk ratios (RRRs),
30
31 with non-obstructed as the reference category. Multinomial logistic regression generalises
32
33 logistic regression to outcomes with more than two possible discrete outcomes. The RRR is
34
35 interpreted as the relative risk of one outcome in relation to the reference category for a
36
37 specified category of an independent variable compared with the reference.^{41;42} Diagnosed
38
39 COPD was analysed as a binary outcome (not reported/reported): logistic regression was
40
41 therefore used to estimate odds ratios (ORs).^{39;41} The overall association for independent
42
43 variables with >2 categories was computed using the adjusted Wald test. The likelihood-ratio
44
45 test was used to estimate the statistical significance of interaction terms: non-significant terms
46
47 were excluded, and models refitted with only the main effects.
48
49
50
51

52 Fifth, to examine risk factors associated with possible under-diagnosis, a four-category
53
54 outcome variable was created combining diagnosed COPD and spirometric criteria as
55
56
57
58
59
60

1
2
3 follows: (1) neither diagnosed nor spirometrically-defined obstruction; (2) physician-
4 diagnosed COPD but no obstructive spirometry; (3) spirometrically-defined but no diagnosed
5 COPD; and (4) both diagnosed and obstructive spirometry.⁴³ FT and LLN cut-offs were
6 analysed separately. RRRs generated from multinomial logistic regressions were used to
7 examine associations between the same set of risk factors listed above and the composite
8 dependent variable.
9

10
11
12 Participants with missing values on covariates were excluded from relevant analyses. Tests of
13 statistical significance were based on two-sided probability ($P<0.05$). Dataset preparation was
14 performed in SPSS 20.0 (SPSS IBM Inc., Chicago, Illinois, USA), Stata 13.1 (StataCorp,
15 College Station, Texas, USA) and R (version 3.0.3; R Foundation, www.r-project.org).
16

17
18 Analysis was conducted in Stata accounting for the complex design of both surveys, using the
19 appropriate weighting variables and Primary Sampling Units. Both datasets are available via
20 the UK Data Service (www.ukdataservice.ac.uk).
21
22

23 24 25 **Sensitivity analyses**

26
27 Analyses were initially undertaken excluding participants with reported diagnosed asthma
28 and then repeated including those with asthma. In accordance with previous UK National
29 Institute for Health and Care Excellence (NICE) recommendations⁴⁴, comparisons between
30 FT and LLN were rerun defining only the subset of FT participants with $FEV_1 < 80\%$
31 predicted (i.e., stage II+) as having obstructed airflow.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

The analytical sample comprised 7879 participants (5936 and 1943 from UKHLS and HSE respectively) aged 40-95 years, who resided in England and Wales, did not report diagnosed asthma, had valid values of height and ethnicity, and provided good-quality spirometry.

Response flowcharts for the UKHLS and HSE are provided in Figures S1 and S2 (online supplementary appendix) respectively. Excluded participants were more likely to be older, engaged in routine occupations, and self-report respiratory symptoms (data not shown).

Differences between the UKHLS and HSE in terms of sex ratio, age, smoking history, NS-SEC, and objective measurements of lung function were not materially important (see online supplementary Table S1).

Descriptive characteristics of the analytical sample according to physician-diagnosed COPD, FT, and LLN are shown as supplementary data (Tables S2-S3). Overall, 46.8% of participants were male, with mean age 57.6 years (SD 12.3), 16.6% were current smokers, 4.6% had >50 pack-years of cigarette smoking, and 36.5% were engaged in professional occupations. 12 (0.1%) and 265 (3.2%) participants had missing values for pack-years and NS-SEC respectively. The prevalence of diagnosed COPD was similar between the sexes ($P=0.349$), but was higher for men using FT and LLN (both $P<0.001$). Participants with diagnosed COPD/obstructive spirometry were more likely to be older, currently smoke, have higher pack-years of smoking, and be engaged in routine occupations (all $P<0.001$).

Prevalence of diagnosed COPD was higher in HSE vs. UKHLS ($P<0.001$), but survey-specific prevalence was similar for FT and for LLN. Participants with diagnosed COPD/obstructive spirometry were more likely to report respiratory symptoms (chronic cough and phlegm) and disease, current use of respiratory medications, cardiovascular disease, breathlessness, poor self-rated health and have, on average, lower (percent-of-predicted) values of FEV₁, FVC and FEV₁/FVC. The prevalence of respiratory symptoms

1
2
3 was 13.7%, 10.2%, and 11.3% among participants classed as having airflow obstruction
4
5 according to diagnosed COPD, FT, and LLN respectively; prevalence of having a score of 3+
6
7 on the MRC dyspnoea scale was 34.8%, 12.3% and 15.9%.
8
9

10 **Prevalence of airflow obstruction**

11
12 The prevalence of airflow obstruction was 2.8%, 22.2%, and 13.1% using diagnosed COPD,
13
14 FT, and LLN respectively (**Table 1**). Using FTs, 11.6%, 8.9%, and 1.7% of participants were
15
16 classed as stage I, stage II, and stage III+ respectively. LLN-derived obstruction was 6.6%
17
18 (stage I) and 6.4% (stage II). For most subgroups, prevalence was highest for FT and lowest
19
20 for diagnosed COPD, with LLN falling in-between. The gap in prevalence between FT and
21
22 LLN increased in older age-groups. Prevalence among participants aged 40-54 years was
23
24 11.9% and 10.7% using FT and LLN respectively. Prevalence among participants aged 75-95
25
26 was 45.0% and 17.2%.
27
28
29

30
31 **Table 2** shows estimates of sensitivity and specificity for FT and LLN, using the alternative
32
33 spirometric cut-off as the reference standard. When using LLN as reference, specificity - the
34
35 percentage of participants classed as non-obstructed using LLN identified as non-obstructed
36
37 using FT – decreased from 94.9% amongst participants aged 40-64 years to 74.4% amongst
38
39 those aged 65-95.
40
41

42 **Multivariate analyses of airflow obstruction**

43
44
45 **Table 3** shows the significant risk factors for diagnosed COPD, and the FT- and LLN-disease
46
47 stage classifications (non-obstructed as reference category). For diagnosed COPD, the
48
49 significant interaction between sex and age-group ($P=0.022$) suggested no difference in odds
50
51 between the sexes among participants aged 40-64 years, but higher odds among men aged 65-
52
53 95. Using FTs, being male was associated with a significantly increased risk of airflow
54
55 obstruction: RRR 1.35 (95% CI: 1.16-1.58), RRR 1.35 (1.12-1.63), and RRR 1.72 (1.08-2.76)
56
57
58
59
60

1
2
3 for stages I, II, and III+ respectively. In contrast, sex differences were not significant using
4
5 LLN: RRR 1.07 (0.88-1.31) for stage I, and RRR 1.20 (0.96-1.50) for stage II.
6
7

8 Odds of diagnosed COPD increased significantly with age only in men ($P=0.022$ for the
9
10 interaction term). Using non-obstruction as reference, RRRs increased significantly with age
11
12 when using FTs ($P<0.001$ for each stage). The age-related difference using LLN was more
13
14 marked for stage II ($P=0.492$ and $P<0.001$ for stages I and II, respectively). A dose-related
15
16 increased risk with pack-years of cigarette smoking was observed across each definition
17
18 ($P<0.001$). The difference between NS-SEC levels was more marked with diagnosed COPD
19
20 ($P=0.012$) and the tightest FT- and LLN-definitions (FT: $P=0.002$ stage III+; LLN: $P<0.001$
21
22 stage II).
23
24

25 26 **Combination of diagnosed COPD and spirometric cut-offs**

27
28 The significant risk factors for the two four-category outcome variables created as a
29
30 composite of diagnosed COPD and obstructive spirometry are shown in **Table 4**. Relative to
31
32 the reference category (neither doctor-diagnosed nor spirometrically-defined airflow
33
34 obstruction), the risk of reporting COPD in the absence of obstructive spirometry was
35
36 significantly lower in men using either spirometric criterion (FT: RRR 0.53 (95% CI: 0.32-
37
38 0.87); LLN: RRR 0.56 (0.35-0.89)). The risk of having obstructed airflow using spirometry
39
40 but with no diagnosed COPD – thereby indicating possible under-diagnosis - was
41
42 significantly higher in men, and in older age-groups, when using FT but not LLN. For both
43
44 spirometric criterion, increases in risk with increasing pack-years of cigarette smoking,
45
46 relative to the reference, was consistent across combinations of COPD/obstructive
47
48 spirometry; the difference between NS-SEC levels was more marked for obstructive
49
50 spirometry; the difference between NS-SEC levels was more marked for obstructive
51
52 spirometry.
53
54

55 56 **Sensitivity analyses**

1
2
3 Repeating analyses by including 1183 participants with reported diagnosed asthma increased
4 prevalence of diagnosed COPD, FT and LLN by 2-3 percentage points (Figure S3, online
5 supplementary appendix), but showed similar patterns of association with risk factors.
6
7

8
9
10 Diagnosed asthma was a strong predictor of diagnosed COPD and obstructive spirometry
11 (P<0.001, data not shown). Narrowing FT-defined obstruction to the subset of FT participants
12 with FEV₁ <80% predicted (i.e., stage II+) more than halved the FT-derived prevalence
13 (22.2% vs. 10.6%). Amongst participants aged 65-95 years, specificity using LLN as the
14 reference standard was 74.4% and 91.1% for FT and FT stage II+ respectively (**Table 2**).
15
16
17
18
19

20 Patterns of association with risk factors using FT stage II+ was similar to those shown for FT.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Consistent estimation of the COPD burden has been hindered by differences in methods, including disagreement among experts over the choice of FT-versus-LLN spirometric cut-offs.⁵⁻⁸ In this study, we combined two nationally-representative surveys, with standardised protocols and objective lung function measurements, to evaluate the impact of different definitions on the prevalence of potential airflow obstruction, and its associations with key risk factors. Participants with diagnosed COPD/obstructive spirometry were more likely to be older, currently smoke, have higher pack-years of cigarette smoking, be in lower socioeconomic groups, and report the presence of respiratory symptoms (chronic cough and phlegm), cardiovascular disease, breathlessness, and poor self-rated health. Among persons aged 40-95 years without physician-diagnosed asthma, prevalence was 2.8%, 22.2%, and 13.1%, according to diagnosed COPD, FT, and LLN respectively. The gap in prevalence between FT and LLN increased in older age-groups. When using LLN as the reference standard, specificity for FT decreased from 94.9% amongst participants aged 40-64 years to 74.4% amongst participants aged 65-95, corresponding to false-positive rates of 5.1% and 25.6% respectively. Sex differences in the risk of obstructed airflow, after adjustment for potential confounders, was sensitive to spirometric criteria, being higher among men for FT, compared with no difference using LLN.

Strengths and limitations

Analyses were based on nationally-representative samples, with identical measurement protocols and specialist equipment for collecting lung function data. Combining the HSE and UKHLS datasets increased statistical precision for spirometry-based estimates, particularly for population subgroups, and allowed detailed analyses to be conducted. Predicted values and Z-scores were obtained from the ERS GLI 2012 reference equations²⁸, facilitating inclusion of older participants, non-white populations and comparability with international

1
2
3 studies. Our study has a number of limitations. Reversibility in airflow obstruction could not
4
5 be assessed due to bronchodilators not being used. Spirometry-based prevalence, therefore,
6
7 may be overestimated. Analysis of the National Health and Nutrition Examination Survey
8
9 (NHANES) 2007-2010 showed that FT- and LLN-prevalence estimates among US adults
10
11 aged 40-79 years decreased, in relative terms, by approximately one-third after administration
12
13 of bronchodilators.⁴⁵ Although recent guidelines from NICE⁴⁶ and ERS¹³ recommend use of
14
15 post-bronchodilator spirometry to confirm the presence of airflow obstruction, debate
16
17 continues over its use in epidemiological settings, with the arguments against including
18
19 ethical issues such as possible side-effects and contraindications.⁴⁷ Potential misclassification
20
21 of disease status through bronchodilators not being used was reduced by excluding
22
23 participants with physician-diagnosed asthma. Some participants in the analytical sample,
24
25 however, may be undiagnosed asthmatics. On the other hand, the disease burden may be
26
27 underestimated through excluding participants with poor-quality spirometry. Participation in
28
29 spirometry, and achievement of good-quality standards among participants with any
30
31 spirometry data, was higher among participants of younger age, engaged in
32
33 professional/managerial occupations, non-smokers, and with no physician-diagnosed COPD.
34
35 Lower survey participation rates amongst socio-demographic groups at higher risk of airflow
36
37 obstruction (e.g., older persons, lower socioeconomic groups) would also have led to an
38
39 underestimation of true prevalence. These limitations, however, are unlikely to affect
40
41 comparisons across definitions, but may have led to an underestimate of risk associations.
42
43 The list of health conditions in the UKHLS interview programme included chronic bronchitis
44
45 and emphysema but not COPD, leading to potential underestimation of self-reported
46
47 physician-diagnosed COPD.
48
49
50
51
52
53

54 **Comparisons with previous studies**

55
56
57
58
59
60

1
2
3 Earlier analyses of HSE data ^{36;38;48} used older reference equations ^{49;50} applicable only to
4
5 white, younger populations. Nevertheless, estimates of prevalence and their substantive
6
7 conclusions of higher prevalence using FT-versus-LLN, with a widening gap in prevalence in
8
9 older age-groups, and sex differences when using FT but not LLN were similar to ours:
10
11 confirming findings reported in the US ⁴⁵, Europe ⁵¹, Korea ¹⁶, internationally ¹², and in recent
12
13 literature reviews.^{6;52} A further strength of our study was the wide range of clinically-relevant
14
15 conditions examined in the context of disease-staging, with higher prevalence of respiratory
16
17 symptoms, respiratory- and cardiovascular-disease, breathlessness, and poor self-rated health
18
19 among participants in the tightest definitions of FT- and LLN-obstruction, confirming similar
20
21 findings in the US.^{53;54} Whilst recent guidelines ^{13;46;55} recommend adopting
22
23 multidimensional definitions of respiratory disease, our study outcomes were defined only
24
25 using spirometry. While we acknowledge the merits of a multidimensional approach, and
26
27 agree that neither spirometric cut-off is able to fully characterise the complex diagnostic
28
29 features of COPD ⁵⁶, our primary aim was to use up-to-date survey data to evaluate
30
31 differences in prevalence according to FT- and LLN-thresholds, to provide baseline data for
32
33 monitoring purposes in the UK, and promote comparability with international studies.
34
35 Current recommendations regarding symptom criteria are less specific than those for
36
37 spirometry. We chose, therefore, to examine the associations between disease-staging
38
39 assessed only using spirometry and presence of respiratory symptoms, rather than broaden
40
41 the definition of disease.
42
43
44
45
46
47

48 **Implications**

49
50 Recent UK studies used administrative primary-care databases to report the number of
51
52 diagnosed and treated patients, thereby missing undiagnosed cases. Such studies have
53
54 reported prevalence below 2%.^{57;58} The disparity in prevalence from clinical-versus-

1
2
3 epidemiological studies led to the development of the COPD prevalence model, with the HSE
4
5 2001 used as input data, to more accurately estimate prevalence.⁵⁹ In accordance with
6
7 previous NICE recommendations⁴⁴, COPD is currently defined in the model as FT stage II+
8
9 (FEV₁/FVC <0.70 and FEV₁ <80% predicted), with the logistic regression models showing
10
11 sharp increases with age and a modifying effect of gender.^{60;61} Similar to the findings
12
13 reported by Jordan et al.³⁶, our study shows that the strength of association between risk
14
15 factors and airflow obstruction varies according to spirometric criterion, with age- and sex-
16
17 differences in risk being more marked for FT, and for FT stage II+, than LLN. In the absence
18
19 of agreement among experts, policy-makers, clinicians, and researchers building the COPD
20
21 epidemiological database, it is important to appreciate the sensitivity of estimates of the
22
23 disease burden, and its distribution across socio-demographic groups, to differences in
24
25 methods, including spirometric cut-offs.
26
27
28

29
30 The prevalence of reported physician-diagnosed COPD in our study was 2.8%, considerably
31
32 lower than spirometry-based estimates, possibly indicating considerable under-recognition by
33
34 both participants and physicians. Using the tightest definitions, prevalence of physician-
35
36 diagnosed COPD among participants with obstructive spirometry was 30.2% (FT stage III+)
37
38 and 14.7% (LLN stage II). Similar low rates of physician-diagnosis among participants
39
40 meeting spirometric criteria have been reported in New Zealand.⁶² Spirometrically-defined
41
42 airflow obstruction but no diagnosed COPD does not necessarily indicate under-diagnosis.
43
44 Definitive diagnosis requires further information on all relevant clinical factors, particularly
45
46 respiratory symptoms and smoking history, as well as post-bronchodilator spirometry.
47
48
49

50 **Conclusion**

51
52 In summary, we have enhanced the COPD epidemiological database by evaluating the impact
53
54 of different definitions on the prevalence of potential airflow obstruction and its associations
55
56 with key risk factors and comorbidities. With no gold standard currently available,
57
58
59
60

1
2
3 longitudinal studies examining differences in unscheduled hospital admissions and risk of
4
5 death between FT and LLN may inform the choice as to the best way to include spirometric
6
7 data in multidimensional assessments of airflow obstruction in both clinical and
8
9 epidemiological settings.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Abbreviations:** COPD, chronic obstructive pulmonary disease; ERS, European Respiratory
4 Society; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FT, fixed
5 thresholds; GLI, Global Lungs Initiative; GOLD, Global Initiative for Chronic Obstructive
6 Lung Disease; HSE, Health Survey for England; LLN, lower limit of normal; NICE, National
7 Institute for Health and Care Excellence; UKHLS, United Kingdom Household Longitudinal
8 Survey
9

10
11 **Acknowledgements:** The authors thank Deborah Jarvis, Janet Stocks and Jessica
12 Sheringham for helpful comments.
13

14 **Ethics approval:** Ethical approval for collecting biosocial data in UKHLS was obtained from
15 the Oxfordshire A Research Ethics Committee (10/H0604/2); approval for HSE 2010 was
16 obtained from the Oxfordshire B Research Ethics Committee (09/H0605/73). Eligible
17 participants gave written consent to participate in spirometry.
18
19

20 **Funding:** The study did not receive any specific funding. The Health Survey for England
21 2010 was funded by the Health and Social Care Information Centre (HSCIC). The views
22 expressed here are those of the authors and not of the HSCIC, Department of Health, or the
23 National Health Service.
24

25
26 **Competing interests:** All authors have completed the Unified Competing Interest form at
27 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
28 declare: no support from any organisation for the submitted work; no financial relationships
29 with any organisations that might have an interest in the submitted work in the previous 3
30 years; no other relationships or activities that could appear to have influenced the submitted
31 work.
32
33

34
35 "The Corresponding Author has the right to grant on behalf of all authors and does grant on
36 behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a
37 worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be
38 published in BMJ editions and any other BMJPGJL products and sublicences such use and
39 exploit all subsidiary rights, as set out in our licence."
40

41
42 **Data sharing:** Both datasets are available via the UK Data Service
43 (www.ukdataservice.ac.uk). Statistical code is available from the corresponding author at
44 s.scholes@ucl.ac.uk.
45

46 **Contributors:** SS, AM, and JM participated in study concept and design, analysis and
47 interpretation of data. SS performed data acquisition and management. SS participated in
48 drafting of the manuscript. AM and JM aided revision of the manuscript and provided
49 relevant intellectual input. SS is the data guarantor. All authors have approved the final
50 version of the manuscript.
51
52
53
54
55
56
57
58
59
60

Reference List

- (1) Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 2007; 370(9589):765-773.
- (2) Raheison C, Girodet PO. Epidemiology of COPD. *Eur Respir Rev* 2009; 18(114):213-221.
- (3) Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380(9859):2095-2128.
- (4) Department of Health. *An Outcomes Strategy for COPD and asthma: NHS Companion Document*. 2012.
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216139/dh_128428.pdf
- (5) Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. *BMC Med* 2011; 9:7.
- (6) Rycroft CE, Heyes A, Lanza L, et al. Epidemiology of chronic obstructive pulmonary disease: a literature review. *Int J Chron Obstruct Pulmon Dis* 2012; 7:457-494.
- (7) McLean S, Wild SH, Simpson CR, et al. Models for estimating projections for the prevalence and disease burden of chronic obstructive pulmonary disease (COPD): systematic review protocol. *Prim Care Respir J* 2013; 22(2):S8-21.
- (8) Salvi SS, Manap R, Beasley R. Understanding the true burden of COPD: the epidemiological challenges. *Prim Care Respir J* 2012; 21(3):249-251.
- (9) Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001; 163(5):1256-1276.
- (10) Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Standardisation of spirometry. *Eur Respir J* 2005; 26(2):319-338.
- (11) Miller MR, Quanjer PH, Swanney MP, et al. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. *Chest* 2011; 139(1):52-59.
- (12) Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. *Thorax* 2008; 63(12):1046-1051.
- (13) Bakke PS, Ronmark E, Eagan T, et al. Recommendations for epidemiological studies on COPD. *Eur Respir J* 2011; 38(6):1261-1277.

- 1
2
3 (14) Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use
4 percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. *Chest* 2007;
5 131(2):349-355.
6
7 (15) Roberts SD, Farber MO, Knox KS, et al. FEV1/FVC ratio of 70% misclassifies
8 patients with obstruction at the extremes of age. *Chest* 2006; 130(1):200-206.
9
10 (16) Hwang YI, Kim CH, Kang HR, et al. Comparison of the prevalence of chronic
11 obstructive pulmonary disease diagnosed by lower limit of normal and fixed ratio
12 criteria. *J Korean Med Sci* 2009; 24(4):621-626.
13
14 (17) Quanjer PH, Cole TJ. COPD and GOLD stage I. *Chest* 2012; 141(4):1122.
15
16 (18) Enright P, Brusasco V. Counterpoint: should we abandon FEV(1)/FVC < 0.70 to
17 detect airway obstruction? Yes. *Chest* 2010; 138(5):1040-1042.
18
19 (19) Quanjer PH, Enright PL, Miller MR, et al. The need to change the method for
20 defining mild airway obstruction. *Eur Respir J* 2011; 37(3):720-722.
21
22 (20) Celli BR, Halbert RJ. Point: should we abandon FEV(1)/FVC <0.70 to detect airway
23 obstruction? No. *Chest* 2010; 138(5):1037-1040.
24
25 (21) Falaschetti E, Swanney MP, Crapo RO, Hankinson JL, Jensen RL, Pedersen OF et al.
26 Diagnosis of COPD. *Thorax* 2007; 62(10):924-925.
27
28 (22) Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and
29 meta-analysis. *Eur Respir J* 2006; 28(3):523-532.
30
31 (23) Mindell J, Biddulph JP, Hirani V, et al. Cohort profile: the health survey for England.
32 *Int J Epidemiol* 2012; 41(6):1585-1593.
33
34 (24) Joint Health Surveys Unit. *The Health Survey for England 2010, Volume 1:*
35 *Respiratory Health*. Craig R, Mindell J, editors. Respiratory health. Leeds, NHS
36 Information Centre, 2011. <http://www.hscic.gov.uk/pubs/hse10report>
37
38 (25) Joint Health Surveys Unit. *The Health Survey for England 2010, Volume 2: Methods*
39 *and Documentation*. Leeds, The Information Centre for Health and Social Care,
40 2011. [http://www.hscic.gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-](http://www.hscic.gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-vol2-meth-rep.pdf)
41 [vol2-meth-rep.pdf](http://www.hscic.gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-vol2-meth-rep.pdf)
42
43 (26) Lynn P. Sample design for Understanding Society. Understanding Society Working
44 Paper Series: 2009-01.
45 [https://www.understandingsociety.ac.uk/research/publications/working-](https://www.understandingsociety.ac.uk/research/publications/working-paper/understanding-society/2009-01.pdf)
46 [paper/understanding-society/2009-01.pdf](https://www.understandingsociety.ac.uk/research/publications/working-paper/understanding-society/2009-01.pdf)
47
48 (27) McFall SL, Petersen J, Kaminska O, et al. *Understanding Society - The UK*
49 *Household Longitudinal Study: Waves 2 and 3 Nurse Health Assessment, 2010-2012*
50 *Guide to Nurse Health Assessment*. Colchester, University of Essex, 2012.
51 [https://www.understandingsociety.ac.uk/d/100/7251_User_Guide_Health_Assmt_w2](https://www.understandingsociety.ac.uk/d/100/7251_User_Guide_Health_Assmt_w2_w3.pdf?1392855567)
52 [_w3.pdf?1392855567](https://www.understandingsociety.ac.uk/d/100/7251_User_Guide_Health_Assmt_w2_w3.pdf?1392855567)
53
54
55
56
57
58
59
60

- 1
2
3
4 (28) Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry
5 for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;
6 40(6):1324-1343.
7
8 (29) Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global
9 Lungs Initiative 2012 all-age reference equations for spirometry. *Eur Respir J* 2013;
10 42(4):1046-1054.
11
12 (30) Hall GL, Thompson BR, Stanojevic S, et al. The Global Lung Initiative 2012
13 reference values reflect contemporary Australasian spirometry. *Respirology* 2012;
14 17(7):1150-1151.
15
16 (31) Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management,
17 and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
18 *Am J Respir Crit Care Med* 2007; 176(6):532-555.
19
20 (32) COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS
21 guidelines for the management of chronic obstructive pulmonary disease. The COPD
22 Guidelines Group of the Standards of Care Committee of the BTS. *Thorax* 1997; 52
23 Suppl 5:S1-28.
24
25 (33) Ferguson GT, Enright PL, Buist AS, et al. Office spirometry for lung health
26 assessment in adults: A consensus statement from the National Lung Health
27 Education Program. *Chest* 2000; 117(4):1146-1161.
28
29 (34) Vaz Fragoso CA, Concato J, McAvay G, et al. The ratio of FEV1 to FVC as a basis
30 for establishing chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*
31 2010; 181(5):446-451.
32
33 (35) Deaths from chronic obstructive pulmonary disease--United States, 2000-2005.
34 *MMWR Morb Mortal Wkly Rep* 2008; 57(45):1229-1232.
35
36 (36) Jordan RE, Miller MR, Lam KB, et al. Sex, susceptibility to smoking and chronic
37 obstructive pulmonary disease: the effect of different diagnostic criteria. Analysis of
38 the Health Survey for England. *Thorax* 2012; 67(7):600-605.
39
40 (37) Bhatt SP, Sieren JC, Dransfield MT, et al. Comparison of spirometric thresholds in
41 diagnosing smoking-related airflow obstruction. *Thorax* 2013.
42
43 (38) Jordan RE, Cheng KK, Miller MR, et al. Passive smoking and chronic obstructive
44 pulmonary disease: cross-sectional analysis of data from the Health Survey for
45 England. *BMJ Open* 2011; 1(2):e000153.
46
47 (39) Woodward M. *Epidemiology Study Design and Data Analysis*. 2nd ed. Boca Raton,
48 Florida: Chapman & Hall/CRC, 2004.
49
50 (40) Loong TW. Understanding sensitivity and specificity with the right side of the brain.
51 *BMJ* 2003; 327(7417):716-719.
52
53
54
55
56
57
58
59
60

- 1
2
3 (41) Rabe-Hesketh S, Skrondal A. *Multilevel and longitudinal modeling using Stata: Volume II: Categorical responses, counts, and survival*. 3rd ed. Texas, United States: Stata Press, 2012.
- 4
5
6
7 (42) UCLA Statistical Consulting Group. Multinomial Logistic Regression.
8 www.ats.ucla.edu/stat/stata/dae/mlogit.htm
9
- 10 (43) Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic
11 obstructive pulmonary disease among patients at risk in primary care. *CMAJ* 2010;
12 182(7):673-678.
13
- 14 (44) Chronic obstructive pulmonary disease. National clinical guideline on management of
15 chronic obstructive pulmonary disease in adults in primary and secondary care.
16 *Thorax* 2004; 59 Suppl 1:1-232.
17
- 18 (45) Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, et al. Estimating the U.S. prevalence of
19 chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry:
20 the National Health and Nutrition Examination Survey (NHANES) 2007-2010. *Respir*
21 *Res* 2013; 14:103.
22
23
- 24 (46) National Institute for Health and Care Excellence (NICE). Chronic obstructive
25 pulmonary disease: management of chronic obstructive pulmonary disease in adults in
26 primary and secondary care. 2010. www.nice.org.uk/Guidance/CG101.
27
28
- 29 (47) Quanjer PH, Stanojevic S, Swanney MP, et al. Recommendations for epidemiological
30 studies on COPD. *Eur Respir J* 2012; 39(5):1277-1278.
31
- 32 (48) Shahab L, Jarvis MJ, Britton J, et al. Prevalence, diagnosis and relation to tobacco
33 dependence of chronic obstructive pulmonary disease in a nationally representative
34 population sample. *Thorax* 2006; 61(12):1043-1047.
35
- 36 (49) Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory
37 flows. Report Working Party Standardization of Lung Function Tests, European
38 Community for Steel and Coal. Official Statement of the European Respiratory
39 Society. *Eur Respir J Suppl* 1993; 16:5-40.
40
- 41 (50) Falaschetti E, Laiho J, Primatesta P, et al. Prediction equations for normal and low
42 lung function from the Health Survey for England. *Eur Respir J* 2004; 23(3):456-463.
43
44
- 45 (51) Maio S, Sherrill DL, MacNee W, et al. The European Respiratory Society spirometry
46 tent: a unique form of screening for airway obstruction. *Eur Respir J* 2012;
47 39(6):1458-1467.
48
- 49 (52) Mohamed Hoesein FA, Zanen P, et al. Lower limit of normal or FEV1/FVC < 0.70 in
50 diagnosing COPD: an evidence-based review. *Respir Med* 2011; 105(6):907-915.
51
- 52 (53) Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes,
53 hypertension and cardiovascular disease in COPD. *Eur Respir J* 2008; 32(4):962-969.
54
55
56
57
58
59
60

- 1
2
3 (54) Ford ES, Wheaton AG, Mannino DM, et al. Elevated cardiovascular risk among
4 adults with obstructive and restrictive airway functioning in the United States: a cross-
5 sectional study of the National Health and Nutrition Examination Survey from 2007-
6 2010. *Respir Res* 2012; 13:115.
7
8 (55) Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management,
9 and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
10 *Am J Respir Crit Care Med* 2013; 187(4):347-365.
11
12 (56) Clini EM, Crisafulli E, Roca M, et al. Diagnosis of chronic obstructive pulmonary
13 disease, simpler is better. Complexity and simplicity. *Eur J Intern Med* 2013;
14 24(3):195-198.
15
16 (57) Haughney J, Gruffydd-Jones K, Roberts J, et al. The distribution of COPD in UK
17 general practice using the new GOLD classification. *Eur Respir J* 2013.
18
19 (58) Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology of chronic
20 obstructive pulmonary disease in England: a national study of 51 804 patients. *Br J*
21 *Gen Pract* 2010; 60(576):277-284.
22
23 (59) Walford H, Ramsey L. *COPD Prevalence Modelling Briefing Document*. 2011.
24 www.apho.org.uk/resource/view.aspx?RID=111137.
25
26 (60) Nacul LC, Soljak M, Meade T. Model for estimating the population prevalence of
27 chronic obstructive pulmonary disease: cross sectional data from the Health Survey
28 for England. *Popul Health Metr* 2007; 5:8.
29
30 (61) Nacul L, Soljak M, Samarasundera E, et al. COPD in England: a comparison of
31 expected, model-based prevalence and observed prevalence from general practice
32 data. *J Public Health (Oxf)* 2011; 33(1):108-116.
33
34 (62) Shirtcliffe P, Weatherall M, Marsh S, et al. COPD prevalence in a random population
35 survey: a matter of definition. *Eur Respir J* 2007; 30(2):232-239.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Prevalence of Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria, Persons aged 40-95 years Without Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

	n	Diagnosed-COPD ^b	Fixed Thresholds ^c			Lower Limit of Normal ^d			
		% (95% CI)	Obstructed % (95% CI)	stage I % (95% CI)	stage II % (95% CI)	stage III+ % (95% CI)	Obstructed % (95% CI)	stage I % (95% CI)	stage II % (95% CI)
All	7879	2.8 (2.3-3.2)	22.2 (21.2-23.2)	11.6 (10.9-12.4)	8.9 (8.2-9.6)	1.7 (1.3-2.0)	13.1 (12.2-13.9)	6.6 (6.0-7.3)	6.4 (5.8-7.0)
Sex:									
Males	3335	3.0 (2.3-3.6)	26.3 (24.8-27.9)	13.2 (12.1-14.4)	10.7 (9.6-11.8)	2.4 (1.8-3.0)	15.0 (13.7-16.4)	7.2 (6.2-8.1)	7.9 (6.9-8.9)
Females	4544	2.6 (2.0-3.1)	18.6 (17.4-19.9)	10.2 (9.2-11.2)	7.4 (6.5-8.2)	1.0 (0.7-1.4)	11.3 (10.3-12.3)	6.2 (5.4-6.9)	5.1 (4.4-5.9)
Age-group:									
40-54	3472	1.7 (1.3-2.2)	11.9 (10.7-13.1)	7.0 (6.1-7.9)	4.6 (3.8-5.4)	0.3 (0.1-0.6)	10.7 (9.6-11.9)	6.7 (5.7-7.6)	4.1 (3.3-4.9)
55-64	2072	3.4 (2.5-4.2)	24.2 (22.2-26.1)	12.6 (11.1-14.1)	9.5 (8.1-10.9)	2.0 (1.4-2.7)	14.2 (12.6-15.8)	6.5 (5.4-7.7)	7.7 (6.4-8.9)
65-74	1557	3.9 (2.8-5.0)	32.6 (30.1-35.1)	16.5 (14.6-18.5)	12.9 (11.1-14.6)	3.2 (2.1-4.2)	15.0 (13.0-17.0)	6.4 (5.1-7.7)	8.6 (7.0-10.2)
75-95	778	3.9 (2.0-5.8)	45.0 (41.1-48.8)	21.1 (18.0-24.2)	19.6 (16.6-22.6)	4.3 (2.5-6.0)	17.2 (14.2-20.1)	7.2 (5.2-9.2)	9.9 (7.6-12.3)
Smoking status:									
Current	1198	4.7 (3.5-6.0)	37.0 (34.1-39.9)	14.5 (12.3-16.6)	18.2 (15.9-20.6)	4.2 (3.0-5.4)	29.8 (27.0-32.6)	13.5 (11.3-15.7)	16.2 (14.0-18.5)
Ex-regular	2547	3.6 (2.7-4.5)	26.8 (24.9-28.7)	14.1 (12.7-15.6)	10.5 (9.2-11.8)	2.2 (1.5-2.9)	14.5 (13.0-16.1)	7.2 (6.0-8.3)	7.4 (6.2-8.5)
Never	4134	1.6 (1.2-2.0)	14.7 (13.5-15.9)	9.2 (8.2-10.1)	5.0 (4.3-5.7)	0.5 (0.2-0.9)	6.8 (5.9-7.7)	4.1 (3.5-4.8)	2.7 (2.1-3.3)
Pack-years^e:									
0-0.9	4299	1.6 (1.2-2.0)	14.8 (13.6-16.0)	9.3 (8.4-10.3)	5.0 (4.3-5.7)	0.5 (0.2-0.8)	6.7 (5.9-7.6)	4.1 (3.5-4.7)	2.6 (2.0-3.2)
1-19.9	1905	2.3 (1.5-3.1)	22.3 (20.3-24.3)	12.9 (11.3-14.5)	7.5 (6.2-8.8)	1.9 (1.1-2.6)	13.4 (11.7-15.1)	7.6 (6.3-8.9)	5.8 (4.6-7.0)
20-49.9	1318	5.0 (3.6-6.5)	36.8 (34.0-39.6)	15.7 (13.5-17.9)	18.1 (15.9-20.4)	2.9 (2.0-3.9)	25.4 (22.8-27.9)	11.6 (9.5-13.6)	13.8 (11.8-15.8)
50+	345	10.5 (7.0-14.1)	53.7 (48.0-59.4)	16.0 (12.0-20.1)	28.0 (23.0-32.9)	9.7 (6.2-13.2)	39.3 (33.5-45.0)	12.4 (8.7-16.2)	26.9 (21.6-32.1)
NS-SEC^e:									
Professional	3050	1.9 (1.4-2.4)	17.1 (15.7-18.5)	10.4 (9.3-11.6)	5.7 (4.9-6.5)	1.0 (0.6-1.4)	9.1 (8.0-10.2)	5.6 (4.6-6.5)	3.6 (2.9-4.3)
Intermediate	1859	2.3 (1.6-3.0)	21.9 (19.9-23.9)	12.5 (10.9-14.1)	8.4 (7.0-9.7)	1.1 (0.5-1.7)	12.0 (10.5-13.5)	6.6 (5.4-7.8)	5.4 (4.3-6.5)
Routine	2705	4.0 (3.1-4.8)	26.6 (24.7-28.5)	11.6 (10.3-12.9)	12.3 (10.9-13.7)	2.7 (2.0-3.5)	17.4 (15.8-19.1)	7.7 (6.6-8.9)	9.7 (8.4-11.0)

Abbreviations used: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in 1 second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the lower 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; UKHLS, United Kingdom Household Longitudinal Survey.

1
2
3
4
5
6
7^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts are unweighted; prevalence estimates were weighted.

8^b HSE: reported diagnosed COPD, bronchitis or emphysema; UKHLS: diagnosed bronchitis or emphysema.

9^c FTs: Obstruction (FT): $FEV_1/FVC < 0.70$. Staging classification: stage I ($FEV_1/FVC < 0.70$ and $FEV_1 \geq 80\%$ of predicted); stage II ($FEV_1/FVC < 0.70$ and FEV_1 50-79% of predicted); stage III+ ($FEV_1/FVC < 0.70$ and $FEV_1 < 50\%$ of predicted).

10
11
12^d LLN: Obstruction (LLN): $FEV_1/FVC < LLN$. Staging classification: stage I ($FEV_1/FVC < LLN$ and $FEV_1 > LLN$); stage II ($FEV_1/FVC < LLN$ and $FEV_1 < LLN$).

13
14^e Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2 Sensitivity and Specificity of Fixed Thresholds and Lower Limit of Normal Spirometric Criteria by Age-group, Persons aged 40-95 years Without Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)

	40-64 (n=5544)	65-95 (n=2335)	40-64 (n=5544)	65-95 (n=2335)
	FT using LLN as reference standard		LLN using FT as reference standard	
False positives, (%)	5.1	25.6	0.4	0.0
False negatives, (%)	2.5	0.0	28.0	57.6
Sensitivity	0.975	1.000	0.720	0.424
Specificity	0.949	0.744	0.996	1.000
PPV	0.720	0.424	0.975	1.000
NPV	0.996	1.000	0.949	0.744
Kappa coefficient	0.801	0.479	0.801	0.479
Likelihood ratio positive	18.98	3.90	200.65	N/A
Likelihood ratio negative	0.027	0.000	0.281	0.576
	FT (stage II+) using LLN as reference standard		LLN using FT (stage II+) as reference standard	
False positives, (%)	1.3	8.9	6.3	5.2
False negatives, (%)	49.2	26.7	16.0	39.1
Sensitivity	0.508	0.733	0.840	0.609
Specificity	0.987	0.911	0.937	0.948
PPV	0.840	0.609	0.508	0.733
NPV	0.937	0.948	0.987	0.911
Kappa coefficient	0.597	0.596	0.597	0.596
Likelihood ratio positive	38.82	8.28	13.27	11.67
Likelihood ratio negative	0.499	0.292	0.170	0.412

Abbreviations used: FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); NPV, negative predictive value; PPV, positive predictive value; UKHLS, United Kingdom Household Longitudinal Survey.

Table 3 Results of Logistic and Multinomial Logistic Regressions for Reported Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria Among Persons Aged 40-95 years, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

Characteristics	Diagnosed-COPD ^b	Fixed Thresholds ^c			Lower Limit of Normal ^d			
		N	OR (95% CI)	Non-obstructed as reference			Non-obstructed as reference	
				stage I	stage II	stage III+	stage I	stage II
		RRR (95% CI) ^e	RRR (95% CI) ^e	RRR (95% CI) ^e	RRR (95% CI) ^e	RRR (95% CI) ^e		
Sex:								
Females ^f	4372	1.00	1.00	1.00	1.00	1.00		
Males	3231	0.60 (0.34-1.05)	1.35 (1.16-1.58)	1.35 (1.12-1.63)	1.72 (1.08-2.76)	1.07 (0.88-1.31) 1.20 (0.96-1.50)		
<i>P</i> -value		0.075	<0.001	0.002	0.024	0.503 0.107		
Age-group:								
40-54 ^f	3416	1.00	1.00	1.00	1.00	1.00		
55-64	2022	1.66 (1.07-2.58)	2.00 (1.63-2.45)	2.13 (1.65-2.73)	6.05 (2.82-12.99)	0.92 (0.72-1.18) 1.57 (1.20-2.06)		
65-74	1451	0.96 (0.54-1.70)	2.85 (2.30-3.53)	3.01 (2.32-3.89)	10.11 (4.55-22.49)	0.83 (0.63-1.09) 1.56 (1.16-2.12)		
75+	714	1.20 (0.39-3.70)	4.72 (3.66-6.07)	6.67 (5.00-8.90)	22.26 (9.45-52.44)	1.06 (0.74-1.51) 2.20 (1.52-3.17)		
<i>P</i> -value		0.104	<0.001	<0.001	<0.001	0.492 <0.001		
Pack-years^g:								
0-0.9 ^f	4165	1.00	1.00	1.00	1.00	1.00		
1-19.9	1835	1.38 (0.88-2.17)	1.61 (1.34-1.93)	1.66 (1.29-2.15)	3.82 (1.80-8.14)	1.94 (1.51-2.49) 2.22 (1.58-3.12)		
20-49.9	1269	2.91 (1.91-4.45)	2.30 (1.86-2.85)	4.56 (3.64-5.72)	5.91 (2.81-12.45)	3.39 (2.61-4.41) 5.43 (3.98-7.41)		
50+	334	5.64 (3.45-9.22)	2.34 (1.63-3.35)	6.83 (4.85-9.63)	17.27 (7.88-37.84)	4.50 (2.96-6.84) 11.20 (7.59-16.52)		
<i>P</i> -value		<0.001	<0.001	<0.001	<0.001	<0.001 <0.001		
NS-SEC^g:								
Professional ^f	3047	1.00	1.00	1.00	1.00	1.00		
Intermediate	1855	1.03 (0.68-1.58)	1.18 (0.97-1.45)	1.34 (1.04-1.72)	1.01 (0.51-2.00)	1.14 (0.88-1.48) 1.35 (0.99-1.85)		
Routine	2701	1.61 (1.13-2.31)	1.07 (0.89-1.29)	1.82 (1.47-2.26)	2.30 (1.36-3.88)	1.28 (1.01-1.63) 2.18 (1.67-2.85)		
<i>P</i> -value		0.012	0.246	<0.001	0.002	0.123 <0.001		
Sample:								
UKHLS ^f	5675	1.00	1.00	1.00	1.00	1.00		
HSE	1928	2.22 (1.60-3.07)	0.95 (0.79-1.14)	0.97 (0.79-1.20)	0.99 (0.62-1.59)	1.05 (0.82-1.33) 0.99 (0.77-1.26)		
<i>P</i> -value		<0.001	0.587	0.798	0.967	0.716 0.913		
Males × age-group:								

40-54 ^e	1319	1.00	-	-	-	-	-
55-64	876	1.16 (0.54-2.45)	-	-	-	-	-
65-74	664	3.21 (1.40-7.39)	-	-	-	-	-
75+	372	2.61 (0.67-10.22)	-	-	-	-	-
<i>P-value</i>		<i>0.022</i>	-	-	-	-	-

Abbreviations used: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; OR, odds ratios; RRR; relative risk ratios; UKHLS, United Kingdom Household Longitudinal Survey.

^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts are unweighted; ORs and RRRs were weighted.

^b HSE: reported diagnosed COPD, bronchitis or emphysema; UKHLS: diagnosed bronchitis or emphysema.

^c FTs: stage I (FEV₁/FVC <0.70 and FEV₁ ≥80% of predicted); stage II (FEV₁/FVC <0.70 and FEV₁ 50-79% of predicted); stage III+ (FEV₁/FVC <0.70 and FEV₁ <50% of predicted). Reference category: FEV₁/FVC ≥0.70.

^d LLN: stage I (FEV₁/FVC <LLN and FEV₁ >LLN); stage II (FEV₁/FVC <LLN and FEV₁ <LLN). Reference category: FEV₁/FVC ≥LLN.

^e The RRR is interpreted as the relative risk of one outcome in relation to the reference category for a specified category of an independent variable compared with the reference category for that independent variable. Using FT stage I as an example, the RRR for males *vs.* females is interpreted as the relative risk for FT stage I *vs.* non-obstruction for males compared with the analogous relative risk for females, adjusted for the other variables in the model.

^f Reference category.

^g Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.

Table 4 Results of Multinomial Logistic Regressions for Combined Outcome Variable Based on Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria Among Persons aged 40-95 years, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-12)^a

Characteristics	Fixed Thresholds ^b			Lower Limit of Normal ^c			
	Neither diagnosed nor obstructive spirometry as reference			Neither diagnosed nor obstructive spirometry as reference			
	Diagnosed alone	Obstructive spirometry alone	Diagnosed and obstructive spirometry	Diagnosed alone	Obstructive spirometry alone	Diagnosed and obstructive spirometry	
	n	RRR (95% CI) ^d	RRR (95% CI) ^d	RRR (95% CI) ^d	RRR (95% CI) ^d	RRR (95% CI) ^d	
Sex:							
Females ^e	4372	1.00	1.00	1.00	1.00	1.00	
Males	3231	0.49 (0.31-0.79)	1.31 (1.16-1.49)	2.23 (1.34-3.71)	0.52 (0.34-0.81)	1.05 (0.90-1.23)	2.15 (1.25-3.71)
<i>P-value</i>		0.003	<0.001	0.002	0.004	0.543	0.006
Age-group:							
40-54 ^e	3416	1.00	1.00	1.00	1.00	1.00	
55-64	2022	1.26 (0.76-2.09)	2.08 (1.76-2.46)	4.06 (2.11-7.79)	1.34 (0.83-2.16)	1.09 (0.90-1.33)	2.91 (1.49-5.68)
65-74	1451	1.47 (0.84-2.55)	3.05 (2.56-3.63)	4.78 (2.38-9.57)	1.27 (0.74-2.15)	1.02 (0.82-1.27)	3.12 (1.53-6.36)
75+	714	1.95 (0.69-5.51)	5.89 (4.76-7.29)	7.55 (3.35-17.02)	1.60 (0.67-3.81)	1.42 (1.08-1.87)	3.47 (1.43-8.40)
<i>P-value</i>		0.388	<0.001	<0.001	0.535	0.085	<0.001
Pack-years^f:							
0-0.9 ^e	4165	1.00	1.00	1.00	1.00	1.00	
1-19.9	1835	1.08 (0.61-1.92)	1.67 (1.42-1.96)	2.84 (1.30-6.23)	1.16 (0.68-2.00)	2.02 (1.63-2.50)	2.58 (1.10-6.01)
20-49.9	1269	3.05 (1.68-5.54)	3.18 (2.70-3.74)	6.70 (3.35-13.40)	2.98 (1.72-5.16)	4.23 (3.44-5.20)	5.74 (2.70-12.20)
50+	334	3.94 (1.70-9.13)	4.15 (3.13-5.49)	18.50 (8.41-40.70)	3.87 (1.81-8.29)	6.83 (4.98-9.37)	17.23 (7.37-40.28)
<i>P-value</i>		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
NS-SEC^f:							
Professional ^e	3047	1.00	1.00	1.00	1.00	1.00	
Intermediate	1855	0.76 (0.45-1.30)	1.20 (1.02-1.41)	1.84 (0.87-3.87)	0.83 (0.50-1.40)	1.19 (0.97-1.47)	1.57 (0.72-3.44)
Routine	2701	0.93 (0.59-1.48)	1.31 (1.12-1.53)	3.65 (1.89-7.06)	1.08 (0.70-1.67)	1.54 (1.27-1.87)	3.37 (1.70-6.68)
<i>P-value</i>		0.612	0.002	<0.001	0.632	<0.001	<0.001
Sample:							
UKHLS ^e	5675	1.00	1.00	1.00	1.00	1.00	
HSE	1928	2.38 (1.54-3.69)	0.94 (0.81-1.09)	1.92 (1.21-3.05)	2.21 (1.46-3.35)	0.96 (0.79-1.16)	2.13 (1.31-3.48)

<i>P-value</i>	<i><0.001</i>	<i>0.420</i>	<i>0.006</i>	<i><0.001</i>	<i>0.664</i>	<i>0.002</i>
----------------	------------------	--------------	--------------	------------------	--------------	--------------

Abbreviations used: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; OR, odds ratios; RRR; relative risk ratios; UKHLS, United Kingdom Household Longitudinal Survey.

^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts unweighted; RRRs estimated using survey weights.

^b FTs: Obstruction (FT): FEV₁/FVC <0.70. Diagnosed COPD: HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.

^c LLN: Obstruction (LLN): FEV₁/FVC <LLN. Diagnosed COPD: HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.

^d The RRR is interpreted as the relative risk of one outcome in relation to the reference category for a specified category of an independent variable compared with the reference category for that independent variable. Using diagnosed alone as an example, the RRR for males *vs.* females is interpreted as the relative risk for diagnosed alone *vs.* neither diagnosed nor objective spirometry for males compared with the analogous relative risk for females, adjusted for the other variables in the model.

^e Reference category.

^f Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.

Title: Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England and Wales

Running head: Comparison of different spirometric cut-offs

Authors: Shaun Scholes *research associate*,^{1*} Alison Moody *research associate*,¹ Jennifer S Mindell *clinical senior lecturer*¹

¹ Health and Social Surveys Research Group, Research Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London WC1E 6BT, United Kingdom

* Corresponding author. (e-mail: s.scholes@ucl.ac.uk)

ABSTRACT

Objectives: Consistent estimation of the burden of chronic obstructive pulmonary disease (COPD) has been hindered by differences in methods, including different spirometric cut-offs for impaired lung function. The impact of different definitions on the prevalence of potential airflow obstruction, and its associations with key risk factors, is evaluated using cross-sectional data from two nationally-representative general population surveys.

Design: Pooled cross-sectional analysis of Wave 2 of the UK Household Longitudinal Survey and the Health Survey for England 2010, including 7879 participants, aged 40-95 years, who lived in England and Wales, without diagnosed asthma, and with good-quality spirometry data. Potential airflow obstruction was defined using self-reported physician-diagnosed COPD; a fixed threshold (FT) forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio <0.70; and an age-, sex-, height- and ethnic-specific lower limit of normal (LLN). Standardised questions elicited self-reported information on demography, smoking history, ethnicity, occupation, respiratory symptoms, and cardiovascular disease.

Results: Consistent across definitions, participants classed with obstructed airflow were more likely to be older, currently smoke, have higher pack-years of smoking, and be engaged in routine occupations. The prevalence of airflow obstruction was 2.8% (95% CI 2.3-3.2), 22.2% (21.2-23.2), and 13.1% (12.2-13.9) according to diagnosed COPD, FT and LLN, respectively. The gap in prevalence between FT and LLN increased in older age-groups. Sex differences in the risk of obstruction, after adjustment for key risk factors, was sensitive to the choice of spirometric cut-off, being significantly higher in men when using FT, compared with no significant difference using LLN.

Conclusions: Applying FT or LLN spirometric cut-offs gives a different picture of the size and distribution of the disease burden. Longitudinal studies examining differences in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

unscheduled hospital admissions and risk of death between FT and LLN may inform the choice as to the best way to include spirometry in assessments of airflow obstruction.

Word count: ~~39403~~3985

Non-text material: 4 Tables

Keywords: airflow obstruction; chronic obstructive pulmonary disease; fixed thresholds; Health Survey for England; lower limit of normal; respiratory; sensitivity; specificity; spirometry; United Kingdom Household Longitudinal Survey

Strengths and limitations of this study

- Estimates of the burden of chronic obstructive pulmonary disease (COPD) using spirometry data collected in epidemiological studies are inconsistent through differences in methods, including different spirometric cut-offs.
- Our study combined two nationally representative samples of adults living in England and Wales, with standardised protocols and objective measurements of lung function, and a wide-range of clinically-relevant conditions including self-reported respiratory symptoms (chronic cough and phlegm) and breathlessness.
- Consistent definitions and up-to-date reference equations were used, providing baseline data for monitoring purposes in the UK, and for facilitating comparison with international studies.
- Prevalence estimates were based on pre-bronchodilator lung function measurements, and so are likely to overestimate true prevalence.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterised by a progressive decline in lung function.^{1,2} 2.9 million deaths were attributed to COPD in 2010, making it the third leading global cause of death.³ The National Outcomes Strategy for COPD estimated that 835,000 people living in the UK are currently diagnosed with COPD, with a further 2.2 million being undiagnosed.⁴ COPD is the second ~~leading-most common~~ cause of emergency hospital admission and is one of the most costly diseases in terms of acute hospital care in England.⁴

~~Healthcare budgeting~~ ~~Budgeting of healthcare~~ is often contingent upon the estimated burden of disease. Spirometry, the mainstay of lung function assessment, has been used in nationally-representative surveys to estimate the COPD burden in terms of prevalence, associated comorbidities, and mortality. Estimation of the disease burden has been hindered, however, by differences in methods, including ~~different~~ spirometric cut-offs.⁵⁻⁸ Fixed thresholds (FTs) use cut-offs for lung function measurements (e.g., forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio <0.70) regardless of age, sex, height, and ethnicity.⁹ An additional threshold for percent-of-predicted FEV₁ (expected for persons of a given age, sex, height and ethnicity) is also commonly used for severity classification. In contrast, a lower limit of normal (LLN) cut-off uses a statistical definition of abnormal/normal (e.g., below/above the lower 5th percentile of the distribution of age-, sex-, height-, and ethnic-specific FEV₁/FVC values from a healthy, lifelong non-smoking population).¹⁰

At present, applying FTs such as FEV₁/FVC <0.70 is the standard approach. However, the European Respiratory Society (~~ERS~~) Task Force on epidemiology recently advocated using the LLN in epidemiological studies as FTs both overestimate airflow obstruction in older

populations, due to the physiological reduction of FEV₁/FVC with age, and underestimate in young adults, compared with LLN.¹¹⁻¹⁶ The controversy over FT-versus-LLN thresholds is well-known ~~and has been fiercely debated~~ with no signs of a consensus among expert groups being agreed.¹⁷⁻²¹

Partly as a result of this controversy, the COPD epidemiological database, ~~within and across countries,~~ shows heterogeneity in ~~both~~ definitions and consequential estimates of the disease burden.^{5,22} ~~Two nationally-representative samples, Wave 2 (2010-2012) of the UK Household Longitudinal Survey (UKHLS, 'Understanding Society') and the Health Survey for England (HSE) 2010, collected lung function data using identical measurement protocols and specialist equipment, providing an opportunity to increase statistical precision by combining both datasets.~~ Therefore, the primary objective of the present study was to compare the prevalence of 'potential' airflow obstruction according to FT- and LLN-thresholds ~~amongin a representative sample of~~ persons aged 40-95 years living in England and Wales: potential in the sense that the administration of bronchodilators to measure the extent of reversibility in airflow obstruction was not used. As a secondary aim, we compared the sensitivity of associations with risk factors including age, sex, smoking history, and socioeconomic position. Using the same variables, we also examined the characteristics associated with spirometry in connection with self-reported physician-diagnosed COPD.

METHODOLOGY

Study design and setting

~~Two nationally-representative samples, Wave 2 (2010-2012) of the UK Household Longitudinal Survey (UKHLS, 'Understanding Society') and the Health Survey for England (HSE) 2010, were pooled to increase sample size.~~ Both the UKHLS and HSE surveys selected

participants using stratified multi-stage probability sampling designs.²³ ~~with similar measurement protocols and specialist equipment for collecting spirometry.~~

Self-reported health information, risk factors and demographics was collected through face-to-face interviews, followed by a visit from a trained nurse during which lung function was measured. Response rates for the Wave 2 interview (among individuals issued) and nurse-visit (among eligible participants in the Wave 2 interview) were 61% and 59% respectively in UKHLS. In HSE 2010, interview (among the estimated total number of adults in sampled households) and nurse-visit (adults in co-operating households) response rates were 59% and 57%. Sampling methods are described ~~in detail~~ elsewhere.²⁴⁻²⁶ Ethical approval was obtained from the Oxfordshire A (UKHLS) and B (HSE 2010) Research Ethics Committees. Ethical approval for the UKHLS was obtained from the Oxfordshire A Research Ethics Committee (10/H0604/2); approval for HSE 2010 was obtained from the Oxfordshire B Research Ethics Committee (09/H0605/73). Eligible participants gave written consent to participate in spirometry.

Questionnaire and procedures

Participants were excluded from spirometry for the following safety reasons: pregnancy; had in the last 3 months abdominal/~~or~~ chest surgery, a heart attack, detached retina or eye or ear surgery; admitted to hospital with a heart complaint in the preceding month; a resting pulse rate >120 beats/minute; or currently taking medications for the treatment of tuberculosis.

Spirometry, without bronchodilator use, was conducted using NDD EasyOne PCC spirometers (NDD Medical Technologies, Zurich, Switzerland). ~~a hand held, battery-operated device that uses an ultrasonic sensor to measure airflow. Calibration of spirometers was checked with a 3l syringe prior to use the following day. Participants performed the manoeuvre in a sitting position wearing a nose clip to prevent air leaks during testing.~~

~~Systematic quality control procedures were used; Quality control was~~ summarised in a session grade based on the number of technically acceptable blows and their reproducibility. ~~Sessions Graded~~ A (3 acceptable manoeuvres, 2 highest FVC and FEV₁ within 100 ml), B (3 acceptable manoeuvres, 2 highest FVC and FEV₁ within 150 ml), and C (2 or 3 acceptable manoeuvres within 200 ml) were considered good-quality. ~~In HSE, 1 in 4 spirometry sessions were over read by an experienced respiratory physiology consultant.~~ Full details on measurement procedures are available elsewhere.²⁵⁻²⁷

The highest values for FEV₁ and for FVC, from at least 3 and up to 8 blows, were used. Age-, sex-, height-, and ethnic-specific predicted values and Z-scores (FEV₁, FVC and FEV₁/FVC) were computed using the ~~ERS~~ ~~European Respiratory Society~~ Global Lungs Initiative (GLI 2012, www.lungfunction.org) reference equations. These have been prepared by an international collaboration based on data spanning 26 countries from ~~≥over~~ 70,000 healthy individuals across four ethnic-groups (Caucasian, African-American, and North- and South-East Asian), valid for persons aged 3-95 years^{28,29} and have been shown to fit contemporary Australasian spirometric data.³⁰

FT and LLN spirometric cut-offs

Using FTs, we applied the 2007 Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification³¹, which was designed for use with post-bronchodilator spirometry: potential airflow obstruction was defined as FEV₁/FVC <0.70 (FT). Disease stage was defined by the reduction in FEV₁ relative to percent-of-predicted values as follows: stage I (FEV₁/FVC <0.70 and FEV₁ ≥80% predicted); stage II (FEV₁/FVC <0.70 and FEV₁ 50-79% predicted); and stage III+ (FEV₁/FVC <0.70 and FEV₁ <50% predicted).³² Participants with FEV₁/FVC ≥0.70 were defined as non-obstructed.

Using the lambda-mu-sigma method (33), participants with $FEV_1/FVC < LLN$ (below the lower 5th percentile of the distribution of Z-scores) were defined as obstructed (LLN). To examine possible heterogeneity among participants with $FEV_1/FVC < LLN$, disease stage was defined by FEV_1 relative to LLN as follows: stage I ($FEV_1/FVC < LLN$ and $FEV_1 \geq LLN$), and stage II ($FEV_1/FVC < LLN$ and $FEV_1 < LLN$).³³ Participants with $FEV_1/FVC \geq LLN$ were defined as non-obstructed. The 5th percentile was chosen due to its established associations with respiratory symptoms and all-cause mortality.³⁴

Physician-diagnosed COPD

In UKHLS, disease status was ascertained through questions asking “*has a doctor or other health professional ever told you that you have [disease]?*” Diagnosed COPD was defined as a positive response to either chronic bronchitis or emphysema. In HSE, diagnosed COPD was defined as a positive response to the question “*did a doctor ever tell you that you had chronic bronchitis, emphysema or COPD?*”

Risk factors, measurements of lung function, and comorbidities

Key subgroups were defined by age (40-54, 55-64, 65-74, 75-95); sex; smoking status (current, former, never); pack-years of cigarette smoking (a cumulative total reflecting the amount and duration of consumption, with 1 pack-year equating to an average of 20 cigarettes smoked/day for 1 year); and socioeconomic position, defined by the National Statistics Socio-Economic Classification (NS-SEC), grouped into professional, intermediate, and routine occupations.

Three lung function measurements (FEV_1 , FVC, and FEV_1/FVC) on a continuous scale, were expressed as percent-of-predicted values. Additional variables included current use of respiratory medicine; area of residence, defined as (urban or rural), used as a possible proxy for traffic-related air pollution; body mass index (BMI: weight in kilograms divided by the

square of height in metres), grouped into normal weight (18.5-24.9-kg/m²), overweight (25.0-29.9-kg/m²), and obese (\geq 30-kg/m²); diagnosed diabetes; poor self-rated health; and reported cardiovascular disease (stroke, angina, myocardial infarction). In HSE, participants were asked to name any long-standing illnesses: respiratory diseases were identified using *International Classification of Diseases, Tenth Revision* codes J00-~~to~~J99. ~~Standard questions in the HSE covered a range of respiratory symptoms including wheeze, dyspnoea, chronic cough, and phlegm. In the HSE, p~~Presence of respiratory symptoms was defined as usually coughing first thing in the morning, for at least 3 months/~~year-a-year~~, and bringing up phlegm from the chest most days for 3 consecutive months in a year. In the HSE, participants with some limitation of activity due to breathlessness during daily ~~living~~fe were identified by a score of 3+ on the Medical Research Council (MRC) dyspnoea scale, ~~a validated method of categorising patients with COPD in terms of their disability (35)~~. Exposure to passive smoking in the HSE was measured by reported number of ~~weekly~~hours/~~week~~ currently exposed to cigarette smoke (0, 1-9, and \geq 10 hours).

Statistical analyses

A lower age limit ~~was used~~ of 40 years ~~was used~~ due to the low prevalence of non-asthma airflow obstruction in the youngest age-groups.³⁵ As bronchodilators were not used, we excluded participants who reported diagnosed asthma.^{34,36-38} Five sets of analyses were conducted across the categories of diagnosed COPD, FT, and LLN. First, participants' characteristics (demographics, ~~health information~~, risk factors, comorbidities and percent-of-predicted FEV₁, FVC, and FEV₁/FVC) were summarised as means, accompanied by standard deviations, or as counts accompanied by percentages. Participants were counted under each relevant definition. Participants with/without obstruction were compared using the χ^2 test and analysis of variance for categorical and continuous variables respectively.³⁹

1
2
3 Secondly, prevalence estimates were computed for a subset of socio-demographic variables
4 defined by age, sex, smoking status, pack-years of cigarette smoking, and NS-SEC. Thirdly,
5
6
7 in the absence of a gold standard, we calculated the sensitivity and specificity of each
8
9
10 spirometric criterion, using the alternative cut-off as the reference standard.⁴⁰

11
12 Fourth, regression analyses were performed using age, sex, pack-years of smoking, and NS-
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

each case, multinomial logistic regressions ~~were~~ used to estimate relative risk ratios (RRRs), with non-obstructed as the reference category. Multinomial logistic regression generalises logistic regression to outcomes with more than two possible discrete outcomes. The RRR is interpreted as the relative risk of one outcome in relation to the reference category for a specified category of an independent variable compared with the reference.^{41;42}

Diagnosed COPD was analysed as a binary ~~outcome dependent variable~~ (not reported/reported): logistic regression was therefore used to estimate odds ratios (ORs).^{39;41}

The overall association ~~for with categorical~~ independent variables with >2 categories was computed using the adjusted Wald test. The likelihood-ratio test was used to estimate the statistical significance of interaction terms: non-significant terms were excluded, and models refitted with only the main effects.

Fifth, to examine risk factors associated with possible under-diagnosis, a four-category outcome variable was created combining diagnosed COPD and spirometric criteria as follows: (1) neither diagnosed nor spirometrically-defined obstruction; (2) physician-diagnosed COPD but no obstructive spirometry; (3) spirometrically-defined but no diagnosed

1
2
3 COPD; and (4) both diagnosed and obstructive spirometry.⁴³ FT and LLN cut-offs were
4
5 analysed separately. RRRs generated from multinomial logistic regressions were used to
6
7 examine associations between the same set of risk factors listed above and the composite
8
9 dependent variable.
10

11
12 Participants with missing values on covariates were excluded from relevant analyses. Tests of
13
14 statistical significance were based on two-sided probability ($P<0.05$). Dataset preparation was
15
16 performed in SPSS 20.0 (SPSS IBM Inc., Chicago, Illinois, USA), Stata 13.1 (StataCorp,
17
18 College Station, Texas, USA) and R (version 3.0.3; R Foundation, www.r-project.org).
19

20
21 Analysis was conducted in Stata accounting for the complex design of both surveys, using the
22
23 appropriate weighting variables and Primary Sampling Units. Both datasets are available via
24
25 the UK Data Service (www.ukdataservice.ac.uk).
26
27

28 **Sensitivity analyses**

29
30 Analyses were initially undertaken excluding participants with reported diagnosed asthma
31
32 and then repeated including those with asthma. In accordance with ~~previous~~ the UK National
33
34 Institute for Health and Care Excellence (NICE) ~~recommendation~~ ~~criteria~~⁴⁴, comparisons
35
36 between FT and LLN were rerun defining only the subset of FT participants with FEV₁ <80%
37
38 predicted (i.e., stage II+) as having obstructed airflow.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

The analytical sample comprised 7879 participants (5936 and 1943 from UKHLS and HSE respectively) aged 40-95 years, who resided in England and Wales, did not report diagnosed asthma, had valid values of height and ethnicity, and provided good-quality spirometry.

Response flowcharts for the UKHLS and HSE are provided in Figures **S1** and **S2** (online supplementary appendix) respectively. Excluded participants were more likely to be older, engaged in routine occupations, and self-report respiratory symptoms (data not shown).

[Differences between the UKHLS and HSE in terms of sex ratio, age, smoking history, NS-SEC, and objective measurements of lung function were not materially important \(see online supplementary Table S1\).](#)

Descriptive characteristics of the analytical sample according to physician-diagnosed COPD, FT, and LLN are shown as supplementary data (Tables **S2-S3**). Overall, 46.8% of participants were male, with mean age 57.6 years (SD 12.3), 16.6% were current smokers, 4.6% had >50 pack-years of cigarette smoking, and 36.5% were engaged in professional occupations. 12 (0.1%) and 265 (3.2%) participants had missing values for pack-years and NS-SEC respectively. The prevalence of ~~reported~~ diagnosed COPD was similar between the sexes ($P=0.349$), but was higher for men using FT and LLN (both $P<0.001$). Participants with diagnosed COPD/obstructive spirometry were more likely to be older, currently smoke, have higher pack-years of smoking, and be engaged in routine occupations (all $P<0.001$).

Prevalence of diagnosed COPD was higher in HSE vs. UKHLS ($P<0.001$), but survey-specific prevalence was similar for FT and for LLN. Participants with diagnosed

COPD/obstructive spirometry were more likely to report respiratory symptoms ([chronic cough and phlegm](#)) and disease, current use of respiratory medications, cardiovascular disease, breathlessness, poor self-rated health and have, on average, lower (percent-of-predicted) values of FEV₁, FVC and FEV₁/FVC. The prevalence of respiratory symptoms

was 13.7%, 10.2%, and 11.3% among participants classed as having airflow obstruction according to diagnosed COPD, FT, and LLN respectively; prevalence of having a score of 3+ on the MRC dyspnoea scale was 34.8%, 12.3% and 15.9%.

Prevalence of airflow obstruction

The prevalence of airflow obstruction was 2.8%, 22.2%, and 13.1% using diagnosed COPD, FT, and LLN respectively (**Table 1**). Using FTs, 11.6%, 8.9%, and 1.7% of participants were classed as stage I, stage II, and stage III+ respectively. LLN-derived obstruction was 6.6% (stage I) and 6.4% (stage II). For most subgroups, prevalence was highest for FT and lowest for diagnosed COPD, with LLN falling in-between. The gap in prevalence between FT and LLN increased in older age-groups. Prevalence among participants aged 40-54 years was 11.9% and 10.7% using FT and LLN respectively. Prevalence among participants aged 75-95 years was 45.0% and 17.2%.

Table 2 shows estimates of sensitivity and specificity for FT and LLN, using the alternative spirometric cut-off as the reference standard. When using LLN as reference, specificity - the percentage of participants classed as non-obstructed using LLN identified as non-obstructed using FT - decreased from 94.9% amongst participants aged 40-64 years to 74.4% amongst those aged 65-95 years.

Multivariate analyses of airflow obstruction

Table 3 shows the significant risk factors for diagnosed COPD, and the FT- and LLN-disease stage classifications (non-obstructed as reference category). For diagnosed COPD, the significant interaction between sex and age-group ($P=0.022$) suggested no difference in odds between the sexes among participants aged 40-64 years, but higher odds among men aged 65-95 years. Using FTs, being male was associated with a significantly increased risk of airflow obstruction: RRR 1.35 (95% CI: 1.16-1.58), RRR 1.35 (1.12-1.63), and RRR 1.72 (1.08-2.76)

1
2
3 for stages I, II, and III+ respectively. In contrast, sex differences were not significant using
4
5 LLN: RRR 1.07 (0.88-1.31) for stage I, and RRR 1.20 (0.96-1.50) for stage II.
6
7

8 Odds of diagnosed COPD increased significantly with age only in men (P=0.022 for the
9
10 interaction term). Using non-obstruction as reference, RRRs increased significantly with age
11
12 when using FTs (P<0.001 for each stage). The age-related difference using LLN was more
13
14 marked for stage II (P=0.492 and P<0.001 for stages I and II, respectively). A dose-related
15
16 increased risk with pack-years of cigarette smoking was observed across each definition
17
18 (P<0.001). The difference between NS-SEC levels was more marked with diagnosed COPD
19
20 (P=0.012) and the ~~tightest-most-restrictive~~ FT- and LLN-~~definitioncategories~~ (FT: P=0.002
21
22 stage III+; LLN: P<0.001 stage II).
23
24

25 26 **Combination of diagnosed COPD and spirometric cut-offs**

27
28 The significant risk factors for the two four-category outcome variables created as a
29
30 composite of diagnosed COPD and obstructive spirometry are shown in **Table 4**. Relative to
31
32 the reference category (neither ~~doctor~~-diagnosed nor spirometrically-defined ~~airflow~~
33
34 obstruction), the risk of ~~reportinghaving-obstructed-airflow-using-diagnosed~~ COPD ~~in the~~
35
36 ~~absence ofbut no~~ obstructive spirometry was significantly lower in men using either
37
38 spirometric criterion (FT: RRR 0.53 (95% CI: 0.32-0.87); LLN: RRR 0.56 (0.35-0.89)). The
39
40 risk of having obstructed airflow using spirometry but with no diagnosed COPD – thereby
41
42 indicating possible under-diagnosis - was significantly higher in men, and in older age-
43
44 groups, when using FT but not LLN. For both spirometric criterion, increases in risk with
45
46 increasing pack-years of cigarette smoking, relative to the reference, was consistent across
47
48 combinations of COPD/obstructive spirometry; the difference between NS-SEC levels was
49
50 more marked for obstructive spirometry.
51
52
53
54

55 56 **Sensitivity analyses**

1
2
3 Repeating analyses by including 1183 participants with reported diagnosed asthma increased
4 prevalence of diagnosed COPD, FT and LLN by 2-3 percentage points (Figure S3, online
5 supplementary appendix), but ~~showed~~ similar patterns of association with risk factors.
6
7
8
9
10 Diagnosed asthma was a strong predictor of diagnosed COPD and obstructive spirometry
11 (P<0.001, data not shown).
12

13
14 ~~Narrowing~~ Restricting FT-defined obstruction to the subset of FT participants with FEV₁
15 <80% predicted (i.e., stage II+) more than halved the FT-derived prevalence (22.2% vs.
16 10.6%). Amongst participants aged 65-95 years, specificity using LLN as the reference
17 standard was 74.4% and 91.1% for FT and FT stage II+ respectively (**Table 2**). Patterns of
18 association with risk factors using FT stage II+ was similar to those shown for FT.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Consistent estimation of the COPD burden has been hindered by differences in methods, including disagreement among experts ~~groups~~ over the choice of FT-versus-LLN spirometric cut-offs.⁵⁻⁸ In this study, we combined two nationally-representative ~~general population~~ surveys, with standardised protocols and objective lung function measurements, to evaluate the impact of different definitions on the prevalence of potential airflow obstruction, and its associations with key risk factors. Participants with diagnosed COPD/obstructive spirometry were more likely to be older, currently smoke, have higher pack-years of cigarette smoking, be in lower socioeconomic groups, and report the presence of respiratory symptoms (~~chronic cough and phlegm~~), cardiovascular disease, breathlessness, and poor self-rated health. Among persons aged 40-95 years without physician-diagnosed asthma, prevalence was 2.8%, 22.2%, and 13.1%, according to diagnosed COPD, FT, and LLN respectively. The gap in prevalence between FT and LLN increased in older age-groups. When using LLN as the reference standard, specificity for FT decreased from 94.9% amongst participants aged 40-64 years to 74.4% amongst participants aged 65-95 ~~years~~, corresponding to false-positive rates of 5.1% and 25.6% respectively. Sex differences in the risk of obstructed airflow, after adjustment for potential confounders, was sensitive to spirometric criteria, being higher ~~amongst~~ men for FT, compared with no difference using LLN.

Strengths and limitations

Analyses were based on nationally-representative ~~samples, random samples of the general population~~, with identical measurement protocols and specialist equipment for collecting lung function data. ~~spirometry conducted by well-trained and supervised nurses using standardised protocols and modern, validated equipment. Combining two datasets ensured a sufficient sample size to estimate prevalence, and infer valid statistical associations. Combining the HSE and UKHLS datasets increased statistical precision for spirometry-based estimates,~~

particularly for population subgroups, and allowed detailed analyses to be conducted.

Predicted values and Z-scores were obtained from defined using the ERS recently developed European Respiratory Society GLI 2012 reference equations²⁸, facilitating inclusion of older participants, non-white populations and comparability with international studies. Our study has a number of limitations. Reversibility in airflow obstruction could not be assessed due to bronchodilators not being used. Spirometry-based prevalence, therefore, may be overestimated. Analysis of the National Health and Nutrition Examination Survey (NHANES) 2007-2010 showed that FT- and LLN-prevalence estimates among US adults aged 40-79 years decreased, in relative terms, by approximately one-third after administration of bronchodilators.⁴⁵ Although recent guidelines from NICE the National Institute for Health and Care Excellence⁴⁶ and ERS European Respiratory Society¹³ recommend use of post-bronchodilator spirometry to confirm the presence of airflow obstruction, debate continues over its use in epidemiological settings, with the arguments against including ethical issues such as possible side-effects and contraindications.⁴⁷ Potential misclassification of disease status through bronchodilators not being used was reduced by excluding participants with physician-diagnosed asthma. Some participants in the analytical sample, however, may be undiagnosed asthmatics. On the other hand, the disease burden may be underestimated through excluding participants with poor-quality spirometry. Participation in spirometry, and achievement of good-quality standards among participants with any spirometry data, was higher among participants of younger age, engaged in professional/managerial occupations, non-smokers, and with no self-reported physician-diagnosed chronic bronchitis, emphysema or COPD. Lower survey participation rates amongst socio-demographic groups at higher risk of airflow obstruction (e.g., older persons, lower socioeconomic groups) would also have led to an underestimation of true prevalence. These limitations, however, are unlikely to affect comparisons across definitions, but may have led to an underestimate of risk associations.

The list of health conditions in the UKHLS interview programme included chronic bronchitis and emphysema but not COPD, leading to potential underestimation of self-reported physician-diagnosed COPD.

Comparisons with previous studies

Earlier analyses of Health Survey for England data^{36;38;48} used older sets of reference equations^{49;50} applicable only to white, and younger populations. Nevertheless, estimates of prevalence and their substantive conclusions of higher prevalence using FT-versus-LLN, with a widening gap in prevalence in older age-groups, and sex differences when using FT but not LLN were similar to ours: confirming findings reported in the US⁴⁵, Europe⁵¹, Korea¹⁶, internationally¹², and in recent literature reviews.^{6;52} A further strength of our study was the wide range of clinically-relevant conditions examined in the context of disease-staging, with higher prevalence of self-reported respiratory symptoms, respiratory- and cardiovascular-disease, breathlessness, and poor self-rated health among participants in the tightest definitions of most restrictive FT- and LLN-obstruction categories, confirming similar findings in the US.^{53;54} Whilst recent guidelines^{13;46;55} recommend adopting multidimensional definitions of respiratory disease, our study outcomes were defined only using spirometry. While we acknowledge the merits of a multidimensional approach, and agree that neither spirometric cut-off is able to fully characterise the complex diagnostic features of COPD⁵⁶, our primary aim was to use up-to-date survey data to evaluate differences in prevalence according to FT- and LLN-thresholds, to provide baseline data for monitoring purposes in the UK, and promote comparability with international studies. Current recommendations regarding symptom criteria are less specific than those for spirometry. We chose, therefore, to examine the associations between disease-staging assessed only using spirometry and presence of respiratory symptoms, rather than broaden the definition of disease.

Implications

Recent UK studies used administrative primary-care databases to report the number of diagnosed and treated patients, thereby missing undiagnosed cases. Such studies have reported prevalence below 2%.^{57;58} The disparity in prevalence from clinical-versus-epidemiological studies led to the development of the COPD prevalence model, with the HSE 2001 used as input data, to more accurately estimate prevalence.⁵⁹ In accordance with [previous NICE National Institute for Health and Care Excellence recommendations criteria](#)⁴⁴, COPD is currently defined in the model as FT stage II+ (FEV₁/FVC <0.70 and FEV₁ <80% predicted), with the logistic regression models showing sharp increases with age and a modifying effect of gender.^{60;61} Similar to the findings reported by Jordan et al.³⁶, our study shows that the strength of association between risk factors and airflow obstruction varies according to spirometric criterion, with age- and sex-differences in risk being more marked for FT, and for FT stage II+, than LLN. In the absence of agreement among expert-groups, policy-makers, clinicians, and researchers building the COPD epidemiological database, it is important to appreciate the sensitivity of estimates of the disease burden, and its distribution across socio-demographic groups, to differences in methods, including spirometric cut-offs. The prevalence of reported physician-diagnosed COPD in our study was 2.8%, considerably lower than spirometry-based estimates, possibly indicating considerable under-recognition by both participants and physicians. Using the [tightest most restricted](#) definitions, prevalence of physician-diagnosed COPD among participants with obstructive spirometry was 30.2% (FT stage III+) and 14.7% (LLN stage II). Similar low rates of physician-diagnosis among participants meeting spirometric criteria have been reported in New Zealand.⁶²

[Spirometrically-defined airflow obstruction but no diagnosed COPD does not necessarily indicate under-diagnosis. Definitive diagnosis requires further information on all relevant clinical factors, particularly respiratory symptoms and smoking history, as well as post-bronchodilator spirometry.](#)

Conclusion

In summary, we have enhanced the COPD epidemiological database by evaluating the impact of different definitions on the prevalence of potential airflow obstruction and its associations with key risk factors and comorbidities. With no gold standard currently available, longitudinal studies examining differences in unscheduled hospital admissions and risk of death between FT and LLN may inform the choice as to the best way to include spirometry data in multidimensional assessments of airflow obstruction in both clinical and epidemiological settings.

Abbreviations: COPD, chronic obstructive pulmonary disease; ERS, European Respiratory Society; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FT, fixed thresholds; GLI, Global Lungs Initiative; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HSE, Health Survey for England; LLN, lower limit of normal; NICE, National Institute for Health and Care Excellence; UKHLS, United Kingdom Household Longitudinal Survey

Acknowledgements: The authors thank Deborah Jarvis, Janet Stocks and Jessica Sheringham for helpful comments.

Ethics approval: Ethical approval for collecting biosocial data in UKHLS was obtained from the Oxfordshire A Research Ethics Committee (10/H0604/2); approval for HSE 2010 was obtained from the Oxfordshire B Research Ethics Committee (09/H0605/73). Eligible participants gave written consent to participate in spirometry.

Funding: The study did not receive any specific funding. The Health Survey for England 2010 was funded by the Health and Social Care Information Centre (HSCIC). The views expressed here are those of the authors and not of the HSCIC, Department of Health, or the National Health Service.

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

"The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be

published in BMJ editions and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence."

Data sharing: Both datasets are available via the UK Data Service (www.ukdataservice.ac.uk). Statistical code is available from the corresponding author at s.scholes@ucl.ac.uk.

Contributors: SS, AM, and JM participated in study concept and design, analysis and interpretation of data. SS performed data acquisition and management. SS participated in drafting of the manuscript. AM and JM aided revision of the manuscript and provided relevant intellectual input. SS is the data guarantor. All authors have approved the final version of the manuscript.

Reference List

- (1) Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 2007; 370(9589):765-773.
- (2) Raheison C, Girodet PO. Epidemiology of COPD. *Eur Respir Rev* 2009; 18(114):213-221.
- (3) Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380(9859):2095-2128.
- (4) Department of Health. *An Outcomes Strategy for COPD and asthma: NHS Companion Document*. 2012.
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216139/dh_128428.pdf
- (5) Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. *BMC Med* 2011; 9:7.
- (6) Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. *Int J Chron Obstruct Pulmon Dis* 2012; 7:457-494.
- (7) McLean S, Wild SH, Simpson CR, Sheikh A. Models for estimating projections for the prevalence and disease burden of chronic obstructive pulmonary disease (COPD): systematic review protocol. *Prim Care Respir J* 2013; 22(2):S8-21.
- (8) Salvi SS, Manap R, Beasley R. Understanding the true burden of COPD: the epidemiological challenges. *Prim Care Respir J* 2012; 21(3):249-251.
- (9) Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001; 163(5):1256-1276.
- (10) Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Standardisation of spirometry. *Eur Respir J* 2005; 26(2):319-338.
- (11) Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. *Chest* 2011; 139(1):52-59.
- (12) Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. *Thorax* 2008; 63(12):1046-1051.

- 1
- 2
- 3 (13) Bakke PS, Ronmark E, Eagan T, Pistelli F, Annesi-Maesano I, Maly M et al.
- 4 Recommendations for epidemiological studies on COPD. *Eur Respir J* 2011;
- 5 38(6):1261-1277.
- 6
- 7 (14) Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use
- 8 percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. *Chest* 2007;
- 9 131(2):349-355.
- 10
- 11 (15) Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastrorarde JG et al.
- 12 FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of
- 13 age. *Chest* 2006; 130(1):200-206.
- 14
- 15 (16) Hwang YI, Kim CH, Kang HR, Shin T, Park SM, Jang SH et al. Comparison of the
- 16 prevalence of chronic obstructive pulmonary disease diagnosed by lower limit of
- 17 normal and fixed ratio criteria. *J Korean Med Sci* 2009; 24(4):621-626.
- 18
- 19 (17) Quanjer PH, Cole TJ. COPD and GOLD stage I. *Chest* 2012; 141(4):1122.
- 20
- 21 (18) Enright P, Brusasco V. Counterpoint: should we abandon FEV(1)/FVC < 0.70 to
- 22 detect airway obstruction? Yes. *Chest* 2010; 138(5):1040-1042.
- 23
- 24 (19) Quanjer PH, Enright PL, Miller MR, Stocks J, Ruppel G, Swanney MP et al. The
- 25 need to change the method for defining mild airway obstruction. *Eur Respir J* 2011;
- 26 37(3):720-722.
- 27
- 28 (20) Celli BR, Halbert RJ. Point: should we abandon FEV(1)/FVC <0.70 to detect airway
- 29 obstruction? No. *Chest* 2010; 138(5):1037-1040.
- 30
- 31 (21) Falaschetti E, Swanney MP, Crapo RO, Hankinson JL, Jensen RL, Pedersen OF et al.
- 32 Diagnosis of COPD. *Thorax* 2007; 62(10):924-925.
- 33
- 34 (22) Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global
- 35 burden of COPD: systematic review and meta-analysis. *Eur Respir J* 2006; 28(3):523-
- 36 532.
- 37
- 38 (23) Mindell J, Biddulph JP, Hirani V, Stamatakis E, Craig R, Nunn S et al. Cohort profile:
- 39 the health survey for England. *Int J Epidemiol* 2012; 41(6):1585-1593.
- 40
- 41 (24) Joint Health Surveys Unit. *The Health Survey for England 2010, Volume 1:*
- 42 *Respiratory Health*. Craig R, Mindell J, editors. Respiratory health. Leeds, NHS
- 43 Information Centre, 2011. <http://www.hscic.gov.uk/pubs/hse10report>
- 44
- 45 (25) Joint Health Surveys Unit. *The Health Survey for England 2010, Volume 2: Methods*
- 46 *and Documentation*. Leeds, The Information Centre for Health and Social Care,
- 47 2011. [http://www.hscic.gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-](http://www.hscic.gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-vol2-meth-rep.pdf)
- 48 [vol2-meth-rep.pdf](http://www.hscic.gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-vol2-meth-rep.pdf)
- 49
- 50 (26) Lynn P. Sample design for Understanding Society. Understanding Society Working
- 51 Paper Series: 2009-01.
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

<https://www.understandingsociety.ac.uk/research/publications/working-paper/understanding-society/2009-01.pdf>

- (27) McFall SL, Petersen J, Kaminska O, Lynn P. *Understanding Society - The UK Household Longitudinal Study: Waves 2 and 3 Nurse Health Assessment, 2010-2012 Guide to Nurse Health Assessment*. Colchester, University of Essex, 2012. https://www.understandingsociety.ac.uk/d/100/7251_User_Guide_Health_Assmt_w2_w3.pdf?1392855567
- (28) Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; 40(6):1324-1343.
- (29) Quanjer PH, Brazzale DJ, Boros PW, Pretto JJ. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. *Eur Respir J* 2013; 42(4):1046-1054.
- (30) Hall GL, Thompson BR, Stanojevic S, Abramson MJ, Beasley R, Coates A et al. The Global Lung Initiative 2012 reference values reflect contemporary Australasian spirometry. *Respirology* 2012; 17(7):1150-1151.
- (31) Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007; 176(6):532-555.
- (32) COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. *Thorax* 1997; 52 Suppl 5:S1-28.
- (33) Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. *Chest* 2000; 117(4):1146-1161.
- (34) Vaz Fragoso CA, Concato J, McAvay G, Van Ness PH, Rochester CL, Yaggi HK et al. The ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010; 181(5):446-451.
- (35) Deaths from chronic obstructive pulmonary disease--United States, 2000-2005. *MMWR Morb Mortal Wkly Rep* 2008; 57(45):1229-1232.
- (36) Jordan RE, Miller MR, Lam KB, Cheng KK, Marsh J, Adab P. Sex, susceptibility to smoking and chronic obstructive pulmonary disease: the effect of different diagnostic criteria. Analysis of the Health Survey for England. *Thorax* 2012; 67(7):600-605.
- (37) Bhatt SP, Sieren JC, Dransfield MT, Washko GR, Newell JD, Jr., Stinson DS et al. Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction. *Thorax* 2013.

- 1
2
3 (38) Jordan RE, Cheng KK, Miller MR, Adab P. Passive smoking and chronic obstructive
4 pulmonary disease: cross-sectional analysis of data from the Health Survey for
5 England. *BMJ Open* 2011; 1(2):e000153.
6
7 (39) Woodward M. *Epidemiology Study Design and Data Analysis*. 2nd ed. Boca Raton,
8 Florida: Chapman & Hall/CRC, 2004.
9
10 (40) Loong TW. Understanding sensitivity and specificity with the right side of the brain.
11 *BMJ* 2003; 327(7417):716-719.
12
13 (41) Rabe-Hesketh S, Skrondal A. *Multilevel and longitudinal modeling using Stata:
14 Volume II: Categorical responses, counts, and survival*. 3rd ed. Texas, United States:
15 Stata Press, 2012.
16
17 (42) UCLA Statistical Consulting Group. Multinomial Logistic Regression.
18 www.ats.ucla.edu/stat/stata/dae/mlogit.htm
19
20
21 (43) Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL et al. Prevalence and
22 underdiagnosis of chronic obstructive pulmonary disease among patients at risk in
23 primary care. *CMAJ* 2010; 182(7):673-678.
24
25 (44) Chronic obstructive pulmonary disease. National clinical guideline on management of
26 chronic obstructive pulmonary disease in adults in primary and secondary care.
27 *Thorax* 2004; 59 Suppl 1:1-232.
28
29 (45) Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S.
30 prevalence of chronic obstructive pulmonary disease using pre- and post-
31 bronchodilator spirometry: the National Health and Nutrition Examination Survey
32 (NHANES) 2007-2010. *Respir Res* 2013; 14:103.
33
34 (46) National Institute for Health and Care Excellence (NICE). Chronic obstructive
35 pulmonary disease: management of chronic obstructive pulmonary disease in adults in
36 primary and secondary care. 2010. www.nice.org.uk/Guidance/CG101.
37
38 (47) Quanjer PH, Stanojevic S, Swanney MP, Miller MR. Recommendations for
39 epidemiological studies on COPD. *Eur Respir J* 2012; 39(5):1277-1278.
40
41 (48) Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco
42 dependence of chronic obstructive pulmonary disease in a nationally representative
43 population sample. *Thorax* 2006; 61(12):1043-1047.
44
45 (49) Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung
46 volumes and forced ventilatory flows. Report Working Party Standardization of Lung
47 Function Tests, European Community for Steel and Coal. Official Statement of the
48 European Respiratory Society. *Eur Respir J Suppl* 1993; 16:5-40.
49
50 (50) Falaschetti E, Laiho J, Primatesta P, Purdon S. Prediction equations for normal and
51 low lung function from the Health Survey for England. *Eur Respir J* 2004; 23(3):456-
52 463.
53
54
55
56
57
58
59
60

- 1
2
3 (51) Maio S, Sherrill DL, MacNee W, Lange P, Costabel U, Dahlen SE et al. The
4 European Respiratory Society spirometry tent: a unique form of screening for airway
5 obstruction. *Eur Respir J* 2012; 39(6):1458-1467.
- 6
7 (52) Mohamed Hoesein FA, Zanen P, Lammers JW. Lower limit of normal or FEV1/FVC
8 < 0.70 in diagnosing COPD: an evidence-based review. *Respir Med* 2011;
9 105(6):907-915.
- 10
11 (53) Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes,
12 hypertension and cardiovascular disease in COPD. *Eur Respir J* 2008; 32(4):962-969.
- 13
14 (54) Ford ES, Wheaton AG, Mannino DM, Presley-Cantrell L, Li C, Croft JB. Elevated
15 cardiovascular risk among adults with obstructive and restrictive airway functioning
16 in the United States: a cross-sectional study of the National Health and Nutrition
17 Examination Survey from 2007-2010. *Respir Res* 2012; 13:115.
- 18
19 (55) Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A et al. Global
20 strategy for the diagnosis, management, and prevention of chronic obstructive
21 pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2013;
22 187(4):347-365.
- 23
24 (56) Clini EM, Crisafulli E, Roca M, Malerba M. Diagnosis of chronic obstructive
25 pulmonary disease, simpler is better. Complexity and simplicity. *Eur J Intern Med*
26 2013; 24(3):195-198.
- 27
28 (57) Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L. The
29 distribution of COPD in UK general practice using the new GOLD classification. *Eur*
30 *Respir J* 2013.
- 31
32 (58) Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology of chronic
33 obstructive pulmonary disease in England: a national study of 51 804 patients. *Br J*
34 *Gen Pract* 2010; 60(576):277-284.
- 35
36 (59) Walford H, Ramsey L. *COPD Prevalence Modelling Briefing Document*. 2011.
37 www.apho.org.uk/resource/view.aspx?RID=111137.
- 38
39 (60) Nacul LC, Soljak M, Meade T. Model for estimating the population prevalence of
40 chronic obstructive pulmonary disease: cross sectional data from the Health Survey
41 for England. *Popul Health Metr* 2007; 5:8.
- 42
43 (61) Nacul L, Soljak M, Samarasundera E, Hopkinson NS, Lacerda E, Indulkar T et al.
44 COPD in England: a comparison of expected, model-based prevalence and observed
45 prevalence from general practice data. *J Public Health (Oxf)* 2011; 33(1):108-116.
- 46
47 (62) Shirtcliffe P, Weatherall M, Marsh S, Travers J, Hansell A, McNaughton A et al.
48 COPD prevalence in a random population survey: a matter of definition. *Eur Respir J*
49 2007; 30(2):232-239.
- 50
51
52
53
54
55
56
57
58
59
60

Table 1 Prevalence of Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria, Persons aged 40-95 years Without Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

	n	Diagnosed-COPD ^b	Fixed Thresholds ^c			Lower Limit of Normal ^d			
		% (95% CI)	Obstructed % (95% CI)	stage I % (95% CI)	stage II % (95% CI)	stage III+ % (95% CI)	Obstructed % (95% CI)	stage I % (95% CI)	stage II % (95% CI)
All	7879	2.8 (2.3-3.2)	22.2 (21.2-23.2)	11.6 (10.9-12.4)	8.9 (8.2-9.6)	1.7 (1.3-2.0)	13.1 (12.2-13.9)	6.6 (6.0-7.3)	6.4 (5.8-7.0)
Sex:									
Males	3335	3.0 (2.3-3.6)	26.3 (24.8-27.9)	13.2 (12.1-14.4)	10.7 (9.6-11.8)	2.4 (1.8-3.0)	15.0 (13.7-16.4)	7.2 (6.2-8.1)	7.9 (6.9-8.9)
Females	4544	2.6 (2.0-3.1)	18.6 (17.4-19.9)	10.2 (9.2-11.2)	7.4 (6.5-8.2)	1.0 (0.7-1.4)	11.3 (10.3-12.3)	6.2 (5.4-6.9)	5.1 (4.4-5.9)
Age-group:									
40-54	3472	1.7 (1.3-2.2)	11.9 (10.7-13.1)	7.0 (6.1-7.9)	4.6 (3.8-5.4)	0.3 (0.1-0.6)	10.7 (9.6-11.9)	6.7 (5.7-7.6)	4.1 (3.3-4.9)
55-64	2072	3.4 (2.5-4.2)	24.2 (22.2-26.1)	12.6 (11.1-14.1)	9.5 (8.1-10.9)	2.0 (1.4-2.7)	14.2 (12.6-15.8)	6.5 (5.4-7.7)	7.7 (6.4-8.9)
65-74	1557	3.9 (2.8-5.0)	32.6 (30.1-35.1)	16.5 (14.6-18.5)	12.9 (11.1-14.6)	3.2 (2.1-4.2)	15.0 (13.0-17.0)	6.4 (5.1-7.7)	8.6 (7.0-10.2)
75-95	778	3.9 (2.0-5.8)	45.0 (41.1-48.8)	21.1 (18.0-24.2)	19.6 (16.6-22.6)	4.3 (2.5-6.0)	17.2 (14.2-20.1)	7.2 (5.2-9.2)	9.9 (7.6-12.3)
Smoking status:									
Current	1198	4.7 (3.5-6.0)	37.0 (34.1-39.9)	14.5 (12.3-16.6)	18.2 (15.9-20.6)	4.2 (3.0-5.4)	29.8 (27.0-32.6)	13.5 (11.3-15.7)	16.2 (14.0-18.5)
Ex-regular	2547	3.6 (2.7-4.5)	26.8 (24.9-28.7)	14.1 (12.7-15.6)	10.5 (9.2-11.8)	2.2 (1.5-2.9)	14.5 (13.0-16.1)	7.2 (6.0-8.3)	7.4 (6.2-8.5)
Never	4134	1.6 (1.2-2.0)	14.7 (13.5-15.9)	9.2 (8.2-10.1)	5.0 (4.3-5.7)	0.5 (0.2-0.9)	6.8 (5.9-7.7)	4.1 (3.5-4.8)	2.7 (2.1-3.3)
Pack-years^e:									
0-0.9	4299	1.6 (1.2-2.0)	14.8 (13.6-16.0)	9.3 (8.4-10.3)	5.0 (4.3-5.7)	0.5 (0.2-0.8)	6.7 (5.9-7.6)	4.1 (3.5-4.7)	2.6 (2.0-3.2)
1-19.9	1905	2.3 (1.5-3.1)	22.3 (20.3-24.3)	12.9 (11.3-14.5)	7.5 (6.2-8.8)	1.9 (1.1-2.6)	13.4 (11.7-15.1)	7.6 (6.3-8.9)	5.8 (4.6-7.0)
20-49.9	1318	5.0 (3.6-6.5)	36.8 (34.0-39.6)	15.7 (13.5-17.9)	18.1 (15.9-20.4)	2.9 (2.0-3.9)	25.4 (22.8-27.9)	11.6 (9.5-13.6)	13.8 (11.8-15.8)
50+	345	10.5 (7.0-14.1)	53.7 (48.0-59.4)	16.0 (12.0-20.1)	28.0 (23.0-32.9)	9.7 (6.2-13.2)	39.3 (33.5-45.0)	12.4 (8.7-16.2)	26.9 (21.6-32.1)
NS-SEC^e:									
Professional	3050	1.9 (1.4-2.4)	17.1 (15.7-18.5)	10.4 (9.3-11.6)	5.7 (4.9-6.5)	1.0 (0.6-1.4)	9.1 (8.0-10.2)	5.6 (4.6-6.5)	3.6 (2.9-4.3)
Intermediate	1859	2.3 (1.6-3.0)	21.9 (19.9-23.9)	12.5 (10.9-14.1)	8.4 (7.0-9.7)	1.1 (0.5-1.7)	12.0 (10.5-13.5)	6.6 (5.4-7.8)	5.4 (4.3-6.5)
Routine	2705	4.0 (3.1-4.8)	26.6 (24.7-28.5)	11.6 (10.3-12.9)	12.3 (10.9-13.7)	2.7 (2.0-3.5)	17.4 (15.8-19.1)	7.7 (6.6-8.9)	9.7 (8.4-11.0)

Abbreviations used: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in 1 second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the lower 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; UKHLS, United Kingdom Household Longitudinal Survey.

1
2
3
4
5
6
7^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts are unweighted; prevalence estimates were weighted.

8^b HSE: reported diagnosed COPD, bronchitis or emphysema; UKHLS: diagnosed bronchitis or emphysema.

9^c FTs: Obstruction (FT): $FEV_1/FVC < 0.70$. Staging classification: stage I ($FEV_1/FVC < 0.70$ and $FEV_1 \geq 80\%$ of predicted); stage II ($FEV_1/FVC < 0.70$ and FEV_1 50-79% of predicted); stage III+ ($FEV_1/FVC < 0.70$ and $FEV_1 < 50\%$ of predicted).

10
11
12^d LLN: Obstruction (LLN): $FEV_1/FVC < LLN$. Staging classification: stage I ($FEV_1/FVC < LLN$ and $FEV_1 > LLN$); stage II ($FEV_1/FVC < LLN$ and $FEV_1 < LLN$).

13
14^e Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.

Table 2 Sensitivity and Specificity of Fixed Thresholds and Lower Limit of Normal Spirometric Criteria by Age-group, Persons aged 40-95 years Without Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)

	40-64 (n=5544)	65-95 (n=2335)	40-64 (n=5544)	65-95 (n=2335)
	FT using LLN as reference standard		LLN using FT as reference standard	
False positives, (%)	5.1	25.6	0.4	0.0
False negatives, (%)	2.5	0.0	28.0	57.6
Sensitivity	0.975	1.000	0.720	0.424
Specificity	0.949	0.744	0.996	1.000
PPV	0.720	0.424	0.975	1.000
NPV	0.996	1.000	0.949	0.744
Kappa coefficient	0.801	0.479	0.801	0.479
Likelihood ratio positive	18.98	3.90	200.65	N/A
Likelihood ratio negative	0.027	0.000	0.281	0.576
	FT (stage II+) using LLN as reference standard		LLN using FT (stage II+) as reference standard	
False positives, (%)	1.3	8.9	6.3	5.2
False negatives, (%)	49.2	26.7	16.0	39.1
Sensitivity	0.508	0.733	0.840	0.609
Specificity	0.987	0.911	0.937	0.948
PPV	0.840	0.609	0.508	0.733
NPV	0.937	0.948	0.987	0.911
Kappa coefficient	0.597	0.596	0.597	0.596
Likelihood ratio positive	38.82	8.28	13.27	11.67
Likelihood ratio negative	0.499	0.292	0.170	0.412

Abbreviations used: FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); NPV, negative predictive value; PPV, positive predictive value; UKHLS, United Kingdom Household Longitudinal Survey.

Table 3 Results of Logistic and Multinomial Logistic Regressions for Reported Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria Among Persons Aged 40-95 years, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

Characteristics	Diagnosed-COPD ^b	Fixed Thresholds ^c			Lower Limit of Normal ^d			
		N	OR (95% CI)	Non-obstructed as reference			Non-obstructed as reference	
				stage I	stage II	stage III+	stage I	stage II
		RRR (95% CI) ^e	RRR (95% CI) ^e	RRR (95% CI) ^e	RRR (95% CI) ^e	RRR (95% CI) ^e		
Sex:								
Females ^f	4372	1.00	1.00	1.00	1.00	1.00		
Males	3231	0.60 (0.34-1.05)	1.35 (1.16-1.58)	1.35 (1.12-1.63)	1.72 (1.08-2.76)	1.07 (0.88-1.31) 1.20 (0.96-1.50)		
<i>P-value</i>		0.075	<0.001	0.002	0.024	0.503 0.107		
Age-group:								
40-54 ^f	3416	1.00	1.00	1.00	1.00	1.00		
55-64	2022	1.66 (1.07-2.58)	2.00 (1.63-2.45)	2.13 (1.65-2.73)	6.05 (2.82-12.99)	0.92 (0.72-1.18) 1.57 (1.20-2.06)		
65-74	1451	0.96 (0.54-1.70)	2.85 (2.30-3.53)	3.01 (2.32-3.89)	10.11 (4.55-22.49)	0.83 (0.63-1.09) 1.56 (1.16-2.12)		
75+	714	1.20 (0.39-3.70)	4.72 (3.66-6.07)	6.67 (5.00-8.90)	22.26 (9.45-52.44)	1.06 (0.74-1.51) 2.20 (1.52-3.17)		
<i>P-value</i>		0.104	<0.001	<0.001	<0.001	0.492 <0.001		
Pack-years^g:								
0-0.9 ^f	4165	1.00	1.00	1.00	1.00	1.00		
1-19.9	1835	1.38 (0.88-2.17)	1.61 (1.34-1.93)	1.66 (1.29-2.15)	3.82 (1.80-8.14)	1.94 (1.51-2.49) 2.22 (1.58-3.12)		
20-49.9	1269	2.91 (1.91-4.45)	2.30 (1.86-2.85)	4.56 (3.64-5.72)	5.91 (2.81-12.45)	3.39 (2.61-4.41) 5.43 (3.98-7.41)		
50+	334	5.64 (3.45-9.22)	2.34 (1.63-3.35)	6.83 (4.85-9.63)	17.27 (7.88-37.84)	4.50 (2.96-6.84) 11.20 (7.59-16.52)		
<i>P-value</i>		<0.001	<0.001	<0.001	<0.001	<0.001 <0.001		
NS-SEC^g:								
Professional ^f	3047	1.00	1.00	1.00	1.00	1.00		
Intermediate	1855	1.03 (0.68-1.58)	1.18 (0.97-1.45)	1.34 (1.04-1.72)	1.01 (0.51-2.00)	1.14 (0.88-1.48) 1.35 (0.99-1.85)		
Routine	2701	1.61 (1.13-2.31)	1.07 (0.89-1.29)	1.82 (1.47-2.26)	2.30 (1.36-3.88)	1.28 (1.01-1.63) 2.18 (1.67-2.85)		
<i>P-value</i>		0.012	0.246	<0.001	0.002	0.123 <0.001		
Sample:								
UKHLS ^f	5675	1.00	1.00	1.00	1.00	1.00		
HSE	1928	2.22 (1.60-3.07)	0.95 (0.79-1.14)	0.97 (0.79-1.20)	0.99 (0.62-1.59)	1.05 (0.82-1.33) 0.99 (0.77-1.26)		
<i>P-value</i>		<0.001	0.587	0.798	0.967	0.716 0.913		
Males × age-group:								

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

40-54 ^e	1319	1.00	-	-	-	-	-
55-64	876	1.16 (0.54-2.45)	-	-	-	-	-
65-74	664	3.21 (1.40-7.39)	-	-	-	-	-
75+	372	2.61 (0.67-10.22)	-	-	-	-	-
<i>P-value</i>		<i>0.022</i>	-	-	-	-	-

Abbreviations used: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; OR, odds ratios; RRR; relative risk ratios; UKHLS, United Kingdom Household Longitudinal Survey.

^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts are unweighted; ORs and RRRs were weighted.

^b HSE: reported diagnosed COPD, bronchitis or emphysema; UKHLS: diagnosed bronchitis or emphysema.

^c FTs: stage I (FEV₁/FVC <0.70 and FEV₁ ≥80% of predicted); stage II (FEV₁/FVC <0.70 and FEV₁ 50-79% of predicted); stage III+ (FEV₁/FVC <0.70 and FEV₁ <50% of predicted). Reference category: FEV₁/FVC ≥0.70.

^d LLN: stage I (FEV₁/FVC <LLN and FEV₁ >LLN); stage II (FEV₁/FVC <LLN and FEV₁ <LLN). Reference category: FEV₁/FVC ≥LLN.

^e The RRR is interpreted as the relative risk of one outcome in relation to the reference category for a specified category of an independent variable compared with the reference category for that independent variable. Using FT stage I as an example, the RRR for males vs. females is interpreted as the relative risk for FT stage I vs. non-obstruction for males compared with the analogous relative risk for females, adjusted for the other variables in the model.

^f Reference category.

^g Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.

Table 4 Results of Multinomial Logistic Regressions for Combined Outcome Variable Based on Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometric Criteria Among Persons aged 40-95 years, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-12)^a

Characteristics	Fixed Thresholds ^b			Lower Limit of Normal ^c			
	Neither diagnosed nor obstructive spirometry as reference			Neither diagnosed nor obstructive spirometry as reference			
	Diagnosed alone	Obstructive spirometry alone	Diagnosed and obstructive spirometry	Diagnosed alone	Obstructive spirometry alone	Diagnosed and obstructive spirometry	
	n	RRR (95% CI) ^d	RRR (95% CI) ^d	RRR (95% CI) ^d	RRR (95% CI) ^d	RRR (95% CI) ^d	
Sex:							
Females ^e	4372	1.00	1.00	1.00	1.00	1.00	
Males	3231	0.49 (0.31-0.79)	1.31 (1.16-1.49)	2.23 (1.34-3.71)	0.52 (0.34-0.81)	1.05 (0.90-1.23)	2.15 (1.25-3.71)
<i>P-value</i>		0.003	<0.001	0.002	0.004	0.543	0.006
Age-group:							
40-54 ^e	3416	1.00	1.00	1.00	1.00	1.00	
55-64	2022	1.26 (0.76-2.09)	2.08 (1.76-2.46)	4.06 (2.11-7.79)	1.34 (0.83-2.16)	1.09 (0.90-1.33)	2.91 (1.49-5.68)
65-74	1451	1.47 (0.84-2.55)	3.05 (2.56-3.63)	4.78 (2.38-9.57)	1.27 (0.74-2.15)	1.02 (0.82-1.27)	3.12 (1.53-6.36)
75+	714	1.95 (0.69-5.51)	5.89 (4.76-7.29)	7.55 (3.35-17.02)	1.60 (0.67-3.81)	1.42 (1.08-1.87)	3.47 (1.43-8.40)
<i>P-value</i>		0.388	<0.001	<0.001	0.535	0.085	<0.001
Pack-years^f:							
0-0.9 ^e	4165	1.00	1.00	1.00	1.00	1.00	
1-19.9	1835	1.08 (0.61-1.92)	1.67 (1.42-1.96)	2.84 (1.30-6.23)	1.16 (0.68-2.00)	2.02 (1.63-2.50)	2.58 (1.10-6.01)
20-49.9	1269	3.05 (1.68-5.54)	3.18 (2.70-3.74)	6.70 (3.35-13.40)	2.98 (1.72-5.16)	4.23 (3.44-5.20)	5.74 (2.70-12.20)
50+	334	3.94 (1.70-9.13)	4.15 (3.13-5.49)	18.50 (8.41-40.70)	3.87 (1.81-8.29)	6.83 (4.98-9.37)	17.23 (7.37-40.28)
<i>P-value</i>		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
NS-SEC^f:							
Professional ^e	3047	1.00	1.00	1.00	1.00	1.00	
Intermediate	1855	0.76 (0.45-1.30)	1.20 (1.02-1.41)	1.84 (0.87-3.87)	0.83 (0.50-1.40)	1.19 (0.97-1.47)	1.57 (0.72-3.44)
Routine	2701	0.93 (0.59-1.48)	1.31 (1.12-1.53)	3.65 (1.89-7.06)	1.08 (0.70-1.67)	1.54 (1.27-1.87)	3.37 (1.70-6.68)
<i>P-value</i>		0.612	0.002	<0.001	0.632	<0.001	<0.001
Sample:							
UKHLS ^e	5675	1.00	1.00	1.00	1.00	1.00	
HSE	1928	2.38 (1.54-3.69)	0.94 (0.81-1.09)	1.92 (1.21-3.05)	2.21 (1.46-3.35)	0.96 (0.79-1.16)	2.13 (1.31-3.48)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

<i>P-value</i>	<i><0.001</i>	<i>0.420</i>	<i>0.006</i>	<i><0.001</i>	<i>0.664</i>	<i>0.002</i>
----------------	------------------	--------------	--------------	------------------	--------------	--------------

Abbreviations used: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); NS-SEC, National Statistics Socio-Economic Classification; OR, odds ratios; RRR; relative risk ratios; UKHLS, United Kingdom Household Longitudinal Survey.

^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts unweighted; RRRs estimated using survey weights.

^b FTs: Obstruction (FT): FEV₁/FVC <0.70. Diagnosed COPD: HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.

^c LLN: Obstruction (LLN): FEV₁/FVC <LLN. Diagnosed COPD: HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.

^d The RRR is interpreted as the relative risk of one outcome in relation to the reference category for a specified category of an independent variable compared with the reference category for that independent variable. Using diagnosed alone as an example, the RRR for males vs. females is interpreted as the relative risk for diagnosed alone vs. neither diagnosed nor objective spirometry for males compared with the analogous relative risk for females, adjusted for the other variables in the model.

^e Reference category.

^f Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.

1
2
3 **SUPPLEMENTARY DATA**
4


5
6 Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons
7
8 aged 40-95 years in England and Wales
9

10
11 **Authors:** Shaun Scholes *research associate*,^{1*} Alison Moody *research associate*,¹ Jennifer S Mindell *clinical senior lecturer*¹
12

13
14 ¹ Health and Social Surveys Research Group, Research Department of Epidemiology and Public Health, University College London, 1-19
15
16 Torrington Place, London WC1E 6BT, United Kingdom
17

18
19 * Corresponding author. (e-mail: s.scholes@ucl.ac.uk)
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Figure S1 Response Flowchart for Wave 2 of UK Household Longitudinal Survey 2010-2012^a




^a Detailed flow diagram of participation in the Wave 2 Nurse Health Assessment can be found in McFall *et al.*

^b Lung function measurements in UKHLS were conducted with two different devices: in England and Wales, the electronic NDD Easy on-PCC spirometer (NDD Medical Technologies, Zurich, Switzerland), and in Scotland the Vitalograph Escort (Vitalograph, Buckingham, UK). For this reason, UKHLS residents living in Scotland were excluded from the analytical sample.


^c Quality criteria for spirometry sessions were as follows (Grades A-C required for inclusion in analytical sample):

Grade	Number of acceptable forced expiratory manoeuvres	Additional criteria
A	At least three	Two highest FVC and FEV ₁ within 100 ml
B	At least three	Two highest FVC and FEV ₁ within 150 ml
C	At least two	Two highest FVC and FEV ₁ within 200 ml
D	Only one	Or best two FEV ₁ or FVC were not within 200 ml
F	None	N/A

Figure S2 Response Flowchart in Health Survey for England 2010



- 3 -




^a Quality criteria for spirometry sessions were as follows (Grades A-C required for inclusion in analytical sample):

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Grade	Number of acceptable forced expiratory manoeuvres	Additional criteria
A	At least three	Two highest FVC and FEV ₁ within 100 ml
B	At least three	Two highest FVC and FEV ₁ within 150 ml
C	At least two	Two highest FVC and FEV ₁ within 200 ml
D	One	Or best two FEV ₁ or FVC were not within 200 ml
F	None	N/A

Figure S3 Prevalence of Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometry-Based Definitions, Persons aged 40-95 years, Including and Excluding Participants With Reported Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)



Abbreviations used: FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the 5th percentile of Z-scores); UKHLS, United Kingdom Household Longitudinal Survey.

Table S1 Participant characteristics for the analytical sample and by survey

	HSE and UKHLS	HSE	UKHLS
N	7,879	1,943	5,936
Male, n (%)	3335 (46.8)	824 (48.4)	2511 (46.2)
Age-group, n (%):			
40-54	3472 (46.6)	868 (45.8)	2604 (46.9)
55-64	2072 (24.8)	497 (24.2)	1575 (25.0)
65-74	1557 (17.4)	369 (17.3)	1188 (17.5)
75-95	778 (11.1)	209 (12.6)	569 (10.6)
Mean age, years (SD)	57.6 (12.3)	57.9 (12.5)	57.5 (12.2)
Smoking status, n (%):			
Current	1198 (16.6)	254 (14.5)	944 (17.3)
Ex-regular	2547 (31.7)	659 (33.1)	1888 (31.3)
Never	4134 (51.7)	1030 (52.4)	3104 (51.5)
Pack-years, n (%):			
0-0.9	4299 (53.9)	1082 (55.0)	3217 (53.5)
1-19.9	1905 (24.3)	493 (25.1)	1412 (24.0)
20-49.9	1318 (17.2)	283 (15.0)	1035 (17.9)
50+	345 (4.6)	80 (4.7)	265 (4.5)
NS-SEC, n (%):			
Professional	3050 (36.5)	772 (36.1)	2278 (36.6)
Intermediate	1859 (23.4)	452 (23.6)	1407 (23.3)
Routine	2705 (36.9)	709 (39.8)	1996 (36.0)
Missing	265 (3.2)	10 (0.5)	255 (4.1)
Lung function (%-of-predicted), mean (SD):			
FEV ₁	92.0 (16.5)	91.9 (16.4)	92.0 (16.5)
FVC	97.1 (15.0)	97.2 (15.0)	97.1 (15.1)
FEV ₁ /FVC	94.2 (9.7)	94.0 (9.9)	94.3 (9.7)

1
2
3 Abbreviations: FEV₁ = forced expiratory volume in one second; FVC, forced vital capacity; HSE = Health Survey for England; NS-
4 SEC = National Statistics Socio-Economic Classification; SD = standard deviation; UKHLS = United Kingdom Household
5 Longitudinal Study
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table S2 Characteristics of Participants in the Analytical Sample, With Diagnosed COPD, and According to Fixed Thresholds and Lower Limit of Normal Spirometry-based Severity Classifications, Persons aged 40-95 years Without Reported Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

	All participants	Reported diagnosed COPD ^b	P value ^c	Fixed Thresholds ^d			P value ^c	Lower Limit of Normal ^e		P value ^c
				stage I	stage II	stage III+		stage I	stage II	
n	7879	207		926	681	116		503	468	
Diagnosed COPD, n (%)	207 (2.8)	207 (100.0)		17 (2.1)	48 (7.1)	33 (30.2)	<0.001	19 (3.9)	65 (14.7)	<0.001
Sex, n (%):										
Males	3335 (46.8)	94 (50.4)	0.349	461 (53.3)	375 (56.0)	75 (66.9)	<0.001	231 (50.5)	255 (57.3)	<0.001
Females	4544 (53.3)	113 (49.7)		465 (46.7)	306 (44.0)	41 (33.1)		272 (49.5)	213 (42.7)	
Age-group, n (%):										
40-54	3472 (46.6)	64 (29.3)	<0.001	235 (28.1)	144 (23.9)	9 (9.3)	<0.001	221 (46.7)	125 (29.8)	<0.001
55-64	2072 (24.8)	69 (30.3)		260 (26.9)	191 (26.5)	38 (29.8)		129 (24.4)	156 (29.6)	
65-74	1557 (17.4)	52 (24.7)		262 (24.8)	195 (25.2)	42 (32.7)		98 (16.8)	115 (23.4)	
75-95	778 (11.1)	22 (15.7)		169 (20.2)	151 (24.5)	27 (28.2)		55 (12.1)	72 (17.2)	
Mean age, years (SD)	57.6 (12.3)	61.8 (11.9)	0.011	62.9 (12.5)	64.4 (12.2)	67.8 (10.1)	<0.001	57.6 (12.1)	61.9 (11.6)	<0.001
Smoking status, n (%):										
Current	1198 (16.6)	61 (28.5)	<0.001	172 (20.7)	218 (33.9)	49 (41.5)	<0.001	156 (33.8)	191 (42.0)	<0.001
Ex-regular	2547 (31.7)	80 (41.6)		369 (38.6)	265 (37.2)	51 (41.8)		174 (34.2)	178 (36.5)	
Never	4134 (51.7)	66 (29.9)		385 (40.8)	198 (28.9)	16 (16.7)		173 (32.0)	99 (21.6)	
Pack-years^f, n (%):										
0-0.9	4299 (53.9)	69 (31.2)	<0.001	406 (43.2)	207 (30.1)	16 (16.7)	<0.001	180 (33.2)	101 (22.1)	<0.001
1-19.9	1905 (24.3)	41 (20.1)		252 (27.0)	137 (20.3)	30 (27.1)		138 (27.8)	101 (22.0)	
20-49.9	1318 (17.2)	63 (31.4)		209 (23.2)	241 (34.9)	38 (29.9)		144 (29.9)	180 (36.9)	
50+	345 (4.6)	33 (17.4)		56 (6.3)	94 (14.3)	32 (26.3)		39 (8.5)	86 (19.1)	
NS-SEC^f, n (%):										
Professional	3050 (36.5)	60 (25.4)	<0.001	312 (32.7)	180 (23.4)	27 (20.8)	<0.001	162 (30.5)	106 (20.3)	<0.001
Intermediate	1859 (23.4)	42 (19.4)		242 (25.2)	152 (21.9)	18 (15.1)		126 (23.3)	97 (19.6)	
Routine	2705 (36.9)	100 (53.2)		322 (36.9)	321 (50.9)	65 (59.6)		195 (43.0)	244 (55.9)	

Abbreviations used: COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the lower 5th percentile of

1
2
3 Z-scores); NS-SEC, National Statistics Socio-Economic Classification; SD, standard deviation; UKHLS, United Kingdom Household
4 Longitudinal Survey.
5

6
7 ^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts unweighted; means and
8 percentages estimated using survey weights.

9 ^b HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.

10 ^c Within each definition of obstruction, Chi-squared test used to compare categorical variables; ANOVA used to compare mean values
11 of continuous variables.

12 ^d Staging classification for FTs: stage I ($FEV_1/FVC < 0.70$ and $FEV_1 \geq 80\%$ of predicted); stage II ($FEV_1/FVC < 0.70$ and FEV_1 50-
13 79% of predicted); stage III+ ($FEV_1/FVC < 0.70$ and $FEV_1 < 50\%$ of predicted).

14 ^e Staging classification for LLN: stage I ($FEV_1/FVC < LLN$ and $FEV_1 > LLN$); stage II ($FEV_1/FVC < LLN$ and $FEV_1 < LLN$).

15 ^f Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table S3 Characteristics of Diagnosed COPD and Potential Airflow Obstruction Using Fixed Thresholds and Lower Limit of Normal Spirometry-based Definitions, Persons aged 40-95 years Without Diagnosed Asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010-2012)^a

	All participants	Reported diagnosed COPD ^b	P value ^c	Fixed Thresholds ^d			P value ^c	Lower Limit of Normal ^e		P value ^c
				stage I	stage II	stage III+		stage I	stage II	
n	7879	207		926	681	116		503	468	
UKHLS, n (%)	5936 (75.3)	121 (59.6)	<0.001	705 (76.2)	517 (75.6)	87 (74.9)	0.932	377 (75.0)	356 (76.1)	0.922
HSE, n (%)	1943 (24.7)	86 (40.4)		221 (23.8)	164 (24.4)	29 (25.1)		126 (25.0)	112 (23.9)	
Exposure to passive smoking, hours per week (p/w), n (%)^f:										
0	1599 (81.1)	64 (74.8)	0.407	184 (81.4)	130 (76.7)	20 (69.6)	0.233	93 (69.9)	86 (73.7)	0.007
1-9	256 (14.1)	16 (19.3)		32 (15.8)	22 (15.0)	6 (24.4)		25 (23.9)	17 (16.8)	
10+	82 (4.8)	4 (6.0)		5 (2.8)	11 (8.3)	2 (6.1)		7 (6.2)	8 (9.5)	
Mean exposure, hours p/w (SD)	1.8 (7.7)	2.4 (10.1)	0.966	1.5 (7.3)	3.5 (11.7)	3.3 (13.0)	0.068	2.5 (9.2)	3.8 (11.7)	0.091
Lung function measurements, percent-of-predicted, mean (SD)^g:										
FEV ₁	92.0 (16.5)	75.0 (23.4)	<0.001	92.7 (10.0)	69.0 (7.8)	40.2 (7.2)	<0.001	87.2 (8.2)	59.4 (12.9)	<0.001
FVC	97.1 (15.0)	88.6 (15.7)	<0.001	109.2 (11.5)	87.5 (10.9)	65.4 (12.9)	<0.001	108.1 (10.2)	82.5 (14.2)	<0.001
FEV ₁ /FVC	94.2 (9.7)	82.8 (18.2)	<0.001	84.6 (4.6)	78.9 (7.9)	62.9 (13.2)	<0.001	80.4 (4.5)	71.6 (10.6)	<0.001
Comorbidities, n (%):										
Respiratory disease ^{f, h}	65 (3.8)	33 (42.1)	<0.001	6 (3.3)	15 (9.0)	15 (51.5)	<0.001	5 (4.2)	24 (21.7)	<0.001
Respiratory symptoms ^{f, i}	69 (4.0)	12 (13.7)	<0.001	14 (6.4)	16 (11.7)	8 (27.3)	<0.001	7 (5.7)	18 (17.4)	<0.001
Respiratory medicine	375 (4.8)	71 (36.1)	<0.001	41 (4.3)	70 (9.6)	49 (42.7)	<0.001	30 (5.8)	95 (20.2)	<0.001
Cardiovascular disease ^j	493 (6.5)	20 (11.5)	0.012	84 (9.9)	74 (11.1)	24 (24.1)	<0.001	32 (6.8)	49 (12.3)	<0.001
Diabetes	543 (7.1)	18 (10.9)	0.128	54 (6.3)	67 (9.6)	17 (13.1)	0.007	20 (4.4)	39 (7.8)	0.087
Poor self-rated health	398 (5.7)	40 (23.4)	<0.001	37 (4.9)	58 (9.1)	23 (22.8)	<0.001	30 (7.2)	55 (12.6)	<0.001
Breathlessness ^{f, k}	100 (6.7)	23 (34.8)	<0.001	10 (6.9)	18 (13.1)	11 (43.9)	<0.001	8 (10.5)	21 (21.6)	<0.001
Area of residence, n (%):										
Urban	5791 (75.8)	154 (77.2)	0.654	656 (72.6)	515 (76.8)	89 (79.3)	0.125	372 (75.1)	358 (78.0)	0.528
Rural	2087 (24.2)	53 (22.8)		270 (27.4)	166 (23.2)	27 (20.7)		131 (25.0)	110 (22.0)	
BMI:										
Normal	2122 (27.0)	56 (25.7)	0.751	347 (38.0)	182 (27.6)	35 (34.7)	<0.001	202 (40.6)	147 (32.6)	<0.001
Overweight	3235 (41.9)	79 (40.4)		393 (43.4)	298 (44.6)	37 (34.3)		214 (42.8)	177 (38.4)	

Obese	2369 (31.1)	66 (33.8)	165 (18.7)	187 (27.8)	36 (31.0)	77 (16.6)	132 (29.0)
-------	-------------	-----------	------------	------------	-----------	-----------	------------

Abbreviations used: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV₁, maximum expiratory volume in one second; FVC, forced vital capacity; FTs, fixed thresholds; HSE, Health Survey for England; LLN, lower limit of normal (below the lower 5th percentile of Z-scores); MRC, Medical Research Council; NS-SEC, National Statistics Socio-Economic Classification; SD, standard deviation; UKHLS, United Kingdom Household Longitudinal Survey.

^a Participants were included under each relevant definition. Bronchodilators were not used. Cell counts unweighted; means and percentages estimated using survey weights.

^b HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.

^c Within each definition of obstruction, Chi-squared test used to compare categorical variables; ANOVA used to compare mean values of continuous variables.

^d Staging classification for FTs: stage I (FEV₁/FVC <0.70 and FEV₁ ≥80% of predicted); stage II (FEV₁/FVC <0.70 and FEV₁ 50-79% of predicted); stage III+ (FEV₁/FVC <0.70 and FEV₁ <50% of predicted).

^e Staging classification for LLN: stage I (FEV₁/FVC <LLN and FEV₁ >LLN); stage II (FEV₁/FVC <LLN and FEV₁ <LLN).

^f Measured in HSE 2010 only.

^g Percent-of-predicted defined as the observed value divided by the predicted value estimated for a person of the same age, gender, ethnicity, and height using the European Respiratory Society Global Lungs Initiative 2012 reference equations ¹.

^h Respiratory disease: ICD-10 codes J00-J99.

ⁱ Respiratory symptoms: defined as usually coughing first thing in the morning, for at least 3 months a year, and bringing up phlegm from the chest most days for 3 consecutive months in a year. Missing data: 1 case with missing value.

^j Cardiovascular disease: HSE (longstanding illness): stroke; heart attack/angina; UKHLS (health conditions): coronary heart disease; angina; heart attack/myocardial infarction; stroke.

^k MRC dyspnoea scale: 63 participants with unspecified shortness of breath excluded. MRC grades as follows: 0, only breathless with strenuous exercise; 1: breathless when hurrying on level or up a slight hill; 2: walk slower than people of same age on the level due to breathlessness or stop for breath when walking on level at own pace; 3: stop for breath after walking 100 yards or a few minutes on the level; 4: too breathless to leave house or breathless when dressing.

Reference List

- (1) Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; 40(6):1324-1343.

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England and Wales

Shaun Scholes, Alison Moody, Jennifer S Mindell

	Item No	Recommendation	Action taken
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes, we have used pooled cross-sectional analysis in the title.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Structured abstract as in BMJ instructions for authors.
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Background and rationale reported.
Objectives	3	State specific objectives, including any prespecified hypotheses	Specific objectives of the study reported.
Methods			
Study design	4	Present key elements of study design early in the paper	Key elements presented. We have pooled 2 recent cross-sectional surveys containing lung function data.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Settings, locations, and dates specified.
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Eligibility criteria and methods of selection explained. Reason for excluding the Scottish component of UKHLS described in Supplementary data. Response flowcharts for HSE and UKHLS provided as supplementary data.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	All variables in the study clearly described, highlighting, where relevant, differences between the two surveys.
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Data sources, including choice of reference equations for predicted values and Z-scores clearly described.

Bias	9	Describe any efforts to address potential sources of bias	We undertook descriptive analysis of participants with and without good-quality spirometry data. Implications of bias are mentioned in the discussion.
Study size	10	Explain how the study size was arrived at	Response flowcharts for HSE and UKHLS provided as supplementary data.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Groupings of quantitative variables clearly set out in the method section.
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Statistical methods described in detail.
		(b) Describe any methods used to examine subgroups and interactions	Statistical methods described in detail.
		(c) Explain how missing data were addressed	Exclusion of participants with missing data for two variables clearly set out in the methods section.
		(d) If applicable, describe analytical methods taking account of sampling strategy	Described in the statistical analyses section. We accounted for the clustering of observations using the svy module in Stata.
		(e) Describe any sensitivity analyses	Sensitivity analyses described in detail.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Response flowcharts for HSE and UKHLS provided as supplementary data.
		(b) Give reasons for non-participation at each stage	Response flowcharts for HSE and UKHLS provided as supplementary data.
		(c) Consider use of a flow diagram	Response flowcharts for HSE and UKHLS provided as supplementary data.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Characteristics of study participants (across all variables) are provided as supplementary data.
		(b) Indicate number of participants with missing data for each variable of interest	Numbers with missing data presented as footnote in the tables.

Outcome data	15*	Report numbers of outcome events or summary measures	Outcome data is presented as prevalence.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Both sets of estimates (unadjusted and adjusted) presented.
		(b) Report category boundaries when continuous variables were categorized	Details provided.
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Results of sensitivity analyses provided.
Discussion			
Key results	18	Summarise key results with reference to study objectives	Details provided.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Limitations and potential biases discussed in detail.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Cautious throughout.
Generalisability	21	Discuss the generalisability (external validity) of the study results	Generalisability briefly discussed.
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Details provided.